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Abstract:
Knowledge of inherited diseases and the ability to rapidly, efficiently and comprehensively
perform genetic testing are advancing steadily. However, the ideal approach to translate
this ability into clinical applications for endocrine disorders has yet to be determined. This
work focuses on aspects of clinically translating knowledge of select heritable endocrine and
metabolic conditions.
For maturity onset diabetes of the young (MODY), a monogenic disorder with no current
consensus guidelines governing testing procedures, this work addresses methods to
improve detection by validating the use of next generation sequencing-based techniques to
identify MODY cases and to detect copy number variations.
For very severe hypertriglyceridemia, a largely polygenic trait, this work explores clinical
differences associated with the underlying genotype, assesses treatment of pancreatitis, the
most severe acute complication of hypertriglyceridemia, and presents a population-based
study of Ontario adults to identify the most important modifiable risk factors associated
with expression of hypertriglyceridemia, and to identify any gaps in appropriate care for this
population.
For heterozygous familial hypercholesterolemia, a condition for which universal genetic
screening has been recommended, this work explores the personal impact of this diagnosis
on the patient in terms of quality of life, lifestyle and self-care habits.
The ultimate goal of this project is to expand the available knowledge on how best to
translate the laboratory ability and findings into the clinical realm for these select endocrine
and metabolic conditions.
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Summary for lay audience
Understanding of the role that genetics plays in human diseases and the technology
available to investigate this influence is increasing. With this knowledge comes the
opportunity to improve the care of clinic patients by incorporating this new information into
their care and treatment plan. In this work, I explore several aspects related to the care of
endocrine and metabolic conditions that have genetic components.
I aimed to improve the ability to detect and diagnose individuals suspected of having an
inherited form of diabetes called maturity onset diabetes of the young (MODY). I did this by
examining ways to improve the testing process for these conditions by using newer
technology and software to avoid missing cases.
I also aimed to improve care and counselling for patients with very high levels of a blood
lipid called triglycerides. To accomplish this, I examined three separate populations. I
looked at a group of patients with a rare condition called familial chylomicronemia
syndrome (FCS), caused by different DNA changes, to assess if there are differences in their
physical symptoms or bloodwork. Secondly, I looked at adults with very elevated
triglyceride levels in Ontario, Canada to evaluate factors that can contribute to these severe
triglyceride elevations. Lastly, I looked at management of pancreatitis, a condition that can
be caused by very high levels of triglycerides to assess what happens naturally to patients
with this complication with no active interventions to lower triglycerides.
Finally, I aimed to assess the positive and negative impacts of genetic testing on the patient.
To do this, individuals with elevated cholesterol who underwent genetic testing were asked
to participate in a survey assessing their experience and perceptions.
Ultimately, the goal of this project is to improve the ability of doctors to use genetic
information in the clinic to provide more personalized and optimized care.
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Epigraph:

“There are only two ways to live your life. One is as though nothing is a miracle. The other is
as though everything is a miracle.”
-Albert Einstein
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1.1 Overview:
Increased appreciation of genetics among clinicians, researchers and the general public
parallels the recognition of its role in the development of many diseases. This enhanced
understanding, along with the advent of new genetic testing technologies, and rapidly
decreasing costs, allows for consideration of genetic testing for a number of clinical
conditions with a suspected genetic etiology. However, the exact role and extent of
genetic testing in these cases has not yet been clearly established. This work seeks to
establish how knowledge of patient and disease genetics can be applied effectively in the
adult endocrine clinic to impact patient management and improve patient satisfaction and
outcomes.
This is explored here using three separate endocrine conditions as illustrative examples of
how this can be effectively achieved. The first of these conditions is maturity onset
diabetes of the young (MODY), a monogenic form of diabetes that is often misclassified as
type 1 or type 2 diabetes. This work aims to improve detection rates by validating the use
of next generation sequencing-based techniques and provider clinical suspicion of MODY to
detect new cases and identify copy number variations.
As a second aim, this work seeks to improve the counselling and management of genetic
triglyceride disorders by evaluating the differences in phenotypic expression for different
molecular etiologies of familial chylomicronemia, the contributing secondary risk factors
associated with expression of hypertriglyceridemia, and the conservative management of
pancreatitis, the most severe acute complication of extreme hypertriglyceridemia.
Finally, this work aims to assess the personal impact of genetic testing results on individuals
with high cholesterol who receive a diagnosis of familial hypercholesterolema in terms of
levels of anxiety, health-related quality of life, perceived cardiovascular risk and healthy
lifestyle changes.
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1.2 Basics of genetic change:
1.2.1 Variant Types:
Several different forms of genetic variants, or mutations, exist and are abundant throughout
the genome. These include single nucleotide variants (SNVs) or single nucleotide
polymorphisms (SNPs), which are changes from the consensus DNA sequence at a single
nucleotide, and may or may not be clinically relevant. Most commonly, an SNV will occur in
a non-coding region of DNA and therefore be clinically silent. An SNV that occurs within or
near a gene may be synonymous, coding for the same amino acid as the original nucleotide
sequence, and would also be expected to be clinically silent. A change may lead to an
amino acid substitution, which may or may not affect the functioning of the resultant
protein. Several features of the substitution can influence the likely effect. Observable
factors that make it more likely the change will have a significant clinical impact include: 1)
the less similar an amino acid is to the one it replaces, 2) the more critical the region of the
substitution is to the overall structure and function of the resultant protein, and 3) the less
frequently a change is seen, or tolerated, at a given site in the genome. In some cases, the
nucleotide change may result in the generation of a premature stop codon, effectively
truncating the protein production early. This change is much more likely to be clinically
significant. The SNV could also occur in a region involved in gene regulation or translation,
such as a promotor region, or splice-site, that could affect protein production processes,
leading to clinical effects.
A change that leads to either an insertion or deletion of a few contiguous nucleotides
(generally between 2 and 50) is known as a small indel (insertion/deletion). These may be
more likely to disrupt protein production, and therefore have a clinical effect, especially if
they lead to a frameshift change (a change in the codon reading frame) of the nucleotide,
causing every subsequent codon to be mis-read. Even if the indel does not shift the
reading frame, insertion of new amino acids, or deletion of amino acids that normally
appear in the mature protein, may affect protein structure and function, leading to clinical
impact.
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Copy number variations (CNVs) are large duplications or deletions, generally between 50
base pairs (bps) and 1 million bps. If affected regions include a gene, deletions may lead to
loss of gene function. In the case of a duplication, extra copies of the gene product may
also be seen. A duplication event may also lead to an insertion of the duplicated fragment
of DNA within another gene, affecting the function of that gene product as well.
Historically, CNVs have been difficult to detect on standard genetic tests or chromosomal
analysis and have only recently become more recognized as an important cause of genetic
variation and possibly genetic disease. In fact, between 5-10% of the entire human genome
may represent CNVs (1).

1.2.2 Determining Pathogenicity:
Even when sequencing methods can detect rare single base-pair changes in a gene of
interest that has been definitively linked to a disease, it does not automatically follow that
this base-pair change is causally linked to the disease. Such DNA changes may be
synonymous, meaning that they encode for the same amino acid as the base pair that was
replaced, or they may be benign, in that the altered amino acid has no biological or clinically
relevant effect on the structure or the function of the translated protein.
The highest level of evidence for the pathogenicity of a detected mutation is a functional
study, usually performed in a research laboratory, where the mutation has been generated
in an in vivo model and shown to result in some objective or quantitative change in an assay
or model that is consistent with the observed clinical phenotype (2). However, this is time
and labour intensive and is not feasible to do for most identified SNVs. Familial segregation
analysis can also provide convincing evidence if the nucleotide change shows complete
phenotype concordance; i.e. each family member who carries the variant also has the
disorder (this type of evidence becomes statistically stronger as more family members are
tested). Conversely, the presence of the mutation in healthy, phenotype-free individuals
argues strongly against pathogenicity (2).
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A second tier of evidence for potential clinical relevance is derived from "bioinformatics" or
analysis using computational models. Here, well established prediction software tools
employ complex but validated mathematical algorithms to rank the effect of the amino acid
change based on the degree of evolutionary conservation of the wild-type amino acid, and
the predicted 3-D structure of the resultant protein, and other circumstantial information to
gauge pathogenicity (2). These also include the rarity of the mutation. Generally any
change that is seen in at least 1% of the population is considered common enough that it is
unlikely to be pathogenic. However, these methods are not clear-cut and sometimes give
inconsistent results for the same mutation. Even when these contentious variants are
manually adjudicated by human genetic experts, there can be dissention regarding the
pathogenicity of a given base pair change. This underscores the perhaps surprising
subjectivity that underlies some genetic testing, and emphasizes the importance of having
highly trained, knowledgeable and skilled individuals available to help interpret nondefinitive genetic testing results, both to avoid incorrectly assigning pathogenicity to a
benign change or conversely ascribing neutral functionality to a change that is actually
pathogenic.

1.2.3 Classifying a variant:
In an attempt to standardize variant calling, the American College of Medical Genetics and
Genomics (ACMG) created a consensus method for determining pathogenicity of variants,
with 5 classifications possible: “pathogenic”, “likely pathogenic”, “likely benign”, “benign”,
and “uncertain significance” (3). However, even variants classified using this scoring system
could be re-classified at a later date if new information comes to light through research,
new discovery or the incorporation of data from additional family members or probands.
This is especially true for variants of uncertain significance (VUSs). There can also be an
element of subjectivity when using the scoring system that could lead two different
investigators to assign different pathogenicity ratings to the same variant.
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1.3 Genetic Sequencing:
1.3.1 Polymerase Chain Reaction:
Most currently available sequencing technologies depend first upon achieving amplification
of available DNA to create multiple copies of the starting DNA sequence that can then be
used to determine the genetic sequence. The most common way this is achieved is
through use of the polymerase chain reaction (PCR). The principle behind PCR is to take
advantage of the natural replicative ability of DNA through the production of
complementary strands. This involves separating the DNA into two single strands, and
creating a complementary stand for each of the two separated DNA chains. Repeating this
process with the newly produced double-stranded DNA fragments will copy the sample
exponentially to produce millions of copies of the target fragment.

1.3.2 Sanger sequencing:
The first sequencing technology that was capable of determining the genetic sequence for a
large chain of DNA was Sanger sequencing, developed in the mid-1970’s by Frederick Sanger
(4). In Sanger sequencing, PCR is conducted with a mixture of normal deoxyribonucelotides
(dNTPs), along with a small proportion of chain-terminating dideoxyribonucelotides
(ddNTPs). As ddNTPS lack the 3’-OH group necessary to form a phosphodiester bond with
the next dNTP in sequence, when these ddNTPS are incorporated at random in a PCR chain
elongation cycle, the extension of the chain will prematurely terminate, leading to a
shortened strand, which will then go on to be amplified in its shortened state during the
next cycle.
This process is repeated at random enough times that a library of oligonucleotide chain
lengths is produced, with representation of every chain length possible between a single
nucleotide length up to the full length of the target region of DNA. The oligonucleotides are
then physically separated by length using gel electrophoresis and each terminal nucleotide
identified. In automatic Sanger sequencing, this process will generate an output with
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different colour peaks in order corresponding to a colour-coded nucleotide sequence,
known as a chromatogram.
This technique is best used to examine small segments of DNA at a time, usually a single
gene or single exon. It allows for a high degree of DNA amplification. It is the most precise
method to look for a single candidate mutation, typically a rare large-effect variant in a
known gene causing a monogenic disorder. This method could be helpful in familial cascade
screening for focussed assessment of the inheritance of a single, previously identified
mutation. It has the added benefit of providing only the desired genetic result with a lower
chance of incidental findings. This method is used both clinically and in research. For the
latter application, Sanger sequencing is often used for 'gold standard' confirmation when
other methods initially detect a potentially causative variant (5, 6).

1.3.3 Next generation sequencing (NGS):
Next-generation sequencing (NGS) refers to a variety of different methods, each of which
use a massively parallel sequencing design to amplify and examine multiple segments of
DNA concurrently (7). This technique is typically applied to detect a rare causative variant
for a monogenic condition when many possible mutations exist, and can be used in a variety
of ways: to sequence 1) a targeted selection of pre-specified genes, accomplished using a
designed panel; 2) the complete collection of all expressed protein-coding sequences
(‘whole exome sequencing’ or WES), which represents approximately 2% of the entire
genome; or 3) whole genome sequencing (WGS) (8), which simultaneously amplifies all DNA
sequences from an individual, including both coding and non-coding regions (7). Because
most common SNPs reside within non-coding regions, WGS allows for both common and
rare variants to be assayed, while WES is optimal for detecting rare coding variants.
Targeted panels can be designed to both screen for rare coding variants and to concurrently
evaluate non-coding regions containing selected common SNPs as part of a polygenic risk
score. The number of these tests that have been clinically validated is on the rise, and the
costs decreasing steadily (9). The current cost of this technology varies depending on how
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many genes are concurrently assessed, with approximate costs of $300 for a targeted panel,
$800-$1200 for a whole exome panel and $5000-$10,000 for a whole genome sequence (8).

1.3.4 Microarray Genotyping:
Genotyping refers to a range of dedicated types of inexpensive genetic testing methods that
directly assay specific known rare variants or common SNVs across individuals. Several
different technical and chemical platforms can be used to determine genotypes, from a few
to a large set of pre-defined SNVs that have been previously associated with certain
conditions of interest. High density genome-wide microarrays can be used in unbiased
genome-wide association studies (GWAS) to discover associations among millions of SNV
markers of chromosome regions and either quantitative or qualitative complex clinical traits
(7).
A microarray chip contains up to hundreds of thousands of oligonucleotide probes arranged
and immobilized in certain positions on the chip. Upon addition of fragmented, singlestranded DNA to the microarray and binding of target DNA sequence, florescence tags are
released that can be detected by photosensors. The intensity and colour of the signal
emitted helps identify which SNV is present. Because this technology is dependent on
probes that are designed to look for and identify known SNVs, it cannot be used to detect
novel or unknown genetic changes. However, it can be used to detect CNVs by looking for
an abnormally high number or low number of SNP signals in contiguous SNPs. For example,
in a deletion, the number of detected SNP fragments will be reduced by approximately half
over the span of the deletion, whereas SNP fragment detection will be roughly 1.5 times the
baseline SNV detection rate (or multiples thereof) for a duplication.
SNVs detected are often common variants that can be associated with genetic conditions,
but may or may not actually be at the site of the pathogenic variant. Microarrays can also
be used to detect known disease-causing variants at specific loci if the mutations are
established as disease-causing and the microarray is designed to look for that variant.
Once certain SNV genotypes have been definitely associated with clinical phenotypes, a
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smaller, cost-effective panel of SNVs can be constructed using dedicated chemistry (e.g.
TaqMan) or custom-made microarrays permitting high throughput cost-effective focused
testing in clinical samples. Most commercially available direct-to-consumer genetic testing
uses this technique, and thus provides information primarily on common SNVs that may
determine susceptibility but are not directly causative for diseases.

1.4 Sequencing options for clinical applications:
1.4.1 Single gene sequencing:
This is the most selective genetic sequencing test. It is highly sensitive in detecting changes
for the gene tested. Cost for this testing will vary based on type of test performed and the
size of the gene. Single gene testing may be useful in a number of clinical settings, such as
when there is a single candidate gene for the condition of interest, or to verify the presence
or absence of a known familial mutation. Disadvantages include the lack of information on
any other gene, which may result in higher costs if sequential single-gene tests are
eventually required (Table 1.1).

1.4.2 Gene panel sequencing:
For this type of sequencing, the coding and surrounding regions of several selected genes
are sequenced simultaneously. These can be designed to capture a number of genes
associated with a particular condition of interest, for example dyslipidemias, epilepsy,
developmental delay etc., or genes grouped together for another reason (ie commonly
tested genes, genes of interest in a particular study protocol etc). Panels can be useful
clinically when they can be focussed on a particular clinical question of interest, and they
allow for selective information to be obtained without the risk for extraneous results. By
focusing on only a few genes, panels also allow for more copies of the DNA sequence to be
generated at each site, increasing the accuracy of variant calls. Panels are also generally
less expensive than other multi-gene sequencing methods (Table 1.1).
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1.4.3 Whole Exome Sequencing (WES);
This type of sequencing captures data from all exomes and surrounding regions (~2% of the
entire genome). It is generally considerably more expensive than testing a gene panel and
may also be less sensitive. It will also be more likely to generate incidental findings
compared to targeted panel sequencing. Some advantages of this type of sequencing is
that it allows researchers to evaluate multiple sequential gene hypotheses without needing
to repeat a sequencing step. The data is also available if a new clinical concern arises in the
future without the need for re-sequencing. Clinically, this sequencing may be useful when
the genetic basis for a condition is poorly or incompletely understood, if multiple gene
testing is desired but no panel is available, or if it is anticipated that the genetic basis for
other conditions may be sought in the future (Table 1.1).

1.4.4 Whole Genome Sequencing (WGS):
This sequencing provides data on most of the entire genome (>99%), including coding and
non-coding regions. Generally, this is an expensive and labour-intensive undertaking and
may not provide much more clinically useful information compared to whole exome
sequencing, as most clinically significant DNA changes will be seen within coding regions.
The addition of non-coding sequence may allow for better examination of regulatory
elements. This type of genetic sequencing is likely best for research endeavors rather than
for regular clinical practices (Table 1.1).

1.4.5 DNA Microarray Genotyping:
Genotyping may be useful clinically as it can provide information of targeted select changes
of interest and can be helpful to detect known genetic variants throughout the genome.
Genotyping is also clinically validated to detect large duplications or deletions known as
copy number variations (CNVs). This is done predominantly by looking for SNVs throughout
the genome. Each genotyping array is designed to detect a pre-specified number of SNVs
with known clinical consequences. It is important to note that this type of genetic testing
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will not provide data on the exact DNA sequence and will be unable to detect novel
changes, or any nucleotide changes that are not designed to be identified in the specific
panel (Table 1.1).

1.4.6 Risk scores for polygenic traits:
Many inherited conditions are not due to a single genetic variant but instead are inherited
through accumulation of several small-effect changes. These common allelic variants each
contribute only fractionally to the development of the condition, but when present in
sufficient numbers in the genome of a single individual they can underlie a phenotype
resembling that of an individual who has a single, rare, large-effect mutation (10-12).
For example, a number of identified independent common SNPs from GWAS on various
chromosomes have been reproducibly shown to be associated with alleles that slightly raise
or lower a lipoprotein fraction, e.g. high density lipoprotein (HDL) cholesterol [C], low
density lipoprotein (LDL)-C or triglyceride (TG) (13). Most people have some alleles that
raise and others that lower lipoproteins, with the usual net result being an average serum
level. However, some individuals, by unlucky chance, will inherit an overburden of alleles
that act to alter the lipid trait in the same direction (e.g. to raise LDL-C) (14). High
cholesterol due to the accumulation of a high burden of small-effect SNPs can be
indistinguishable clinically from a single gene rare variant cause. However, this genetic
mechanism of disease will not be detected by standard genetic testing, e.g. WES or targeted
exon sequencing that is not designed to concurrently detect common non-coding SNPs
associated with the trait of interest (14, 15). Methods to evaluate these lipid trait-altering
SNP genotypes include TaqMan-based amplification assays, SNP microarrays, or targeted
NGS panels that have been consciously designed to detect non-coding SNPs.
Once these key SNPs have been genotyped, they can be entered into a scoring system to
estimate their cumulative effect on the respective clinical trait. These systems sum the
expected effect of each individual SNP in a given patient to derive a score that is then
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compared to a healthy reference population. These scores use a simple weighted sum of
the identified risk alleles to generate a risk score, normalized to the average population risk:
(score = �

𝑛𝑛

𝑖𝑖=1

(𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛 𝑜𝑜𝑜𝑜 𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟 𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎) ∗ (𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 𝑜𝑜𝑜𝑜 𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑙𝑙𝑒𝑒 𝑜𝑜𝑜𝑜 𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 𝑜𝑜𝑜𝑜 𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖) )

with the number of risk alleles ranging between 0 to 2 for each trait.

If an individual has a high SNP score, such as >75th percentile compared to the reference
population (meaning that only 25% of individuals would have such a high burden of traitaltering alleles), this would be expected to predispose to the development of clinically
apparent trait.
Since targeted NGS is the method of choice to detect rare large-effect disease-causing
variants, in most diagnostic laboratories it would be most efficient to expend some excess
capacity on such targeted panels to also sequence the non-coding regions harboring the key
SNPs comprising a polygenic risk score (PRS). This means that both rare and common DNA
variation underlying a clinical condition can be concurrently evaluated using a single
laboratory method, which saves time, effort and expense. The use of NGS data to generate
a PRS for certain conditions can add valuable information regarding the underlying genetic
contribution to a phenotype, and can help fill in the missing genetic gap for many disorders.
This is especially important in conditions such as in FH, where up to one-third of clinicallyascertained cases without a discrete rare large-effect mutation will actually have a high
polygenic score (15); a similar pattern is seen in patients with extremely low or high levels
of HDL-C (16).
SNP scores have been generated using a small number of SNPs, several hundred SNPs and
recently several million SNPs (12). While there is no consensus yet for the most clinically
useful or practical method of generating a polygenic risk score, the numerical predictive
value of the score tends to increase with the greater number of SNPs incorporated (Table
1.1).
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Table 1.1: Genetic Testing Methods
Method:

Description:

Strengths:

Weaknesses:

Detection Possible:
CNV:

Sanger
Sequencing

Targeted
NG
Sequencing:

Amplification
using individual
primer pairs in
separate
amplification
and sequencing
reactions

-Gold standard
for diagnosis of
small DNA
changes

Simultaneous
screen of a preselected subset
of genes

- Maximize
diagnostic yield
and minimize
off-target
results

-Highest depth
of coverage

-Labour intensive

No

Rare
Variants:

Common
Variants:

Yes

No

Best Use:
PRS:
No

-Highest cost
when done in
high volumes

-Single gene tests
-Confirmation of
presence/absence of a known
mutation in familial cascade
testing

-will not find
mutations in
genes outside
the panel design

Yes*

Yes

Yes~

Yes~

-Investigating a condition with
multiple causal/contributing
genes

-potential for offtarget results

Yes*

Yes

No

No

-Conditions with an unclear
genetic basis

-High depth of
coverage
Whole
Exome
Sequencing:

Simultaneous
screen of all
exons in an
individual (2%
of total DNA)

-Can identify
new or
unexpected
genes
-Could be reexamined for
other conditions
at a later date

-higher
probability of
uncertain results

-Conditions expected to be
genetic but without a cause
identified on other testing

1

Whole
Genome
Sequencing:

Genotyping:

Polygenic
Trait Score:

Simultaneous
screen of all
DNA in an
individual,
including
mitochondrial

Rapid screen of
entire genome
using an array
of common
variant SNPs

Derived by
summing the
minor effects of
several
common
variants to
generate an
overall
estimate of risk

-Includes all
genetic
material,
including
regulatory
regions

-Lower depth of
coverage

-Could be reexamined for
other conditions
at a later date

-Labour intensive

-Rapid

-Cannot detect
novel variants

-Lower cost
-Entire genome
examined
-Can provide
information on
risk that will not
be apparent
with other
forms of
sequencing

Yes

Yes

Yes

Yes

-Same as for whole exome but
provides more comprehensive
data

Yes

Yes~

Yes~

Yes

-Can be used to look for disease
risk, ethnicity and to determine
familial relationships

N/A

N/A

N/A

N/A

-Used as a complement to
traditional sequencing to help
provide an additional clinical
prediction of risk

-higher probably
of uncertain and
off target results

-No sequencelevel data

-Ethnic variations
can limit use
-Predictive value
varies with each
score

PRS: Polygenic Risk Score; *With specialized bioinformatics tools; ~If designed to target
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1.5 Benefits, Drawbacks and Indications for Genetic Testing:
1.5.1 Potential Benefits of Genetic Testing:
The promise of genetic testing for the individual is securing a definitive diagnosis. This has
several possible benefits, including the ability to alter management to better suit the
individual patient, depending on the condition. The genetic diagnosis in such instances
could reduce the delay in selecting an appropriate treatment (17). Additionally, a genetic
diagnosis is required in order to procure funding or eligibility for targeted therapies in some
conditions. This is the case in certain jurisdictions for obtaining third party private coverage
for injectable inhibitors of proprotein convertase subtilisin kexin 9 (PCSK9) for the
treatment of familial hypercholesterolemia (FH).
Some genetic syndromes may have other associated features, or carry risks, that are not
readily apparent early in the condition, such as genitourinary or hepatic manifestations in
maturity onset diabetes of the young (MODY) diabetes caused by mutations in HNF1B,
hepatic cirrhosis or other organ infiltration in cholesteryl ester storage disease (CESD) or
Wolman syndrome due to bi-allelic LIPA variation (18). Confirmation of these genetic
syndromes can allow for these complications to be monitored for and potentially prevented
or their consequences ameliorated. Additionally, some conditions can mimic a
presentation of a classic clinical condition, but have a different etiology, such as
sitosterolemia, which can present like FH, but require very different management strategies
(19). Knowing the underlying genetics can help tailor therapy most effectively to the
individual patient.
Furthermore, many genetic conditions are picked up later in life, as they often fail to
present with overt symptoms, such as atherosclerosis in the case of FH, until well into the
disease course (20). Because there are effective therapies for early prevention and
management that have been shown to prevent or delay onset of complications, there is a
large potential benefit to identifying and treating these individuals aggressively as early as
possible.
1

Beyond the individual patient, there may be a significant window of opportunity for early
detection and intervention for children or other family members of identified individuals
who have a discrete molecular cause for their condition. For instance, heterozygous FH
(HeFH) and MODY both follow an autosomal dominant transmission pattern, meaning that
approximately half of all first-degree relatives would also have the condition (5). Many of
these individuals may be in the pre-clinical stage of cardiovascular disease and would
benefit from an early diagnosis. Having a definite DNA diagnosis could also have
implications for family planning, especially for the parents of children presenting with
severe homozygous conditions which would be expected to be manifest in approximately
25% of their future offspring, or for adults who are considering starting a family and wish to
consider the potential risks. Often a genetic counsellor can help explain these risks to
families and allow them to make more informed decisions about their future plans.
There are also other non-clinical benefits of genetic testing that come in the form of patient
empowerment. Knowing a diagnosis, even if there are no interventions or prevention
strategies, can allow an individual an awareness of the expected natural course and provide
the opportunity for advanced planning and more emotional and mental control over their
healthcare (21). There can also be a significant sense of relief for at-risk individuals who
test negative for a genetic condition, and reduction in costs of surveillance (21).
On a societal level, genetic testing can contribute to a better understanding of the
pathophysiology of a condition. This in turn can lead to the development of new, more
effective pharmacological treatments or management strategies. A prime example of this is
the development of PCSK9 inhibitors, which owe their inception and development to
studies of patients and later families identified as having low LDL-C and low rates of
cardiovascular disease.

1.5.2 Potential drawbacks of Genetic Testing:
A major limitation to the widespread use of genetic testing is the cost, which can be
prohibitive, especially for larger analyses such as WES or WGS. However, the cost is
2

dropping rapidly following upon Moore's law of the economics of new technologies (9).
From the first completed whole DNA sequence in 2000 which cost $2.7 billion, the costs are
now down to a minuscule fraction of that, at approximately $5-10,000 for a whole genome
and much less for a whole exome. With the costs expected to continue to decrease, this
barrier is increasingly overcome.
There are, however, other ethical and societal considerations to the widespread use of
genetic testing. Ethical dilemmas arise when researchers obtain unexpected off-target
results, for instance incidental findings unrelated to the disease of interest that are present
in WES or WGS. There is some debate surrounding whether these need to be looked for
and communicated to tested patients, or if genetic researchers or technicians should report
only on the specific genes or diseases for which the test was conducted. For example, if a
test in a patient with dyslipidemia picked up a mutation in a known breast cancer (BRCA)
gene, what is the obligation to look for this finding and report it to the patient. Similarly,
there are hundreds to thousands of incidental variants of unknown significance (VUSs) that
are picked up during the sequencing process (2). There is significant debate regarding the
most appropriate way for these to be evaluated and communicated. There is also a conflict
of interest that can arise between the researcher or physician ‘duty to inform’, especially in
the case of at-risk family members, and the individuals’ ‘right not to know’ (22, 23).
Furthermore, genetic testing could be seen as infringing on the privacy of other family
members, as a genetic result will indirectly provide information about them as well (22).
The ACMG has recommended that incidental findings related to several severe medical
conditions should be communicated to patients if detected (24), although this is an active
area of debate.
There is a prevalent concern that genetic information may be used to determine eligibility
for work or for insurance, or otherwise lead to forms of ‘genetic discrimination’ (22, 25).
Legislation in many countries, including the United States and Canada is intended to protect
against genetic discrimination in the workplace, and by tentative consensus for the
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insurance providers, but the issues regarding who would be able to access genetic
information, and for what purpose, remain unresolved.
There is also often a commonly held misbelief that genetic testing is an absolute certainly,
where the results are either positive or negative. However, genetic testing is prone to the
same limitation of false positives and negatives as any other diagnostic test, though the
exact sensitivity and specificity of genetic testing is often impossible to determine due to
the lack of a reference standard (25-27). This misconception can potentially lead to both
unnecessary anxiety in the case of a false positive (i.e. when a VUS in a known causal gene is
deemed pathologic when it is in fact benign, or when two causal mutations for a
homozygous trait are present on the same allele but are reported to be disease-causing as a
compound heterozygote), or inappropriate reassurance in the case of a false negative (i.e. a
mutation exists in a gene not yet associated with the disease) (27).
There are also financial limitations to consider. While the number of clinically validated
tests available is increasing, the guidelines surrounding indications for their use or guidance
for interpretation is slower to emerge, as is insurance and government reimbursement (9,
21).

1.5.3 Testing Indications:
In general, the argument to proceed with genetic testing is strengthened when there is
strong suspicion (no secondary causes are apparent, a strong family history, values are far
outside standard reference ranges, there are other possibly syndromic features, or the
patient is young) AND when there might be a change in management, monitoring or
intervention that could affect outcomes for the patient or family members (i.e. will affect
eligibility for new drugs, would potentially lead to a different choice of therapy) OR if there
a strong patient desire to have a definitive diagnosis (Table 1.2) (21, 27, 28).
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Table 1.2: Indications for Genetic Testing in Inherited Endocrine Conditions:
Testing might change management
Strong clinical suspicion
Patient preference
Family planning
Early interventions available
Eligibility for new drugs
Strong family history
Other, related syndromic features

5

1.6 Maturity Onset Diabetes of the Young:
1.6.1 What is MODY?
Maturity-onset diabetes of the young (MODY) is an umbrella term for a genetically
heterogeneous collection of monogenic (single gene) diabetes syndromes, inherited in an
autosomal dominant manner (29). The term had its origin in the now outdated
classification of diabetes as either juvenile-onset (type 1) diabetes, or maturity-onset (type
2) diabetes. The Canadian Diabetes Association (CDA) categorizes MODY under "genetic
defects of beta-cell function", with sub-classification according to the gene defect (30).
Many subtypes of MODY are characterized by deficiencies in the signaling pathways for
insulin production, release or responsiveness, that are often linked to insufficient glucosemediated insulin release from the pancreatic beta cells. Unlike type 1 diabetes, which is an
autoimmune condition resulting in immune-mediated destruction of the pancreatic beta
cells, the complement of beta cells in MODY is usually normal. In MODY, deficiencies in
insulin production are due to inherited defects that are often sufficient on their own to lead
to hyperglycemia and a diagnosis of diabetes without any additional trigger. MODY
subtypes generally follow an autosomal dominant inheritance pattern. Penetrance and
expressivity can vary considerably in different kindreds depending on the mutation involved
and even amongst family members with the same mutations. In some milder forms of
MODY, environmental or other metabolic factors may influence the expression of the
MODY phenotype, by either exacerbating or ameliorating the effect of the inherited defect.
Exacerbating factors could include a hypercaloric diet high in carbohydrates, development
of overweight or obesity, or a sedentary lifestyle. Conversely, ameliorating factors could
include higher fiber, lower simple carbohydrate diet, regular physical activity and
maintenance of ideal body weight. Many of the exacerbating factors can be similar to
those that predispose to insulin resistance, which contributes to the development of type 2
diabetes, but individuals with MODY mutations may develop a diabetes phenotype more
readily in the presence of these influences. However, in the majority of MODY cases, the
inherited deficits are sufficient on their own to manifest a diabetic phenotype irrespective
6

of other influencing factors, and will occur at a young age even in the absence of any other
identifiable risk factors.

1.6.2 MODY Subtypes:
The prevalence of MODY has been estimated at 0.5-6.5% of new-onset diabetes cases,
depending on the population studied (29), with MODY2 (glucokinase or GCK gene) and
MODY3 (hepatocyte nuclear factor 1-alpha or HNF1A gene) being the most prevalent forms,
involving about three-quarters of all MODY patients (Table 1.3). To date, 14 different
MODY subtypes (MODY1 – 14) have been described (Table 1.3). While initially these were
described numerically, there has been a shift in recent years to classify the MODY subtypes
according to the underlying gene defect. Both naming terminologies are used here, with
preference for classifying by genetic defect.
GCK-MODY (alias MODY2) is caused by mutations in the GCK gene, encoding glucokinase, a
hexokinase enzyme that catalyzes the phosphorylation of glucose to glucose-6-phosphate,
the first step in glycolysis (31-37) (Figure 1). Heterozygous mutations in this gene have been
linked to a mild, non-progressive form of diabetes that is usually asymptomatic with mild
elevations in fasting blood sugar and mildly increased post-prandial glucose excursions. In
contrast, MODY1 and MODY 3-7, 9 and 11 each result from rare mutations in transcription
factors, which regulate the embryonic development of beta-cells, in addition to their
proliferation and programmed cell death (38) (Figure 1). These transcription factors also
govern expression of insulin, glucose transporters, and related beta-cell factors (38, 39).
MODY1 and MODY 3-7, 9 and 11 are collectively termed “transcription factor MODY” (38,
39).
1.6.2.1 HNF4A MODY (MODY 1) and HNF1A MODY (MODY 3):
HNF1A-MODY (MODY 3) is the most common form of transcription factor MODY, and
accounts for 30-60% of all MODY cases. It is caused by mutations in the HNF1A gene
encoding hepatocyte nuclear factor (HNF) 1-alpha (40). HNF1A is expressed in the
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pancreas, liver, kidney and intestine and is involved in glucose transport and metabolism, as
well as mitochondrial metabolism in pancreatic beta cell (41).
HNF1A-MODY patients generally have normal fasting glucose levels, but exaggerated postprandial hyperglycemia, i.e. > 5 mmol/L blood glucose excursion, that worsens with time
(38-40) due to progressively reduced beta-cell proliferation and increased apoptosis (38).
HNF1A-MODY patients are often very responsive to sulfonylureas (SUs) or meglitinides, with
glycated hemoglobin (HbA1c) improvement of 4-5% in absolute terms compared to
metformin (40). These agents bind to receptors on the beta cell surface, leading to an influx
of calcium which induces the direct release of insulin from storage vesicles within the beta
cell, bypassing the normal glucose trigger for insulin release, which is defective in this type
of MODY (41). Consequently, low-dose SUs are first line therapy in HNF1A-MODY and may
be able to be used effectively as monotherapy for decades (40). However, since HNF1AMODY is progressive, patients often eventually progress to requiring other therapies,
including insulin.
Patients with HNF1A-MODY are notable for an usually low renal threshold for glucose (41).
They can also be more susceptible to the development of microvascular complications over
time, especially retinopathy, with inadequate glycemic control (39, 40).
HNF4A-MODY (MODY 1) is caused by mutations in the HNF4A gene, encoding for
hepatocyte nuclear factor 4-alpha (HNF4-alpha), which is an upstream regulator of HNF1alpha, the transcription factor involved in the pathogenesis of HNF1A-MODY (MODY 3).
Thus HNF1A-MODY (MODY 3) and HNF4A-MODY (MODY 1) patients have similar clinical
features, course and recommended treatment (38, 42). Individuals with HNF4A-MODY may
have a history of higher birthweight or macrosomia, and a history of transient neonatal
hypoglycemia (41). Mutations in HNF4A account for approximately 5-10% of all identified
MODY mutations (41).
1.6.2.2.GCK-MODY (MODY 2):
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The first causative gene found for MODY, GCK, encoding glucokinase (MODY2), was isolated
using a candidate gene approach (40). Glucokinase (GCK) is expressed in the liver and
pancreas and catalyzes the first reaction in the glycolytic pathway, namely the conversion of
glucose to glucose-6-phosphate (40). In pancreatic beta cells, the rate of glucose
phosphorylation by GCK is directly proportional to serum glucose concentration, allowing it
to function as a glucose sensor (38, 40). In GCK-MODY patients with GCK deficiency, the
threshold glucose level required to stimulate insulin release is higher than in normal
subjects, but the overall secretion curve and response are similar. This results in a higher,
but stable, overall set point for plasma glucose, essentially shifting the dose-response curve
to the right (40, 42). This explains the generally benign course of GCK-MODY, in which
affected individuals have mild elevations in fasting glucose, generally between 6 to 8
mmol/L, that deteriorates minimally over time, and rarely leads to microvascular
complications (39, 40). Oral glucose tolerance testing shows mildly increased 2-hour
increments in glucose from baseline, usually < 3.0 mmol/L and off-treatment HbA1c rarely
exceeds 7.5-8% (38, 40, 43, 44). Mutations in this gene are a common form of MODY, with
an overall prevalence of ~1 in 1000 individuals (31-37, 44), and accounts for 30-60% of all
MODY cases.
1.6.2.3 PDX1-MODY (MODY 4):
PDX1-MODY is a rare transcription factor MODY subtype, resulting from mutations in the
PDX1 gene encoding for pancreatic and duodenal homeobox 1, which is involved in
pancreatic development and beta cell maturation, as well as regulating insulin gene
expression (36, 41).
1.6.2.4 HNF1B-MODY (MODY 5):
Mutations in HNF1B lead to MODY5, and are responsible for 5-10% of all MODY cases (45,
46). This condition is also known as renal cysts and diabetes syndrome. Whole gene
deletions of one copy of HNF1B are responsible for up to 50% of cases of MODY5, with
virtually all of these being chromosome 17q12 deletions of varying magnitude (45-48). The
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majority (~70%) of these deletions arise de novo (48). The "17q12 deletion syndrome" is a
term that refers to more extensive deletions of ~1.4 Mbps that encompass HNF1B and
several surrounding genes (47-49). Clinical manifestations of 17q12 deletion syndrome
include a mild to moderate, progressive diabetes with a mean onset of age 24, but which
can present from the neonatal period up to middle age (46, 48).
Individuals with the condition can have congenital or later-onset urogenital malformations,
and also have frequent renal, pancreatic or hepatic complications, including cysts,
hypomagnesemia, hyperuricemia, or exocrine pancreatic deficiencies (46-48). Primary
hyperparathyroidism also appears with higher prevalence (46). Cognitive impairment
and/or developmental delay is common, presenting in 50% of those with 17q12 deletion
syndrome (46-48). Individuals with impaired function of HNF1B may respond initially to
low-dose oral sulfonylurea therapy but insulin is often required (46, 50). Progressive loss of
renal function that is distinct from development of diabetic nephropathy can also be seen in
these individuals (41). Due to these extra-pancreatic manifestations, these individuals may
warrant periodic monitoring for genitourinary, parathyroid, hepatic or other complications.
1.6.2.5 NEUROD1-MODY (MODY 6):
Mutations in NEUROD1, encoding for a basic helix-loop-helix protein transcription factor
known as neurogenic differentiation 1, is responsible for NEUROD1-MODY, a rare MODY
subtype. This transcription factor is thought to be involved in the development of
endocrine cell lineages as well as regulates expression of insulin (INS), GCK and GLUT2 genes
(36). Minimal clinical data is available on this form of MODY, but most individuals with this
type of MODY seem to require insulin (36).
1.6.2.6 KLF11-MODY (MODY 7):
KLF11-MODY is a rare form of MODY caused by mutations in KLF11, encoding for kruppellike factor 11, an SP1-like zinc finger transcription factor that is thought to be involved in
activating the insulin promoter in response to hyperglycemia (51). In has been described in
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3 kindreds with impaired glucose tolerance and early onset apparent type 2 diabetes (51).
Minimal data is available on optimal treatment strategies or clinical course.
1.6.2.7 CEL-MODY (MODY 8):
CEL-MODY, also known as diabetes and pancreatic exocrine dysfunction syndrome, is a rare
MODY subtype caused by mutations in the CEL gene, encoding for carboxyl-ester lipase, an
enzyme produced by the adult pancreas that aids in the digestion of fats (52-55). In
addition to early-onset diabetes, this form of MODY presents with progressive decline in
pancreatic exocrine function, lipomatosis, or fatty replacement, of pancreatic tissue, and
the development of pancreatic cysts (52-55). While the clinical course of individuals
carrying these mutations is not well-described, insulin is likely be required due to the
progressive pancreatic destruction seen in these cases.
1.6.2.8 PAX4-MODY (MODY 9):
PAX4-MODY is caused by mutations in the PAX4 gene, encoding for paired box 4, a member
of the paired box family of transcription factors. Along with PAX6, PAX4 is thought to be
involved in differentiation of the endocrine pancreas and pancreatic islet and beta cell
development (56).
1.6.2.9 INS-MODY (MODY 10):
INS-MODY is caused by mutations in the INS gene, encoding for the peptide hormone
insulin that is expressed in the pancreatic beta cells in response to rising glucose levels and
is the main hormone responsible for regulating metabolism of carbohydrates. Mutations in
INS that affect the post-translational processing of insulin have been linked to the
development of this rare form of MODY (57, 58). Other mutations in this gene have been
linked to permanent neonatal diabetes and hyperproinsulinemia. Limited data is available
with respect to clinical course and optimal management, but case reports suggest effective
management may range from diet alone to small doses of insulin.
1.6.2.10 BLK-MODY (MODY 11):
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BLK-MODY is a rare subtype of MODY caused by mutations in the BLK gene, encoding for B
lymphocyte kinase, a tyrosine kinase expressed mainly in human lymphatic organs, but also
shows expression in pancreatic islet cells, where it is thought to modulate insulin synthesis
and secretion, possibly through upregulation of PDX1 transcription (59, 60). While data on
this form of MODY, as well as clinical course, are lacking, available data suggests that
additional factors, such as elevated body mass index (BMI) or otherwise diabetogenic
environment may be required to fully express this phenotype (59).
1.6.2.11 ABCC8-MODY (MODY 12) and KCNJ11-MODY (MODY 13):
ABCC8-MODY is a rare form of MODY caused by mutations in the ABCC8 gene, which
encodes for ATP-binding cassette C8, also known as the sulfonylurea receptor. This protein
encodes for the binding domain for ATP in ATP-sensitive K+ channels in pancreatic beta cells
(61).
KCNJ11-MODY is caused by mutations in the KCNJ11 gene, that encodes for potassium
channel, inwardly rectifying, subfamily J, member 11 (62, 63). This potassium channel
forms an octameric complex of KCNJ11 along with inclusion of ATP-binding cassette C8
(ABCC8), to form an ATP-responsive potassium channel that is an essential component in
the pathway for glucose-induced insulin secretion from the pancreatic beta cells.
Binding of SUs to the ABCC8 receptor, or interaction with glucose-derived ATP, blocks the
outflux of potassium from the pancreatic beta cell, subsequently leading to depolarization
and the opening of voltage-gated calcium channels, leading to the fusion of insulincontaining intracellular vesicles to the cell membrane and release of insulin from the beta
cell (61).
Mutations in ABCC8 and KCNJ11 are most often associated with transient or permanent
neonatal diabetes, or neonatal hypoglycemia (61, 63). In cases of transient neonatal
hypoglycemia or diabetes, these patients will often re-present later in life with diabetes
(63). It is unclear if mutations in ABCC8 are truly associated with MODY, or more
appropriately a cause of neonatal conditions that may have been missed until they re12

present at a later age. Mutations in KCNJ11 have been associated in two separate kindreds
with MODY phenotypes (62). Individuals with these mutations who develop diabetes later
in life generally respond well to SUs.
1.6.2.12 APPL1-MODY (MODY 14):
APPL1-MODY is caused by mutations in the APPL1 gene, which encodes for adaptor protein,
phosphotyrosine interaction, PH domain, and leucine zipper-containing Protein 1, which
interacts in its role as an adaptor protein with several critical proteins in the insulinsignaling pathway (64). One of these key interactions is with the serine/threonine kinase
AKT, allowing AKT to translocate to the cell membrane, become phosphorylated and
propagate the insulin signal (64). While only limited data is available, this form of MODY
has shown later onset (average age onset ~38) and incomplete penetrance, suggesting
onset may be partially influenced by environmental factors (64).
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Table 1.3: Molecular and clinical features of MODY subtypes
Type/
OMIM

Prev.

Gene

Gene
Location

Gene Product
Description

Mechanism of
Deficiency

Age of Onset

Hyperglycemia
Severity

Microvascular
Complications

Treatment

Other features

MODY1

510%

Hepatocyte
nuclear factor 4-α

20q13.12

Transcription
factor
regulating
transcription of
many genes,
involved in βcell
development
and function,
including
HNF1α

Impaired
glucosedependent
insulin
release;
decreased Bcell mass over
time

Adolescence/ early
adulthood

Severe,
progressive

Frequent

OHA (SU) >>
insulin

Low TG, HDL,
high LDL.

7p13

Phosphorylates
glucose into
glucose-6phosphate;
regulates
carbohydrate
catabolism

Defective
glucose
sensing

Childhood (birth)

Mild

Rare

None often;
monitor in
pregnancy

125850

(HNF4α)

(29, 36,
38-40,
42, 65,
66)

MODY2

3070%

125851

Glucokinase
(GCK)

(29, 36,
38-40,
42, 66,
67)
MODY3

3070%

Hepatocyte
nuclear factor 1-α
(HNF1α)

12q24.31

Transcription
factor
regulating
transcription of
many genes,
involved in βcell
development
and function

Impaired
glucosedependent
insulin
release;
decreased Bcell mass over
time

Adolescence/ early
adulthood

Severe
progressive

Frequent

OHA (SU) >>
insulin

Low renal
glucose
threshold; high
HDL

<<1%

Pancreatic and
duodenal
homeobox 1
(PDX1)

13q12.2

Transcription
factor necessary
for pancreatic
development
and β-cell
maturation.
Role in insulin
gene expression

Impaired
pancreatic
development;
impaired
expression of
islet hormones

Early adulthood

Mild,
progressive

Minimal data

diet, OHA,
insulin

Pancreatic
agenesis if
homozygous

600496
(29, 36,
38-40,
42, 6567)
MODY4
606392
(29, 36,
38-40,
42, 65)

14

MODY5

510%

137920

Hepatocyte
nuclear factor 1β

17q12

Transcription
factor involved
in embryonic
development
and ongoing
function of
pancreas, liver,
kidneys,
genitals and gut

Impaired
glucosedependent
insulin
release;
insulin
resistance

Adolescence/ early
adulthood

Severe,
progressive

Retinopathy
seen; Prone
to early ESRD

insulin > OHA

2q31.3

Transcription
factor involved
in development
of endocrine
cell lineages.
Regulates
expression of
insulin, GCK and
GLUT2 genes

Impaired
insulin gene
expression;
abnormal islet
morphology

Adolescence/ early
adulthood

Minimal data.

Frequent
nephropathy

insulin > OHA

(HNF1β)

(29, 36,
38-40,
42, 65)

MODY6

<1%

606394

Neurogenic
differentiation 1
(NEUROD1)

(29, 36,
38, 42,
65)

MODY7

<<1%

Kruppel-like
factor 11 (KLF11)

2p25.1

Activates the
insulin
promoter in
response to
hyperglycemia

Impaired
glucosedependent
insulin release

Minimal data

Minimal data

Minimal data

Minimal data

<<1%

carboxyl-ester
lipase (CEL)

9q34.13

Enzyme
produced by the
adult pancreas
and aids in the
digestion of fats

Likely
destruction of
beta cells over
time due to
pancreatic
infiltration

Minimal data

Minimal data

Minimal data

Minimal data

<<1%

Paired box gene 4
(PAX4)

7q32.1

Member of the
paired box
(PAX) family of
transcription
factors.
Involved in
pancreatic islet
development

Defective
beta-cell
development;
impaired betacell
proliferation

Minimal data

Minimal data

Minimal data

Minimal data

610508
(38, 51)
MODY8
609812
(38, 65)
MODY9
612225
(56)
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Renal
cysts/failure;
genital
malformations;
pancreatic
atrophy; high
uric and
transaminases;
low Mg

Pancreatic
atrophy;
Exocrine
pancreatic
dysfunction

MODY10

<1%

Insulin (INS)

<<1%

B lymphocyte
kinase (BLK)

11p15.5

613370
(38, 57,
65)
MODY11
613375

8p23.1

(59)

MODY12

Minimal data

Rare

diet alone,
OHA (SU) >
insulin

Expression may
be triggered by
increasing
weight

Tyrosineprotein kinase
that modulates
insulin synthesis
and secretion;
upregulates
PDX-1

Impaired
glucosedependent
insulin release

Adolescence/early
adulthood

Minimal data

Minimal data

Minimal data

Expression may
be triggered by
increasing
weight

11p15.1

Target for SUs.
Binding domain
for ATP in ATPsensitive K+
channels

Impaired
glucosedependent
insulin release

Childhood

Minimal data

Minimal data

OHA (SU*) >
insulin

Not clearly
causal for
MODY;
associated with
permanent
neonatal
diabetes

<<1%

potassium
channel
subfamily J,
member 11
(KCNJ11)

11p15.1

ATP-sensitive K+
channel;
couples cell
metabolism to
membrane
excitability

Impaired
glucosedependent
insulin release

Minimal data

Minimal data

Minimal data

OHA (SU*) >
insulin

Often
associated with
permanent
neonatal
diabetes

<<1%

Adaptor Protein,
Phosphotyrosine
Interaction, PH
domain, and
Leucine Zippercontaining
Protein 1

3p14.3

Involved in
regulation of
endocytosis,
signal
transduction
and mitogenesis
through RAB5
pathway

Impaired
glucosedependent
insulin release

Early to mid
adulthood

Mild to
moderate

Minimal data

Diet/OHA/

Shows later
onset (average
age onset ~38),
incomplete
penetrance;
onset may be
influenced by
environmental
factors

(38, 62,
65)

616511
(64)

Childhood

ATP-binding
cassette C8
(ABCC8)

616329

MODY
14

Abnormal
posttranslational
processing of
insulin

<<1%

(61)

MODY13

Peptide
hormone
produced by β
cells; regulates
metabolism of
carbohydrates
and fats

insulin

(APPL1)

abbreviations: OMIM, Online Mendelian Inheritance in Man; Prev., prevalence; Tx, Treatment; OHA, oral hyperglycemic agent; SU, sulfonylurea; TG,
triglycerides; *high dose
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Figure 1.1: Pancreatic beta cell signalling pathway with MODY gene products identified
Within the pancreatic beta cell, insulin is synthesized from the INS gene under the control of
number of transcription factors. Insulin is subsequently packaged into vesicles for release
into the extracellular space and transport to target organ tissue receptors throughout the
body. Circulating blood glucose enters the beta cell through the GLUT2 glucose
transporters on the beta cell surface. Glucokinase (GCK) then catalyzes the first step in the
breakdown of glucose through glycolysis. The ATP generated from glucose catabolism leads
to closure of the ATP-gated potassium channel. This leads to beta cell depolarization and
the opening of voltage-gated calcium channels. The subsequent influx of calcium leads to
the expulsion of vesicle-stored insulin from the beta cell into circulation. Insulin binds to its’
receptors on target tissues, allowing for the expression of GLUT4 receptors on the cellular
surface and glucose uptake. Genetic alterations that affect several points in this pathway
have been linked to MODY and to other forms of genetic glucose dysregulation. The class of
medications known as the sulfonylureas (SUs) act by binding to the ATP-gated potassium
channels, promoting the subsequent steps leading to insulin release in the absence of a
glucose signal.
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1.6.3 Suspecting MODY clinically:
Before the causative genes were defined, MODY was recognized to follow vertical
transmission in families (36, 39, 40). Characteristic features of MODY are shown in (Table
1.4) and include onset before age 25 with a strong multi-generational family history of
diabetes and an autosomal dominant pattern of inheritance (29, 38-40, 66-68). Other
features include non-insulin dependence with detectable circulating C-peptide levels for five
years following diagnosis, absence of autoantibodies, no episodes of diabetic ketoacidosis
and prolonged survival after onset of symptoms (38-40). MODY patients are also generally
not overweight and lack other physical features associated with insulin resistance such as
acanthosis nigricans (39, 40).
Suggestive features for MODY include: 1) age of diagnosis <25 years; 2) normal BMI; 3) noninsulin dependence or no episodes of diabetic ketoacidosis (DKA); 4) a strong family history
following an autosomal dominant (AD) inheritance pattern, although de novo mutations are
possible (69); and 5) robust response to SU treatment in some forms.
Clinical prediction calculators, and other diagnostic tools, are also available to aid clinicians
in selecting patients who may benefit from genetic testing (70, 71). Strategies that
incorporate the use of fasting blood sugars and response to an oral glucose tolerance test to
predict a potential MODY diagnosis may also be effective as a screening tool (72).
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Table 1.4: Clinical factors that raise suspicion for maturity onset diabetes of the young
(MODY)

Key Features

Age at diagnosis <25 years
Family history of diabetes (>2 generations)
Autosomal dominant inheritance pattern

Supporting Evidence

Non-obese or non-overweight patient
Negative autoantibodies
Non-ketotic in absence of insulin therapy
Non-insulin dependence or significant C-peptide levels while on
insulin for at least 5 years after diagnosis
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1.6.4 Health and management implications of MODY diagnosis:
A diagnosis of MODY can significantly alter the management and expected clinical course of
diabetes (34). Consequently, suspecting and confirming a diagnosis can be important for
optimal patient care.
As outlined above, specific treatment recommendations depend on the MODY subtype
identified (50, 73-75). For example, MODY2, caused by mutations in GCK, is a benign, nonprogressive form of mild hyperglycemia that does not require monitoring or management
(34, 73, 76). MODY1 and MODY3 are caused by mutations in HNF4A and HNF1A,
respectively, and can often be managed with low-dose sulfonylurea (SU) monotherapy for
many years, with significantly improved glycemic control compared to insulin or other oral
agents (77). MODY5, caused by mutations in HNF1B, is associated with other
manifestations that warrant regular screening, such as renal or hepatic cysts,
hypomagnesemia, hyperparathyroidism or exocrine pancreatic insufficiency (46, 47, 73).
Recommendations for optimal management of hyperglycemia in pregnancy are also
different for individuals with MODY, who may be misdiagnosed as having gestational
diabetes (GDM), or type 1 or type 2 diabetes during routine pregnancy screening, and can
depend on the genotype of the offspring. Pregnancy may also be a time when many
women are found to have previously unidentified hyperglycemia, and the prevalence of
MODY amongst women presumptively diagnosed with GDM has been estimated to be
approximately 5% (78).

1.6.5 Cost-Benefit of genetic testing for MODY:
There can be a significant financial benefit to establishing a diagnosis of MODY, especially if
the individual was misdiagnosed with type 1 diabetes, which may allow for discontinuation
of insulin and switch to a low dose oral SU with improved glycemic control. Similarly a
diagnosis of GCK-MODY would prompt discontinuation of surveillance, treatment or follow
up for diabetes, which could result in significant cost-savings.
One Australian study conducted a cost-benefit analysis of universal MODY screening using a
multi-gene sequencing panel (cost estimated at $500 Australian dollars (AUD)/test) in all
patients with presumed type 1 diabetes (79). In this model, incremental costs and quality
adjusted life years gained from universal MODY screening were modelled over a 30 year
period. The model estimated a MODY detection prevalence of 2.14% with universal
screening, compared to 0.7% in standard practice, and the estimated rates of successful
conversion to SU, improvements in HbA1c and proportion of GCK-MODY patients in whom
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treatment could be discontinued (79). The model reported multi-gene panel sequencing
for MODY was less costly than standard care, with 26 quality adjusted life years (QALYs)
gained and $1,016,000 AUD saved per 1000 patients screened. Cost of screening was fully
offset within 10 years. Universal screening remained cost-effective until prevalence rates
fell below 1.1% (79). Further selecting presumed type 1 patients based on absence of
autoantibodies and preserved c-peptide levels could further improve the cost effectiveness,
with these selection criteria yielding a detection rate of 1 case of MODY detected for every
5 patients tested (80).

1.6.6 Suspecting MODY:
Despite the benefits of optimized management seen when individuals are correctly
identified as having MODY diabetes, several studies have suggested that MODY is undersuspected and under-recognized clinically, and therefore under-diagnosed by genetic
confirmation. In a UK cohort of 74 children diagnosed with presumptive type 1 diabetes,
who had persistent insulin reserve, as demonstrated by detectable c-peptide levels and
negative autoantibodies, 20 (27%) were ultimately re-classified as MODY following genetic
testing (81). Similarly, in a US cohort of 586 pediatric patients with diabetes, insulin reserve
and negative autoantibodies, 47 (8%) were re-classified as MODY following genetic testing
for causal variants in GCK, HNF1A and HNF4A (82). In another US study that assessed
individuals presumptively diagnosed with type 2 diabetes under the age of 30, or under the
age of 45 with no features of metabolic syndrome, testing for GCK, HNF1A and HNF4A
reclassified 13 (4%) of subjects as having MODY diabetes (83).
The barriers to recognition of these cases may include a bias towards diagnoses of the more
common diabetes subtypes (type 1 or type 2 diabetes). Suspecting a diagnosis can also be
more challenging given the fact that the features of MODY can also overlap with other
diabetes classifications. Furthermore, a significant barrier may be the lack of available
and/or affordable genetic testing to confirm these diagnoses. This work examines the role
of provider clinical suspicion coupled with available NGS testing in ultimately making a
MODY diagnosis in chapter 2.2.

1.6.7 Confirming a genetic diagnosis:
Confirmation of MODY is via genetic testing to rule out mutations in one of the 14 known
causative genes (29, 31, 33, 39, 44, 66, 67, 84) (Table 1.3).
Early genetic testing for MODY was often accomplished by Sanger sequencing, using a stepwise candidate gene approach. More recently, however, there has been a shift to primarily
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using NGS techniques, which allow for the identification of SNVs, small-scale insertions or
deletions, as well as small-scale frameshift and null mutations for multiple MODY genes
simultaneously (44, 66, 85, 86). However, neither of these sequencing methods are
optimized to detect large-scale CNVs (87).

1.6.8 Copy number variations in MODY:
CNVs are large-scale deletions or duplications of DNA that may encompass part of a gene, a
whole gene, or several contiguous genes (88-90). Traditionally CNVs were difficult or
impossible to detect using sequencing technology. This was due to the fact that the
affected sequence of duplicated or deleted genomic DNA in a CNV appears qualitatively
normal, but there is instead a quantitative change affecting the dosage of genetic material,
CNVs can be difficult to detect and confirm with traditional sequencing methods that are
optimized to detect small qualitative changes in the genetic code. Without a robust
quantitative analytical tool, even when there appears to be an increase or decrease in the
amount of genetic material replicated in certain DNA sections, it is impossible to distinguish
a true deletion or duplication from the natural variability in chemical amplification of DNA
that is used in most sequencing platforms (Figure 1.2, Figure 1.3)
In the past, a separate methodology, such as high definition cytogenetic analysis, or
comparative genomic hybridization with DNA microarrays or multiplex dependent primer
amplification (MLPA) were required. Secondary non-sequencing-based dedicated targeted
DNA analytical methods using specific probes to assess for CNVs are costly and of uncertain
value in MODY, although a few gene deletions have been detected this way (33, 91).
Recently, new bioinformatic techniques have been developed to provide the robustness
needed to assess for CNVs using NGS output data, without requiring additional testing.
These tools may offer a cost-effective strategy to increase diagnostic accuracy for MODY.
These methods take advantage of the fact that current NGS protocols generate large
numbers of short partially overlapping DNA fragments that are assembled computationally
to seamlessly reflect the genomic sequence of the source material (87). In addition, the
total number of these synthetically-generated DNA fragments reflects the amount of
starting material in the genome. This has enabled the development of new algorithms that,
through tallying the numbers of chemically-generated DNA fragments, can impute
deviations in the amount of starting material from the normal diploid two copies (i.e.
maternal and paternal) for any particular chromosomal region. This approach has
successfully been applied to detect CNVs using NGS data for several genes causing
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dyslipidemias (6, 89, 92, 93). This work attempts to validate this method of CNV detection
for MODY and clarify the value of seeking CNVs for this condition in chapter 2.3.

1.6.9 Case finding:
Given the potential positive impact on both quality of life and optimization of management
that results from making a MODY diagnosis, ensuring that optimal methods of identifying
individuals that are likely to benefit from testing, and ensuring that the genetic tests used
are comprehensive and cost effective are important goals.
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Figure 1.2: Copy number variations
In large-scale deletion and duplication events, or copy number variations, amplified
sequences appear normal in standard NGS analysis.
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Figure 1.3: Using Depth of Coverage ratios to identify suspected deletions or duplications
Following polymerase chain reaction (PCR) amplification of a region of interest, amplified
sequences from starting material containing either a deletion or duplication appear
qualitatively normal. There is a natural degree of variation in the number of copies of each
section of DNA that is amplified. It can therefore be difficult to ascertain if the number of
copies amplified by PCR represents a normal complement state or a duplication or deletion
state, making determination of copy number variation (CNV) challenging. A statistically
significant difference in the ratio of depth of coverage (DOC; i.e. the number of copies of
amplified DNA containing the region of interest) in the affected individual when compared
to a reference population sequenced using the same panel and conditions is suggestive of a
possible CNV. A ratio of approximately 0.5 would be suggestive of a deletion. A ratio of 1.5
or higher would be suggestive of duplication.
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1.7 Hypertriglyceridemia:
Hypertriglyceridemia (HTG) is a common clinical diagnosis, sometimes defined when plasma
triglyceride (TG) concentration rises above a threshold value, such as the 90th or 95th
percentile for age and sex. HTG frequently co-exists with secondary conditions, including
poor diet, alcohol use, obesity, metabolic syndrome, and type 2 diabetes (94, 95). HTG
is sometimes classified as primary, when a familial or inherited basis is suspected, or
secondary, when one or more secondary factors contribute to the clinical presentation (94).
Genetic factors can also influence the severity of the plasma TG elevation in the presence of
a secondary factor (95).

1.7.1 Clinical Diagnosis of HTG
HTG is usually a biochemical diagnosis, based on fasting plasma TG concentration above a
certain cut point. For instance, the 95th percentile for plasma TG is ~3.0–3.4 mmol/L for
North American adults. Severe HTG is sometimes diagnosed as fasting plasma TG
concentration >10 mmol/L (885mg/dL) or >1000mg/dL (11.2 mmol/L) (94-98). Proposed
HTG definitions vary (Table 1.5). For instance, the Adult Treatment Panel III guidelines of
the National Cholesterol Education Program has suggested four discrete categories: normal
fasting TG is <1.7 mmol/L (<150 mg/dL), borderline high TG is 1.7–2.3 mmol/L (150–199
mg/dL), high TG is 2.3–5.6 mmol/L (200–499 mg/dL) and very high TG is >5.6 mmol/L (>500
mg/dL) (99). The Endocrine Society has proposed another system with five clinical strata:
normal TG is <1.7 mmol/L (<150 mg/dL), mild HTG is 1.7–2.3 mmol/L (150–199 mg/dL),
moderate HTG is 2.3–11.2 mmol/L (200–999 mg/dL), severe HTG is 11.2–22.4 mmol/L
(1000–1999 mg/dL) and very severe HTG is >22.4 mmol/L (>2000 mg/dL)(100). Other
systems have been proposed, but no single scheme has become predominant in the clinic.
A well-established classification system—known as the Fredrickson or World Health
Organization (WHO) International Classification of Diseases (ICD) hyperlipoproteinemia
(HLP) phenotypes—is based on patterns of lipoprotein fractions (Table 1.6) (95, 96, 101),
though this classification system is largely being replaced due to improved understanding of
the molecular etiology of triglyceride states.
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Table 1.5: Hypertriglyceridemia: some proposed clinical definitions.
General clinical definition

Category
Normal

Serum TG
(mmol/L)
<2.3

Hypertriglyceridemia 2.3-10

NCEP Guidelines

Category

Serum TG
(mmol/L)

Endocrine Society

Category

Serum TG
(mmol/L)

Normal

<1.7

Normal

<1.7

Borderline
High

1.7-2.3

Mild

1.7-2.3

Moderate

2.3-11.2

Severe
hypertriglyceridemia

>10

High

2.3-5.6

Severe

11.2-22.4

Very Severe
hypertriglyceridemia

>20

Very high

>5.6

Very severe

>22.4

Abbreviations: TG, triglyceride; NCEP: National Cholesterol Education Program
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Table 1.6 Classification of hypertriglyceridemia (modified Fredrickson)
Primary
Lipoprotein
Abnormality

Lipid
Profile

Familial
chylomicronemia (HLP
type 1)

Elevated
chylomicrons

↑↑↑
TG

Combined
hyperlipidemia (HLP
type 2B)

Elevated VLDL,
Elevated LDL

↑↑TG

Dysbetalipoproteinemia
(HLP type 3)

Elevated IDL,
Elevated
chylomicron
remnants

Primary simple
hypertriglyceridemia
(HLP type 4)

Elevated VLDL

Name

Clinical manifestations

Population
Prevalence

- Cutaneous eruptive xanthomata,
lipemia retinalis, failure to thrive,
recurrent epigastric pain,
hepatosplenomegaly,
pancreatitis, focal neurologic
symptoms

1 in 1
million

1 in 40

↑↑TC

- Physical stigmata such as
xanthomas or xanthelasmas are
uncommon;

↑↑TG

Tuberous and palmar xanthomata

1 in 10,000

↑↑TC

Elevations in atherogenic IDL
results in increased risk for CVD

↑TC

Associated with increased risk of
CVD, obesity, DM2, hypertension,
hyperuricemia, insulin resistance

1 in 20

↑↑↑
TG

Similar clinical manifestations as
Type I but develops in adulthood

1 in 600

↑↑↑
TC

Frequently exacerbated by
secondary factors

↑↑TG
↑TC

Primary mixed
hyperlipidemia (HLP
type 5)

Elevated
chylomicrons,
Elevated VLDL

Abbreviations: as in Table 1.5, plus: HLP, hyperlipoproteinemia; TC, total cholesterol; VLDL,
very-low-density lipoprotein; LDL, low-density lipoprotein; IDL, intermediate density
lipoprotein; TG, triglyceride.
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1.7.2 Chylomicronemia:
Chylomicronemia is characterized by the pathological persistence of chylomicrons in the
serum, usually manifest with TG levels >10 mmol/L, after a fasting period of 12–14 h (9496). In individuals with normal metabolism (Figure 1.4), chylomicrons are cleared from
plasma within 3–4 h of eating (94-96, 102, 103).

1.7.3 Primary Hypertriglyceridemia:
The genetic basis for primary chylomicronaemia is heterogeneous. Before the human
genome era, all primary HTG was thought to be monogenic, by analogy with other
monogenic lipid disorders, namely FH. But while FH results from mutations of strong effect
in genes that perturb low-density lipoprotein (LDL) receptor function and visibly segregate
with high LDL cholesterol concentrations in family pedigrees, most cases of familial HTG are
polygenic rather than monogenic disorders (95-97, 104). This critical distinction is necessary
for any current review of this topic.
While cases of HTG cluster in families, HTG within a family does not typically follow classical
Mendelian patterns of inheritance. HTG does not consistently show vertical transmission in
family pedigrees. But the idea that most HTG states are monogenic has persisted in the
literature and textbooks over decades, likely because the term familial is included in the
names of several classical primary HTG disorders. However, a familial disorder should not be
confused with a monogenic disorder: while many HTG cases are familial, they are usually
not monogenic (95-97, 104).
The term ‘familial chylomicronaemia’ (formerly known as type 1 hyperlipoproteinaemia
(HLP) has traditionally referred to the subgroup that has a monogenic basis. Monogenic
chylomicronaemia results from loss-of-function mutations within genes that encode key
check-point molecules in lipolysis (105). These disorders typically show autosomal recessive
inheritance, with onset in childhood or young adulthood, often associated with failure to
thrive and pancreatitis together with relatively low levels of all other classes of lipoprotein
fractions. The estimated population prevalence of this rare phenotype is ~1 in 1 million (9496). In contrast, the overall population prevalence of individuals with fasting triglyceride
levels >10 mmol/L from polygenic or secondary causes is ~1:600 adults in the general
population.
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1.7.4 Clinical Features of Chylomicronemia:
Development of physical findings in HTG is less common today that in the past, likely due to
earlier diagnosis and treatment. Presence of physical findings is generally related to the
degree of TG elevation.
Familial chylomicronemia or familial chylomicronemia syndrome (FCS) often presents during
infancy or childhood, and generally becomes manifest by adolescence (94, 102). Clinical
features include failure to thrive, eruptive xanthomas, lipemia retinalis,
hepatosplenomegaly, recurrent abdominal pain, nausea and vomiting, and risk of acute
pancreatitis (102, 106). Less common clinical features include intestinal bleeding, pallor,
anemia, irritability, diarrhea, seizures and encephalopathy (102, 106).
Plasma from individuals with chylomicronemia appears lipemic: turbid and milky (106). If
allowed to settle overnight, it develops a cream-like supernatant above a virtually clear
infranatant (94). Fasting serum TG concentration is generally >10 mmol/L), and sometimes
can exceed 100 mmol/L (107). Concomitant lipid abnormalities include a modest elevation
in serum total cholesterol, with decreases in LDL and HDL cholesterol (94).
Eruptive xanthomas appear on extensor surfaces of the extremities, the buttocks and the
shoulders as raised crops of small yellowish papules encircled by erythematous halos (108).
Xanthomas erupt when plasma TG is severely elevated, and gradually disappear over weeks
to months as TG levels improve (109). Microscopically, xanthomas contain lipid-laden
macrophages (foam cells) within the superficial reticular dermis, as well as infiltrations of
lymphocytes and neutrophils (108).
Lipemia retinalis refers to a whitish-pink appearance of retinal vessels on fundoscopic
examination, and is due to the presence of chylomicron-rich serum. This finding is more
likely to be present when TG is > 30 mmol/L) (94). Vision is unaffected (109).
Hepatosplenomegaly is also related to the degree of TG elevation and results from lipid
accumulation within cells of the reticuloendothelial system. Hepatosplenomegaly is rapidly
reversible with correction of plasma TG levels (94).
Patients with familial chylomicronemia have increased lifelong risk of recurrent pancreatitis
(110). Pancreatitis due to HTG can be serious and sometimes fatal, (mortality 5-6% overall)
(111-115). Retrospective studies have shown that at least 15% of patients with severe
hypertriglyceridaemia have a history of pancreatitis (116) with five-year rates of pancreatitis
of at least 3.5% (117). Although most patients present with low-risk clinical features,
mortality can approach 30% in select subgroups with severe clinical symptoms (111-115).
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The highest mortality has been linked to the development of pancreatic necrosis in patients
who also develop infected abscesses or have persistent multiple organ failure (113-115).
The absolute and relative risks of developing pancreatitis increase when triglyceride levels
are >10 mmol/L (94, 106, 118) and sharply increase when triglyceride levels are >20 mmol/L
(116).
Pancreatitis in patients with HTG is hypothesized to be a consequence of the pathological
release of normally exocrine pancreatic lipase into local pancreatic capillaries, which results
in partial lipolysis of lipoproteins and generates free fatty acids that prematurely activate
trypsinogen and lead to autodigestion of the pancreas (94, 112, 118). Increased
chylomicrons might further worsen the process by causing capillary plugging and local
ischemia (94, 118). Risk of pancreatitis in patients with chylomicronaemia is markedly
reduced after lower triglyceride levels are achieved (119).
The relationship between chylomicronaemia and atherosclerotic cardiovascular end points
is less well understood. In monogenic chylomicronaemia (ie FCS), the occasional reports of
premature atherosclerosis seem to be the exception and corroborate the clinical rule that
elevated chylomicrons in isolation are not atherogenic (120). Younger patients with
chylomicronemia are less prone to develop ASCVD than patients with other lipid disorders
(121). Autopsies of some familial chylomicronemia patients showed no significant burden of
atherosclerosis (107), possibly because chylomicrons are too large to penetrate the
endothelial surface (107). In addition, LDL cholesterol is relatively low in patients with
chylomicronemia (107). Small case studies suggest that some patients with
chylomicronemia can still develop premature atherosclerosis (107). However, the presence
of atherosclerosis in this situation could have been due to pro-atherogenic effects of
modified chylomicron remnants, or to the impact of low HDL cholesterol in these patients
(107).
However, in polygenic chylomicronaemia there is a much broader range of associated lipid
disturbances, including increased levels of apolipoprotein B-48 (apoB-48)-containing
chylomicron remnants, as well as increased levels of apoplipoprotein B-100 (apoB-100)containing VLDL, VLDL remnants and intermediate density lipoproteins (IDL), together with
reduced levels of HDL (122). Chylomicronaemia in this instance is a marker for postprandial
lipaemia, which is increasingly being appreciated as a proatherogenic metabolic state (122).
In particular, triglyceride-rich lipoprotein remnants that accumulate postprandially, both of
intestinal origin (apoB-48-containing chylomicron remnants) and of hepatic origin (apoB100-containing VLDL remnants) are considered to be proatherogenic (109), although
standardized procedures for measuring these entities in the clinic have proven to be elusive.
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While large triglyceride-rich particles such as chylomicrons and VLDL cannot cross the
endothelial membrane, smaller VLDL or other triglyceride-rich remnant particles may be
able to enter the artery walls, and lead to atherosclerotic change (123, 124). Furthermore,
when triglyceride levels are elevated, cholesterol ester transport protein (CETP) mediates
the transfer of triglycerides from chylomicrons and VLDL to LDL and HDL in exchange for
cholesterol ester (CE) from LDL and HDL, leading to CE-enriched remnant particles and a
shift towards smaller, denser LDL particles, which may both contribute to an atherogenic
environment (123, 125, 126).

1.7.5 Molecular Basis of Monogenic Chylomicronemia:
Patients with fasting triglyceride levels >10 mmol/L probably have a component of
chylomicronaemia and should be investigated following a step-wise approach. First,
evidence of clinical features of chylomicronaemia syndrome should be sought and
secondary causes such as uncontrolled type 1 or type 2 diabetes mellitus, hypothyroidism,
poor diet, alcohol use, nephrotic syndrome or use of associated medications should be
ruled out (94). For younger patients with few or no secondary factors a monogenic cause
can be searched for, of which LPL deficiency is the most probable cause. In the past,
biochemical studies were used to determine whether LPL or apoC-II activities were
depressed or deficient (107, 120, 121), but today gene sequencing has become the
diagnostic method of choice. At the DNA level, patients with monogenic
hyperchylomicronaemia have homozygosity or compound heterozygosity for rare loss-offunction mutations in causative genes, such as LPL, APOC2, APOA5, LMF1 or GPIHBP1 (127,
128). These genes can be included as part of a targeted next-generation sequencing
diagnostic panel for monogenic dyslipidaemias (129). Having a molecular diagnosis could
aid in the early identification of at-risk family members and also in establishing candidacy
for emerging therapies targeting primary LPL deficiency, especially when patients present at
a young age. On the basis of the current standard of genetic investigation in these patients,
a new diagnostic classification of primary chylomicronaemia that is founded on a molecular
diagnosis might be warranted.
Monogenic chylomicronaemia typically presents in infancy or childhood, and by
adolescence at the latest (102, 103). The most common gene affected in these individuals is
LPL (encoding lipoprotein lipase; also known as LPL), in which loss-of-function mutations
account for >90% of cases (105) (Table 1.7). More than 114 mutations in LPL have been
described as leading to chylomicronaemia, including frameshift, missense and nonsense
mutations; however, no single mutation in LPL predominates (103, 105, 130-137). LPL
localizes to muscle and adipose tissue and catalyzes the hydrolysis and uptake of
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triglycerides into peripheral tissues (Figure 1.4) (138); in the absence of LPL, chylomicrons
accumulate in the plasma (102). Biallelic LPL deficiency has an estimated prevalence of 1 in
106, but has a carrier frequency of 1 in 40 persons in some founder populations (95).
Mutations in APOC2 are the second most frequently reported cause of monogenic
chylomicronaemia (103, 139-141). Mutations in other genes causing monogenic
chylomicronaemia are even rarer, with only a handful of kindreds described in the literature
for each. These other mutations include those in APOA5 (encoding the LPL cofactor
apolipoprotein A-V; commonly known as apoA-V), LMF1 (encoding the LPL chaperone lipase
maturation factor 1; also known as LMF1) and GPIHBP1 (encoding
glycosylphosphatidylinositol-anchored high density lipoprotein-binding protein 1; also
known as GPIHBP1. ApoA-V is believed to stabilize the lipoprotein–enzyme complex and to
enhance lipolysis; thus, when apoA-V is defective or absent, the efficiency of LPL-mediated
lipolysis is decreased (142, 143). Mutations in APOA5 have been described in 3 families
(142, 144-146). GPI-HBP1 directs the transendothelial transport of LPL and helps anchor
chylomicrons near LPL on the endothelial surface, thus supporting lipolysis. Mutations in
GPIHBP1 have been reported in 10 families (142, 144, 147-156). LMF1 is a chaperone
molecule required for the proper folding and expression of LPL on the endothelial cell
surface; mutations in LMF1 lead to reduced LPL expression and have been reported in two
families (96, 144, 157). It seems that apoA-V, LMF1 and GPIHBP1 are enhancers or
modifiers of chylomicron hydrolysis; carriers of recessive mutations in the genes encoding
these proteins tend to present later and with less severe phenotypes than individuals with
deficiencies in LPL and apoC-II (Table 1.7)(96, 144). However, given the rarity of monogenic
chylomicronemia, not much is known about the potentially different presentations
associated with these different molecular etiologies. This work attempts to expand on
current knowledge of these rare phenotypes in chapter 3.2.
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Table 1.7: Genetic basis of primary monogenic chylomicronaemia
Gene (gene
product)

Homozygote
prevalence

Gene product
role

Clinical features

Molecular
features

% of
monogenic
mutations

References

LPL (LPL)

~1 per
million(109)

Hydrolysis of
triglycerides
and peripheral
uptake [

Severe
chylomicronaemia
in infancy or
childhood

Severely
reduced or
absent LPL
enzyme activity

95

(109, 130, 134,
138)

APOC2 (apoCII)

10 families
reported

Required
cofactor of LPL

Severe
chylomicronaemia
in childhood or
adolescence

Absent or nonfunctional
apoC-II

2

(109, 139)

GPIHBP1 (GPIHBP1)

10 families
reported

Stabilizes
binding of
chylomicrons
near LPL

Chylomicronaemia
in late adulthood

Absent or
defective GPIHBP1

2

(149, 153)

Supports
lipolysis
APOA5 (apoAV)

3 families
reported

Enhancer of LPL
activity

Chylomicronaemia
in late adulthood

Absent or
defective
apoA-V

0.6

(142, 143)

LMF1 (LMF1)

2 families
reported

Chaperone
molecule
required for
proper LPL
folding and/or
expression

Chylomicronaemia
in late adulthood

Absent or
defective LMF1

0.4

(157)

Abbreviations: apoA-V, apolipoprotein A-V; apoc-II, apolipoprotein C-II; GPI-HBP1, glycosylphosphatidylinositol-anchored high
density lipoprotein-binding protein 1; LMF1, lipase maturation factor 1; LPL, lipoprotein lipase
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Figure 1.4: Triglyceride-rich lipoprotein metabolism.
Shaded molecules indicate those implicated in monogenic chylomicronaemia. Dotted lines
indicate a key functional role of the apolipoprotein in the indicated process. In normal
individuals, dietary fat is hydrolysed by pancreatic lipase, which requires emulsification with
bile salts. Fatty acids enter intestinal cells via fatty acid binding proteins. Triglyceride-rich
lipoproteins of intestinal origin are assembled in a multistep process requiring DGAT and
MTP, and through the lymphatics enter the circulation as chylomicrons, which are ~90%
triglycerides, with a small amount (1–3%) of cholesterol ester and surrounded by a
phospholipid envelope containing several apolipoprotein molecules, including the
chylomicron-specific apoB-48 as well as apoA-I, apoA-V, apoC-II, apoC-III and apoE.(102) By
contrast, endogenously derived triglyceride-rich lipoproteins of hepatic origin are
assembled de novo, also requiring MTP and DGAT, and circulating plasma within apoB-100containing VLDL particles. Chylomicrons are usually cleared from the circulation within
minutes by LPL-mediated hydrolysis, which is assisted by the essential cofactor apoC-II and
enhanced and stabilized by apoA-V (dashed lines indicate the facilitatory role of
apolipoproteins).(102, 158) Kinetic studies indicate that chylomicrons compete with VLDL
for saturable catabolism by LPL. GPIHBP1 directs the transendothelial transport of LPL, helps
anchor chylomicrons to the endothelial surface and enhances lipolysis.(102) Fatty acids
liberated by lipolysis are taken up by peripheral cells, where they can be oxidized for energy
or stored as triglycerides, depending on the cell type. After lipolysis, chylomicron remnants
are removed by the liver, likely through LRP1 receptor, which contrasts with postlipolytic
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VLDL remnants, most of which undergo further processing, ultimately resulting in LDL.
Abbreviations: A-I, apolipoprotein A-I (apoA-I); A-IV, apolipoprotein A-IV (apoA-IV); A-V,
apolipoprotein A-V (apoA-V); B-48, apolipoprotein B-48 (apoB-48); B-100, apolipoprotein B100 (apoB-100); C-II, apolipoprotein C-II (apoC-II); C-III, apolipoprotein C-III (apoC-III); DGAT,
diacylglycerol O-acyltransferase; E, apolipoprotein E (apoE); FABP, fatty acid-binding
protein; FAS, fatty acid synthase; FFAs, free fatty acids; GPI-HBP1,
glycosylphosphatidylinositol-anchored high density lipoprotein-binding protein 1; LRP1, LDL
receptor related receptor 1 ; LMF1, lipase maturation factor 1; LPL, lipoprotein lipase;
MTTP, microsomal triglyceride transfer protein.
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1.7.6 Polygenic or Complex HTG
Polygenic HTG has a complex genetic etiology. First, certain common small effect variants
(SNPs) are consistently overrepresented in the genomes of adult patients with all subtypes
of HTG (96, 97, 104, 159). Second, the genetic pool of adult HTG patients is enriched for rare
heterozygous large-effect mutations within genes that are associated with elevated plasma
TG levels (96, 97, 104). Finally, secondary factors can push a genetically susceptible
individual over the edge metabolically, resulting in clinical presentation (94).
Polygenic chylomicronaemia is also ‘familial’ in the sense that multiple predisposing genetic
variants cluster within families, although the disease trait does not show sharp vertical
transmission across generations. Instead, susceptibility results from the accumulation of
multiple genetic variants, which include both heterozygous rare variants with large
metabolic effects and common variants with small effects (that is, single nucleotide
polymorphisms (SNPs) )(95-98, 104, 159-162). These variants all reside on different
chromosomes and are co-inherited stochastically. Individual variants are insufficient to
cause a clinical phenotype, instead each variant incrementally increases the risk of
developing chylomicronaemia. When a sufficient number of these genetic variants are
simultaneously inherited, they cumulatively create a state of predisposition, which is further
modulated by secondary factors such as poor diet, obesity, alcohol intake and uncontrolled
type 1 or 2 diabetes mellitus. The metabolic phenotype in patients with polygenic
chylomicronaemia tends to be less severe than those with monogenic chylomicronaemia.
Individuals with polygenic chylomicronaemia tend to present later in life, usually as adults
and often not until middle age, and have lower levels of triglycerides, less severe physical
manifestations and fewer complications (102, 144) (Table 1.8).
The same SNPs identified in genome-wide association studies as being associated with
subtle variations in triglyceride levels in the healthy general population are also associated
with increased risk of severe hypertriglyceridaemia and chylomicronaemia (95-98, 103,
104). Heterozygous rare variants that in the homozygous state cause autosomal recessive
chylomicronaemia are also markedly over-represented in patients with polygenic HTG. The
proportions of patients with these heterozygous rare variants are ~15% and ~6% for HTG
patients and normolipidemic individuals, respectively (160, 163)}. Furthermore, in patients
with polygenic chylomicronaemia, the number of rare heterozygous variants found within
hypertriglyceridaemia-associated genes (discovered from SNP genotypes in genome-wide
association studies and from animal model studies) is increased (97). HTG patients as a
group have significantly higher polygenic risk scores (PRS) than normolipidemic patients
(159-161). A very high or very low genetic risk score can discriminate between HTG and
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normolipidemic subjects at the extremes of the distribution; however there is substantial
overlap of scores between patients and healthy subjects in the middle of the distribution (
96, 97, 104, 159).
Despite advances in our understanding of the genetic basis of both monogenic and
polygenic chylomicronaemia (Table 1.9), ~30% of patients with chylomicronaemia neither
have any recessive rare variants identified nor have an increased number of heterozygous
rare variants or common SNPs in known HTG-associated genes (105). This information
suggests that additional, as yet unidentified, genes or factors are be involved in the
development of chylomicronaemia.

38

Table 1.8: Common DNA polymorphisms associated with hypertriglyceridemia.
CHR

Gene

SNP

Risk allele

OR (95% CI)

P-value

11

APOA5

rs964184

G

3.43 (2.72–4.31) 1.12 × 10−25

2

GCKR

rs1260326

T

1.64 (1.36–1.97) 1.97 × 10−7

8

LPL

rs12678919

A

2.21 (1.52–3.22) 3.5 × 10−5

8

TRIB1

rs2954029

A

1.50 (1.24–1.81) 3.8 × 10−5

1

ANGPTL3

rs2131925

T

1.51 (1.23–1.85) 1.0 × 10−4

7

MLXIPL

rs7811265

A

1.63 (1.25–2.13) 3.3 × 10−4

4

KLHL8

rs442177

T

1.36 (1.13–1.64) 1.5 × 10−3

10

CYP26A1

rs2068888

G

1.29 (1.08–1.55) 5.9 × 10−3

19

CILP2

rs10401969

T

1.72 (1.16–2.54) 6.8 × 10−3

2

APOB

rs1042034

T

1.28 (1.02–1.61) 0.032

Abbreviations: CHR, chromosome; SNP, single nucleotide polymorphism; OR, odds ratio for
hypertriglyceridemia per risk allele; CI, confidence interval; APOA5, gene encoding
apolipoprotein A-V; LPL, gene encoding lipoprotein lipase; TRIB1, gene encoding Tribbles
homolog 1; ANGPTL3, gene encoding angiopoietin-like protein 3; MLXIPL, gene encoding
MLX interacting protein-like 1; KLHL8, gene encoding Kelch like protein 8; CYP26A1, gene
encoding cytochrome P450 26A1; CILP1, gene encoding cartilage intermediate layer protein
2; APOB, gene encoding apolipoprotein B (159-162).
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Table 1.9: Primary chylomicronemia: monogenic and polygenic forms
Features

Monogenic chylomicronaemia

Polygenic chylomicronaemia

Former designations

Familial chylomicronaemia
Type 1 hyperlipoproteinaemia
(WHO)(164)[

Mixed dyslipidaemia
Type 5
hyperlipoproteinaemia(164)
(WHO)

Main lipoprotein disturbances

Increased number of chylomicron
particles only(94, 165)

Transient increase in levels of
triglyceride-rich lipoproteins
Increased number of chylomicron
particles, Increased levels of VLDL
Increased number of chylomicron
remnants Increased levels of VLDL
remnants(109)

Associated lipoprotein
disturbances

Reduced levels of VLDL, LDL and
HDL

Usually reduced levels of HDL,
sometimes reduced levels of LDL

Typical onset

Paediatric or adolescent

Adulthood

Clinical features

Failure to thrive
Abdominal pain
Nausea
Vomiting
Eruptive xanthomas
Lipaemia retinalis
Pancreatitis
Hepatosplenomegaly(94)

Abdominal pain
Nausea
Vomiting
Eruptive xanthomas (rare)
Lipaemia retinalis (rare)
Pancreatitis (~1% risk per
year)(109)

Association with ASCVD

Minimal

Some evidence of increased risk
(121, 122)

Prevalence

~1:100,000 to ~1:1,000,000(109)

~1:600 (102)

Contribution of secondary
factors

Minimal

Major

Inheritence pattern

Autosomal recessive

Familiar clustering, but no discrete
classical pattern

Genetic causes

Mutation in LPL(109), APOC2(109),
APOA5(145), GPIHBP1(153) and
LMF1(157)

Genetic pool of affected
individuals has increased
prevalence of:
- heterozygous rare variants in LPL,
APOC2, APOB, GCKR, APOA5,
LMF1, GPIHBP1 and CREBH with
large effect(159, 161)
- common variants (SNPs) with
small effects in ~40 genes
identified in genome-wide
association studies(161)

Current treatment

Dietary control: restriction of fat
intake ± increased consumption of
MCTGs
Pharmacologic control: minimal
effect of fibrates, niacin, ω-3 fatty
acids, statins.

Dietary control: reduced intake of
calories, fats, simple sugars and
alcohol
Control of secondary factors
Pharmacologic control: ω-3 fatty
acids and niacin (both have
variable efficacy)

Abbreviations: CVD, cardiovascular disease; MCTGs, medium chain triglycerides; SNPs, single nucleotide
polymorphisms.
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1.7.7 Secondary Factors Contributing to Polygenic HTG
Most cases of adult-onset hypertriglyceridemia result, at least in part, from secondary
causes, often in conjunction with inherited partial impairment in TG metabolism (96, 166169), and are manifested only under conditions that increase TG production or impair
clearance. Previous studies have suggested that secondary causes of VS-HTG, include
obesity and metabolic syndrome, poorly controlled diabetes (170-172), diet with high
positive energy-intake balance and high fat or high glycemic index, excessive alcohol
consumption (165, 173, 174), pregnancy (particularly in the third trimester) (165, 173, 174),
nephrotic syndrome, severe hypothyroidism, oral estrogen or tamoxifen, glucocorticoids,
non-cardioselective beta blockers, bile acid sequestrants, cyclophosphamide, retinoids and
HIV antiretroviral regimens and second generation antipsychotic agents (94, 175, 176).
The actual mechanisms whereby these factors increase chylomicronemia risk are complex
and include increased production of triglyceride-rich lipoproteins, which could saturate
genetically compromised lipolytic machinery (165, 177). Alternatively, some factors may
directly down-regulate lipolysis, which could magnify partial impairment due to inherited
factors. While some work has been done to determine which of these factors are most
important in leading to the expression of severe triglyceride phenotypes, this is
incompletely understood. This work attempts to further this understanding in chapter 3.3.

1.7.8 Non-Pharmacologic Management
Non-pharmacologic therapy is the only therapy required in patients with borderline-high TG
levels (150–199 mg/dL). However, non-pharmacologic interventions (178) must be
optimized, since HTG is often exacerbated by modifiable factors. Non-pharmacologic
management includes: 1) strict glycemic control in patients with diabetes or impaired
glucose metabolism; 2) treatment with levothyroxine in patients with hypothyroidism; 3)
avoidance (if possible) of medications that increase TG (such as beta-blockers or thiazide
diuretics); 4) limitation or abstinence of alcohol; 5) avoidance of simple carbohydrates; 6)
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low fat diet (<30% of total daily caloric intake) and when TG level >10mmol/L, a very low fat
diet (<15% of total daily caloric intake); and 7) weight loss in patients who are overweight or
obese (94).
For patients with monogenic chylomicronaemia, the mainstay of therapy is a diet very low
in fat (15–25% of daily caloric intake), which equates to ~30–50 g of fat daily (102, 103).
Adherence to this diet can markedly improve the clinical manifestations of primary
chylomicronaemia, including resolution of hepatosplenomegaly, abdominal pain and
xanthomas, and a greatly reduced risk of pancreatitis. Unfortunately, such extreme diets are
difficult to maintain and long-term compliance, especially in younger patients, is poor.
Given this strict dietary regimen, supplementation with essential fatty acids (such as walnut
oil or sunflower oil topically) (179) and fat soluble vitamins must be considered. The support
of a dietician or nutritionist is also generally required for patients to achieve and maintain
low-fat intake targets. Introducing oils high in medium-chain triglycerides, such as coconut
oil, has had some anecdotal success in patients with chylomicronaemia, particularly in
young, growing individuals with a high-energy demand and also possibly in pregnant
women; the incorporation of medium-chain triglycerides into chylomicron particles is lower
than that of longer-chain fatty acids (157, 180).

1.7.9 Standard Pharmacologic Management
In addition to non-pharmacologic therapy, pharmacologic intervention using fibrates,
statins, niacin, ezetimibe, or fish oil may be required if TG ≥ 2.3 mmol/L. Note that bile acid
sequestrants should be avoided in patients with moderate to severe HTG due to their
potential for further increasing TG levels.
1.7.9.1 Fibrates
In patients with TG ≥ 5 mmol/L, fibrates such as gemfibrozil, bezafibrate, and fenofibrate
may be the preferred pharmacologic therapy. Fibrates may also be used in patients with TG
≥ 2.3 mmol/L to help attain non-HDL cholesterol targets after LDL cholesterol target have
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been met. Fibrates are weak agonists of peroxisome proliferator-activated receptor (PPAR)α and lower TG by up to ~40-60% by: 1) inhibiting hepatic synthesis and secretion of TG; and
2) stimulating degradation of TG-rich lipoproteins (181). However, while randomized clinical
trials clearly demonstrate the TG-lowering efficacy of fibrates, they have shown inconsistent
impact on reduction of ASCVD (182-191).
1.7.9.2 Niacin
Niacin (nicotinic acid or vitamin B3, in high doses) is a therapeutic option for patients
with TG ≥ 2.3 mmol/L who are unable to attain their non-HDL cholesterol goals, and also for
patients with TG ≥ 5 mmol/L. It acts in the liver to decrease VLDL production via
Diacylglycerol acyltransferase-1 (DGAT-1) inhibition and peripherally by increasing LPL
sensitivity (192). Given crystalline niacin’s main side effect of flushing and vasodilation,
extended-release preparations of niacin (ERN) are preferred for use compared to niacin or
nicotinic acid. Doses of 500–2000 mg of ERN can lower TG by 5%–35% (193).
1.7.9.3 Omega-3 Fatty Acids
The exact mechanism of action of omega-3 fatty acids (PUFAs) is unknown but is proposed
to be related to a number of effects including inhibition of hepatic TG synthesis and VLDL
secretion, decreased TG content of VLDL and increased FFA oxidation, with some of this
action mediated through Apo CIII inhibition (194, 195). PUFAs are available in two forms,
docosahexaenoic acid (DHA) and Eicosapentaenoic acid (EPA) and when consumed in
quantities of 2-4g/day have been shown to reduce TG by 20-50% (194, 196). The TGlowering efficacy is related to baseline TG values (197). They are generally well tolerated,
with minimal side effects other than a concern for increased LDL with DHA use, thought to
be due to the increased conversion of VLDL to IDL (194). Occasional mild gastrointestinal
side effects of nausea and diarrhea may also occur in up to 27% of individuals taking a dose
of 4g/day (198).
There are three prescription formulations of omega 3 fatty acids available in the United
States: 1) omega 3 fatty acid ethyl esters (EPA + DHA, ie Lovaza (Glaxo-Smith-Kline), Omacor
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(Reliant Pharmaceuticals)); 2) icosapent ethyl (EPA, ie Vascepa (Amarin Pharma)); and 3)
omega 3 carboxylic acids (EPA, DHA and docosapentaenoic acid (DPA), ie Epanova
(AstraZeneca))(198, 199). Vascepa has also been approved for use by Health Canada.
1.7.9.4 Statins
Statins act through inhibition of hydroxyl-methyl-glutaryl coenzyme A (HMG-CoA) reductase
to prevent de novo cholesterol synthesis in the liver, thereby causing increased expression
of the LDL receptor and increased removal of cholesterol from the bloodstream (192, 200202). Their effect on plasma triglyceride levels may be due in part to increased large TG-rich
lipoprotein lipolysis and increased plasma clearance of remnant particles (192, 201-203). In
addition, statins may have pleiotropic effects, including anti-inflammatory, anti-thrombotic,
and anti-proliferative properties that may prevent plaque growth and rupture (204). Statins
also have proven cardiovascular morbidity and mortality benefit.
Individual statins have varying efficacy and potency but generally reduce TG in a dose
dependent manner by 10-30%, with greater efficacy in patients with higher baseline TGs
and with rosuvastatin and atorvastatin having the most robust effect (200, 205-209).
Statins are relatively ineffective in lowering TG among patients with severe HTG, but can
help simultaneously achieve LDL cholesterol targets among patients with TG in the 2.3-5
mmol/L range.
Although statins are generally well-tolerated drugs they do occasionally have adverse
effects. These range from disruptive side effects such as gastrointestinal (GI) disturbances
and myalgias, to modest to severe elevations in liver transaminases and life threatening
events such as rhadomyolysis (200).
Combination therapy with a statin and fibrate can help normalize several components of
the lipid profile (210, 211). In combination therapy with statins, fenofibrate is preferred to
other fibrates, particular gemfibrozil, which has a higher rate of rhabdomyolysis when
combined with a statin (212).
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1.7.9.5 Ezetimibe
Ezetimibe inhibits intestinal absorption of dietary and biliary cholesterol through its effect
on the Niemann-Pick C1 like 1 (NPC1L1) cholesterol transporter protein (200, 207). It is
primarily indicated as an adjunct to statin therapy, or in patients with statin intolerance, to
reduce LDL cholesterol, and has only minimal TG-lowering efficacy, generally 5-10% from
baseline (207). While some patients may experience nausea or bloating with ezetimibe use,
it is generally well-tolerated (194, 200).
1.7.9.6 Incretin-based therapies
Incretin-based therapies, including glucagon-like peptide 1 (GLP-1) agonists, such as
exenatide and liraglutide, and Dipeptidyl peptidase-4 (DPP-4) inhibitors, such as sitagliptin,
are employed as adjunct agents to improve glycemic control in patients with type 2
diabetes mellitus by increasing post-prandial insulin secretion (213). Their role in TG
lowering is unclear but may be attributed to decreased intestinal TG absorption and
decreased hepatic VLDL production (194). Since the incretin-based therapies have been
primarily tested for glycemic control outcomes, not all trials report the effects on TG, but
reductions range between 12-25%, with greater effects seen in those with high baseline TG
levels (194, 214-217). The main observed adverse effects of incretin therapies are nausea
and GI disturbance, with some hypoglycemia in the exenatide group (215, 216).

1.7.10 Approach to acute pancreatitis
Severe hypertriglyceridemia (S-HTG) is implicated in ~9% of acute pancreatitis cases (218223). Cohort studies suggest that HTG-associated pancreatitis may have greater risk of
complications and mortality than pancreatitis from other etiologies (224-226). As with nonHTG-related pancreatitis, conservative treatment consists of withholding oral intake plus
supportive measures such as intravenous hydration. Insulin and/or heparin infusions and,
more rarely, plasmapheresis have also been recommended in the past (223, 227). Heparin
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and/or insulin infusions have been successfully used in cases of HTG-related pancreatitis,
especially when hyperglycemia was present (219, 223, 228-238).
1.7.10.1 Therapeutic plasmapheresis or plasma exchange
In patients with chylomicronaemia with acute pancreatitis, direct removal of triglyceriderich lipoproteins by plasmapheresis or plasma exchange has been used and reported in a
few case reports and case series (158, 239-246). However, no controlled data indicate
whether plasmapheresis is associated with better clinical outcomes or even superior lipid
profile trajectories than supportive measures that combine fasting, hydration, pain relief
and control of secondary factors. In the acute situation, when oral intake is halted,
supportive measures applied and secondary causes managed, plasma levels of triglycerides
decrease precipitously (50% reductions from baseline within 48–72 h) without
plasmapheresis (221) . Small clinical trials comparing plasmapheresis to conservative
management showed that plasmapheresis had no overall benefit (112, 247, 248). Also,
plasmapheresis is costly, requires a specialized centre and staff, involves exposure to blood
products and only temporarily improves triglyceride levels without addressing the original
cause (249). A case series published in 2014 suggests that when chylomicronaemia occurs
in association with uncontrolled diabetes mellitus, fasting plus insulin infusion leads to more
rapid and effective triglyceride lowering than plasmapheresis (250). Given the lack of data,
optimal management of HTG-associated pancreatitis is not yet determined. This work
attempts to address some of these unresolved issues in chapter 3.4.
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1.8 Familial Hypercholesterolemia:
The term familial hypercholesterolemia (FH) refers to a autosomal semi- or co-dominant
genetic form of hypercholesterolemia generally associated with elevated total cholesterol
and LDL-C levels >95% percentile compared to the general population. This disorder
predisposes to silent and premature accumulation of cholesterol plaques in the coronary,
central and peripheral vasculature that, without timely intervention, can lead to early-onset
atherosclerotic cardiovascular disease (ASCVD), including coronary heart disease, stroke and
peripheral limb ischemia.

1.8.1 Epidemiology
Heterozygous FH (HeFH) was traditionally taught to have a prevalence of 1 in 500; however,
data now suggest a higher frequency (251, 252). For instance, a survey of 69,106 individuals
in Denmark using the Dutch Lipid Clinic Network (DLCN) diagnostic criteria found a
frequency of 1 in 219 for HeFH (253). Prevalence estimates from studies conducted in
Australia (254) (n = 18,322), China (255) (n = 9,324), and the USA (256) (National Health and
Nutrition Examination Survey; n = 36,949) were 1 in 229 to 350, 1 in 322, and 1 in 250,
respectively. Pooled data from 19 studies totalling 2,458,456 individuals similarly estimated
the overall prevalence of HeFH to be ~ 1 in 250 (257). The prevalence of homozygous FH
(HoFH) has also been revised upwards to ~1 in 300,000 (range 1 in 160,000 to 1,000,000)
(258, 259).

1.8.2 Diagnosis
Agreement exists on the elements required to diagnose FH, but the weighting of these
elements varies between algorithms (260). Two clinical scoring systems are in general use:
the Simon Broome Register (SBR) criteria (261) and the DLCN criteria (262) (Table 1.10). The
US Make Early Diagnosis-Prevent Early Death (MED-PED) system(263) is less widely used
(Table 1.10). Other proposed algorithms include that used by the American Heart
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Association (AHA) (264) and the Canadian simplified FH definition (265) (Table 1.10).
Concordance between these various algorithms is inconsistent (251, 266).
Most FH diagnostic algorithms score and assign weights to: lipid values (total cholesterol
and/or LDL-C levels); presence of physical stigmata considered pathognomonic for FH, such
as tendon xanthomas, xanthelasmas, or arcus cornealis; and personal or family history of
premature ASCVD; or pathogenic DNA variants (Table 1.10). Secondary causes of elevated
LDL-C level, such as obstructive liver disease, hypothyroidism, and nephrotic syndrome,
must first be ruled out (265). Physical stigmata were observed in >50% of patients reported
to have FH as recently as the 1970s, but these physical findings are found in only 5–20% of
contemporary, well-characterized FH cohorts, owing possibly to early diagnosis and
treatment or less careful ascertainment; nonetheless, physical stigmata are a highly specific
diagnostic feature when present (265). An algorithm from Wales includes normal
triglyceride levels to increase specificity of diagnosis (267); this modification excludes
possible cases of combined hyperlipidaemia, a related but distinct and essentially polygenic
phenotype (268).
A generally accepted diagnostic criterion is the presence of a pathogenic variant in one of
three main genes associated with HeFH: APOB, LDLR, or PCSK9 (15, 269, 270). However,
many patients meet clinical criteria without a detected pathogenic variant; these patients
also carry substantial ASCVD risk compared with the general population (271).
Genetic confirmation rate in patients with suspected FH varies depending on patient
ascertainment. In cardiology cohorts, pathogenic variants are seen in ~2% of patients with
an LDL-C level >5 mmol/L and early ASCVD (271). By contrast, in tertiary care lipid clinics, a
genetic basis is found in up to two-thirds of patients referred with suspected FH (15).
Untreated LDL-C levels >8 mmol/L were associated with ~90% genetic confirmation (that is,
presence of a pathogenic variant) among patients with suspected FH (15, 269). Other
predictors of a positive DNA test result included a personal or family history of tendon
xanthomas, a personal history of CVD, or imaging evidence of increased atheroma burden
(272, 273).
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1.8.3 Pathophysiology
The chronically excessive levels of LDL-C in FH cause ASCVD (274). LDL has manifold
deleterious effects on vascular function, including corruption of the normal arterial
response to vasodilatory stimuli, promotion of vascular inflammation through multiple
mechanisms, and pathological internalization by arterial wall macrophages when LDL
particles become oxidized or are otherwise modified (95, 275). When overloaded with
cholesterol, arterial wall macrophages become foam cells, which are components of
atherogenic plaques that can eventually occlude arteries, leading to tissue ischaemia (275).
About two-thirds of plasma cholesterol is transported within LDL particles (274); the
majority of these particles are removed by LDL receptors, which reside on most cell surfaces
but are especially concentrated on hepatocytes (276). Increased LDL-C levels in FH results
from impaired LDL-receptor activity, which is often caused by different classes of mutations
that directly affect the receptor (276). The functional domains of the LDL receptor include
the ligand or apoB-binding domain, epidermal growth factor-like domain, O-linked sugar
domain, and transmembrane domain, as well as the anchoring cytoplasmic tail domain
(276). Pathogenic DNA variants have been observed in all domains. Because of the central
role of the LDL receptor in FH, its life cycle is briefly summarized (Figure 1.5), including the
roles of several interacting proteins (276-282).
Given the plethora of interacting proteins, it is perhaps remarkable that genes encoding
most of these proteins have not been reported to harbour FH-associated DNA variants.
Mutations in three genes acting in receptor-associated pathways cause HeFH: the LDLR
gene itself (259, 283); receptor-binding defects in APOB (259, 283), and PCSK9 gain-offunction mutations (284). Mutations in the LDLRAP1 gene (also known as ARH) cause a
severe, recessive phenotype (285). Although no variants in the MYLIP gene (also known as
IDOL) cause FH, a common polymorphism is associated with mildly increased LDL-C level
(286). Rare variants in particular genes encoding proteins involved in LDL-receptor
trafficking cause multisystem disorders, such as X-linked intellectual disability owing to rare
CCDC22 variants; elevated LDL-C level is a component sub-phenotype (278). The absence of
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mutations in other genes encoding receptor-associated proteins suggests that dysfunctional
variants are embryonically lethal.

1.8.4 Inheritance of FH
For five FH-causing genes (APOB, APOE, LDLR, PCSK9, and STAP1) one copy of a mutant
allele acts dominantly to produce the disease phenotype, adhering to the conventional idea
of HeFH (259, 283). For the APOB, LDLR, and PCSK9 genes, many patients who inherit two
mutant alleles have a more severe phenotype, consistent with HoFH, which some groups
designate as autosomal dominant homozygous FH (287). However, the inheritance pattern
is more accurately viewed as autosomal semi-dominant, given that both variant alleles from
each affected parent contribute to the phenotype, additively raising the LDL-C level.
For LDLRAP1, LIPA, ABCG5, and probably ABCG8, two mutant alleles act recessively,
producing a severe phenotype consistent with HoFH (258, 259, 283, 287). Here, the
recessive label is appropriate, because carrier parents have normal lipid levels. Before nextgeneration DNA sequencing was used to identify pathogenic variants in ABCG5, ABCG8,
APOE, and LIPA in a few patients with FH, these four genes were known to cause distinctive
non-FH dyslipidaemia syndromes: sitosterolaemia (ABCG5 and ABCG8),
dysbetalipoproteinaemia (APOE), and cholesterol ester storage disease (LIPA) (288). The
reason why FH is expressed instead of the classical disease phenotypes in these patients is
unclear.
1.8.4.1 LDLR gene
Most cases of monogenic FH are caused by LDLR variants, with >2,000 rare variants
reported (15, 264) and ~3,000 deposited in the ClinVar database. Variant types include:
large-scale DNA CNVs (289); nonsense mutations within the coding region; small insertions
or deletions (insertion–deletion variants or ‘indels’) within or near the coding sequence,
some of which might shift the reading frame; splicing mutations, typically non-coding and
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occurring at intron–exon boundaries; and missense mutations altering a single amino acid
residue (15, 270).
These LDLR variants affect all stages of receptor-mediated endocytosis, but the mutation
types and classes can be reduced to two categories: those resulting in synthesis of either no
protein or a completely nonfunctional receptor (that is, receptor-negative or receptor-null
mutations) and those resulting in synthesis of an ineffective receptor (that is, receptordefective mutations). About 10% of LDLR variants that have been deemed pathogenic have
actually been studied functionally in cell biology experiments in vitro (290).
1.8.4.2 LDLR DNA copy number variation in FH
The LDLR locus is particularly prone to CNVs because of an abundance of Alu repeat
sequences mostly within introns (289). These underlie predominantly in-frame, whole-exon
events: at least 56 unique deletions and 27 unique duplications of LDLR have been reported
in patients with FH (289). More than 90% of LDLR CNVs are heterozygous deletions
spanning multiple exons (289).
Given that CNVs account for >10% of pathogenic LDLR variants, especially in some founder
populations (291), diagnostic laboratories must be able to detect CNVs in addition to single
nucleotide variants. But because dedicated laboratory methods were required to detect
CNVs, many laboratories decided to forego the expense and accepted the compromised
ability to detect variants (292). However, next-generation DNA sequence data can now be
bioinformatically processed to detect LDLR CNVs with complete concordance with previous
methods (92). CNVs in other FH-related genes have not yet been reported.
1.8.4.3 APOB, PCSK9 and LDLRAP1 genes
Genetic mapping and next-generation sequencing studies in families with FH and no LDLR
mutations revealed additional causative loci. Mutations in the region of APOB encoding the
receptor-binding domain of apoB, the structural protein for LDL and an essential ligand for
the receptor, cause an FH phenotype referred to as familial defective apoB, which accounts
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for 5–10% of patients with FH (15, 266, 283, 285). Rare gain-of-function mutations in PCKS9
account for ~1% of patients with FH (15, 266, 283, 285). Additionally, rare mutations in
LDLRAP1, a gene that encodes LDL receptor adaptor protein 1, can cause an autosomal
recessive form of FH (251, 259, 269). Dysfunction in any of these gene products impairs LDL
clearance via receptor-mediated endocytosis, leading to the elevated LDL-C levels common
to all definitions of FH.
1.8.4.4 Minor genes
FH-like phenotypes have also been seen in families with rare heterozygous variants in APOE
(293), encoding apoE, and STAP1 (294), encoding signal-transducing adaptor protein 1(15).
Next-generation DNA sequencing of patients with severe, recessive hypercholesterolaemia
have found rare bi-allelic mutations of other dyslipidaemia genes: ABCG5 (295), encoding
ATP-binding cassette sub-family G member 5, and LIPA, encoding lysosomal acid lipase
(296), showing that mutations in these genes can cause an FH-like phenotype (15).
Comprehensive exome-wide and genome-wide sequencing efforts have not identified other
FH-related genes (297).
1.8.4.5 Polygenic influences
A polygenic trait is influenced simultaneously by functional alleles of many different
genomic loci (298). Plasma lipid levels, including LDL-C levels, are polygenic traits (298).
Furthermore, polygenic predisposition is recognized to cause high LDL-C levels in up to half
of patients referred to lipid clinics who have possible or probable HeFH (15, 299-301).
Instead of a single large-effect variant, many of these patients have inherited numerous
small-effect alleles of single nucleotide polymorphisms (SNPs) that are common in the
population (298). Each SNP genotype is associated in GWAS studies with subtle but
reproducible and significant increases in LDL-C level (162, 302). More than 50 genomic loci
have been associated with increased LDL-C levels (302); some examples are shown in Table
1.11. These small-effect loci can cumulatively raise LDL-C level into the same range as with a
single HeFH-causing rare variant in APOB, LDLR, or PCSK9 (299-301). Also, these small52

effect polygenic loci encompass some gene products that result in LDL overproduction,
which is distinct from the monogenic forms that are predominantly catabolic defects.
This polygenic basis of FH was clearly demonstrated by Talmud and Humphries, who
showed that many patients with FH and no monogenic mutation had a high score based on
12 common LDL-C-associated SNPs from GWAS (301). Using a reduced six-SNP score, they
claimed that 88% of mutation-negative patients with FH had a polygenic basis (299).
However, the proportion of patients with a polygenic basis depends on the cut-off point of
the score distribution. From our lipid clinic, ~30%, ~50%, and ~80% of mutation-negative
patients with possible FH have a polygenic score in the top 10th, 25th, and 50th percentiles,
respectively (15). When the median polygenic score is chosen to represent high risk, a large
proportion of mutation-negative patients are captured. However, half of the normal
population also has a score this high, weakening its discriminatory power in an individual
patient with FH.
Some of the top small-effect loci associated with LDL-C level overlap with large-effect loci
such as APOB, LDLR, and PCSK9 (162, 302), whereas others have no connection to lipid
metabolism (Table 1.12). Determination and distribution of polygenic scores for LDL-C level
are shown in Figure 1.6.
A high polygenic score can worsen the biochemical phenotype when a heterozygous largeeffect FH variant is present (303), although not always (304). Also, patients with FH owing
to polygenic risk seem to have less severe preclinical atherosclerosis in non-invasive imaging
studies compared with individuals with large effect FH-causing mutations (305).

1.8.5 Phenotypic variability
Among carriers of the identical FH-causing variant, a wide range of LDL-C levels exists (306).
Mean untreated LDL-C levels vary more predictably when individuals are grouped according
to causative gene and mutation. For instance, LDLR variants are associated with higher
LDL-C levels than APOB variants (15). Among LDLR variants, CNVs and splicing and nonsense
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variants are associated with the highest mean LDL-C levels, with the lowest LDL-C levels
seen with missense variants (15, 307). Patients with null variants have a more severe
phenotype than patients with defective variants, presenting with significantly higher plasma
levels of total cholesterol, LDL-C, and apoB (308). A further complication is that LDL-C levels
in monogenic FH are higher in the branch of the family that presented to medical attention;
mean LDL-C levels in affected relatives in more distant branches can be less extreme (304).
This observation suggests the modulatory influence of background genetic effects, gene–
environment interactions, or other biological factors in addition to simple Mendelian
inheritance, even in the most apparently straightforward families with FH.
Variations in lipid levels among individuals with similar FH-causing mutations can also be
caused by interacting genetic effects, either large-effect variants (309-311), polygenic
effects (303), gene–environment interactions (including the effects of diet and lifestyle)
(312-314), or non-Mendelian mechanisms (315). The non-Mendelian mechanisms include
environmentally induced epigenetic effects (316), mitochondrial influences (317), or
somatically acquired DNA variation in the liver or other tissues.

1.8.6 Cascade versus universal screening
The best screening method to find new cases of FH has been debated (272, 318-323).
Universal population-wide screening has been proposed in the adult, adolescent, child, or
infant populations, using lipid values, DNA testing, or both (324, 325). A pilot screening
project obtained capillary blood samples from 10,095 children aged 1–2 years during
routine immunization visits and tested for both cholesterol levels and known genetic
mutations; family members of positive cases were then also screened (324). This
programme had an overall case-finding utility of eight FH cases identified for every 1,000
children screened (four children and four parents), allowing for early monitoring and
intervention (324). Other childhood universal screening programmes using lipid levels and
prediction scores have shown success (326). Universal screening programmes minimize
missed cases, but can be costly especially if genetic testing is included (264, 327). However,
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preventing morbidity and mortality makes universal screening potentially cost-effective
(264, 327, 328), especially with declining costs for DNA analysis.
By contrast, cascade screening tests all first-degree relatives of patients identified with FH,
followed by all first-degree relatives of further identified cases, and so on (301, 320, 329,
330). The target population is enriched for positive cases because first-degree, seconddegree, and third-degree relatives will have a 50%, 25%, and 12.5% likelihood, respectively,
of carrying the causative mutation, which maximizes cost-effectiveness (320, 327, 330).
Both lipid-only and genetic-only screening of relatives has been proposed, as has a
combination approach, whereby relatives are screened with lipid levels followed by genetic
testing when values exceed diagnostic thresholds (330).
Current Canadian Cardiovascular Society and National Institute for Health and Care
Excellence guidelines support cascade screening (265, 331). The US Preventive Services Task
Force cites insufficient evidence for or against universal screening in childhood or
adolescence (318). The National Heart, Lung, and Blood Institute (332), endorsed by the US
National Lipid Association (333), the AHA (264), and the American Academy of Pediatrics
(332), recommends universal lipid screening in paediatric and adolescent patients aged
between 9–11 years and 17–21 years and referral for genetic testing if thresholds are met
(332), although adherence among providers to this testing strategy was found to be low
(16–18%) (334).

1.8.7 Genotype-guided management
Determining the causative gene could theoretically guide tailored management in FH; for
example, patients with PCSK9 gain-of-function mutations might respond well to PCSK9
inhibitors. Some studies suggest pharmacogenomics could identify patients with HeFH who
are less likely to respond to traditional therapies, allowing for earlier use of costly secondline agents (335-337). Testing for the underlying mutations might be more important in
predicting drug response in HoFH (338).
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The mean LDL-C response to statin treatment might vary by genotype in patients with HeFH
(339). In Brazilian patients with HeFH, achieving target LDL-C levels was greatest in those
with no mutation detected (that is, putative polygenic FH), intermediate in those with a
receptor-defective allele, and worst in those with a receptor-negative allele, who
coincidentally had the highest baseline LDL-C levels (340). The Spanish SAFEHEART registry
of 2,752 adult patients with genotyped HeFH showed that those with a receptor-defective
allele were more likely to reach their LDL-C goal than those with a receptor-negative allele
(341). Several other unvalidated genetic determinants of response to statins have been
reported (342).
Genetic factors have been studied with respect to response to PCSK9 inhibitors. Subgroup
analyses of trials in patients with HeFH showed that baseline LDL-C level was related to the
type of LDLR mutation, but no between-genotype differences were found in relative
reductions in LDL-C level (343, 344). Clinical response seemed to be related to the ability of
the wild-type allele to be upregulated. Furthermore, patients with heterozygous APOBbinding defective mutations (343) and those with heterozygous PCSK9 gain-of-function
mutations (345) responded equally well to PCSK9 inhibitors, and no differently from
patients with heterozygous LDLR mutations.
In patients with HoFH, genotype seems to determine response to PCSK9 inhibitor
treatment. For instance, in two studies, evolocumab given to patients with HoFH reduced
LDL-C level by 31% and 21% compared with placebo (346, 347). Subgroup analyses showed
that response was restricted to individuals with one or no receptor-defective alleles,
whereas those with two receptor-negative alleles had no response (346, 347). In vitro
studies of cells from patients with HoFH indicate that response to PCSK9 inhibition depends
on having one or more receptor-defective allele whose residual function can be upregulated
(348, 349).
Genetic prediction of treatment-related adverse effects has not been studied specifically in
patients with FH. In individuals with FH, pharmacogenetic algorithm-based statin dose
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adjustment might reduce statin-associated muscle symptoms or elevated muscle enzymes
(350).
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Figure 1.5: LDL-receptor lifecycle.
Normally, low intracellular cholesterol levels cause upregulation of the LDLR gene via the
transcription factor sterol regulatory element binding protein 2 (SREBP2) (277, 278). LDL
receptors (LDLRs) are synthesized in the endoplasmic reticulum (ER) and glycosylated in the
Golgi; mature receptors reach the cell surface and cluster within clathrin-coated pits. The
apolipoprotein B-binding domain of the receptor binds to circulating LDL particles and the
receptor–ligand complex is internalized through clathrin-coated vesicles, which fuse with
58

early endosomes (277, 278). Internalization depends on the NPxY motif within the
cytoplasmic tail of the receptor, which is the binding site for several proteins including the
LDL receptor adaptor protein 1 (LDLRAP1, encoded by LDLRAP1) and a multiprotein complex
called CCC that includes coiled-coil domain-containing proteins and COMM domaincontaining protein (MURR1); collectively these proteins determine whether the receptor
proceeds through endocytosis or is recycled (277-279). As the receptor–LDL complex is
exposed to lower pH in the endosome, the receptor dissociates and is recycled to the cell
surface; a single receptor can be recycled ≥100 times (277, 278). The retained LDL particles
proceed from late endosomes through to lysosomes (277-279). After particle degradation,
cholesterol is released into the cell, facilitated by NPC intracellular cholesterol transporter 1
and 2 (280). In response to cellular cholesterol content, the LDLR is degraded either by
PCSK9 or by the E3 ubiquitin-protein ligase MYLIP (also known as IDOL). PCSK9 mediates
receptor degradation both intracellularly and extracellularly (281, 282). In both instances,
the LDLR is chaperoned to endosomes. PCSK9 perturbs the normal pH-dependent
conformational switch, causing the receptor to remain within the endosome, leading to its
degradation within lysosomes (281, 282). By contrast, internalization and degradation of the
LDLR by MYLIP in response to increased intracellular cholesterol levels occurs through
ubiquitination, endocytosis that is independent of clathrin and LDLRAP1, and an alternate
pathway leading to the lysosome (277-279). The stars indicate proteins that when mutated
cause FH.
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Figure 1.6: Polygenic influences on plasma LDL-cholesterol concentrations.
Illustrative distributions for polygenic risk scores for LDL-cholesterol (LDL-C) levels in the
general normolipidaemic population (blue) and in clinically ascertained patients with
suspected familial hypercholesterolaemia (FH) but no monogenic mutation (red). Scores are
calculated from single nucleotide polymorphism genotypes such as those shown in Table
1.12. Scores are comprised either by simply tallying trait-raising alleles, or they can be
further weighted according to effect sizes for the alleles reported in genome-wide
association studies (162, 302). Because polygenic LDL-C loci are scattered throughout the
genome and segregate independently during meiosis, most individuals have an overall
balance between LDL-C-raising and LDL-C-lowering alleles. Rare individuals at the high
extreme of polygenic scores have inherited a preponderance of LDL-C-raising alleles; they
comprise a substantial proportion of individuals with suspected FH but no detected
mutation. Cut-off points for 10th, 50th, and 90th percentiles for the general population are
shown. No standard definition exists for a high polygenic score: choosing the median for the
general population captures the majority of patients with FH but no detected mutation;
however, it also captures half the normal population. By contrast, the more stringent 90th
percentile is much more specific for patients with FH, but leaves about two-thirds of these
patients with an unexplained genetic basis.
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Table 1.10: Comparison between clinical scoring systems for FH
Criteria

Simon Broome
Register(261)

Dutch Lipid
Clinic
Network(262)

MEDPEDa,(263)

AHA(264)

Canadian Criteria22

>7.5 (adult) (a)
>6.7 (child) (a)

NA

NA

NA

NA

>4.9 (adult) (a)
>4.0 (child) (a)

>8.5 (8)
6.5–8.4 (5)
5.0–6.4 (3)
4.0–4.9 (1)

>5.7–9.3b

>5.0 (adult)
(a)
>4.0 (child)
(a)

>4.0 (child) (a)
>4.5 (18–39 years) (a)
>5.0 (>40 years) (a)
>8.5 (b)

Personal

Tendon
xanthoma (b)

Tendon
xanthoma (6)
Arcus cornealisc
(4)

NA

NA

Tendon xanthoma (c)

Family

Tendon
xanthoma in
one relative (b)

Tendon
xanthoma or
arcus cornealis
(2)

NA

NA

NA

Premature
CADd (2)
Premature CVD
or PVDd (1)

NA

Premature
CAD in one
relative (b)

Premature CAD in
one relatived (d)

LDL cholesterol
(mmol/l)

MI aged
<50 years in
two relatives or
aged <60 years
in one relative
(d)
>7.5 in one or
two relatives (e)

Child with LDLcholesterol
>95th
percentile (2)

NA

One
affected
relative (c)

One relative with high
LDL-cholesterol level
(d)

Genetics

NA

NA

Known FH in
family
member

NA

FH mutation in one
family member (c)

APOB, LDLR, or
PCSK9 gene
mutation (c)

APOB, LDLR, or
PCSK9 gene
mutation (8)

NA

APOB, LDLR,
or PCSK9
gene
mutation (d)

APOB, LDLR, or PCSK9
gene mutation (c)

Lipids
Total
cholesterol
(mmol/l)
LDL cholesterol
(mmol/l)
Physical stigmata

Family history
CAD

Genetics
Genetic
mutations
Diagnosis
Diagnosis of FH

Definite: a + b
Definite: >8
Meets
a + (b or c)
Definite: (a + c) OR b
or c
Probable: 6–8
adjusted LDL- OR d
Probable: a + d
Probable: a + d
Possible: 3–5
cholesterol
OR a + e
cut-off point
a
Requires a diagnosis of FH in a family member. bCut-off based on year and degree of separation from affected
relative. cArcus cornealis when aged <45 years. dAged <55 years in men and aged <60 years in women. CAD,
coronary artery disease; CVD, cerebrovascular disease; FH, familial hypercholesterolaemia; ICD, International
Classification of Diseases; MED-PED, Make Early Diagnosis – Prevent Early Death; MI, myocardial infarction;
NA, not applicable; PVD, peripheral vascular disease.
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Table 1.11: Major and minor monogenic determinants of FH
Gene
Inheritance
OMIM
Proportion
Mutation types
pattern
number of patients
with FH (%)

Refs

Major determinants
LDLR

Autosomal
co-dominant

606945

80–85

Splicing,
frameshift, copy
number
variation,
nonsense, and
missense

(259,283)

APOB

Autosomal
co-dominant

107730

5–10

Frameshift,
missense,
nonsense, and
splicing

(259,283)

PCSK9

Autosomal
co-dominant

607786

<1

Frameshift and
missense

(259,283)

LDLRAP1

Autosomal
recessive

605747

<1

Frameshift,
missense, and
nonsense

(258, 259)

Minor determinants
APOE

Autosomal
dominant

107741

<<1

Missense

(293)

STAP1

Autosomal
dominant

604298

<<1

Missense

(294)

LIPA

Autosomal
recessive

613497

<<1

Frameshift

(296)

ABCG5

Autosomal
recessive

605459

<1

Nonsense

(295)

ABCG8

Autosomal
recessive

605460

<<1

Unproven (only
by analogy with
ABCG5)

(

295)

FH, familial hypercholesterolaemia; OMIM, Online Mendelian Inheritance in Man.
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Table 1.12: SNPs used to calculate polygenic genetic risk scores
SNP number

Location

Gene

LDL-C-raising

Effect on LDL-C

allele

level (mmol/l)

rs6511720

19:11202306

LDLR

G

0.26

rs12740374

1:109817590

CELSR2

G

0.23

rs515135

2:21286057

APOB

C

0.16

rs6544713

2:44073881

ABCG8

T

0.15

rs11206510

1:55496039

PCSK9

T

0.09

rs3846663

5:74655726

HMGCR

T

0.07

rs1501908

5:156398169

TIMD4

C

0.07

rs2650000

12:121388962

HNF1A

A

0.07

rs6102059

20:39228784

MAFB

C

0.06

rs10401969

19:19407718

NCAN

T

0.05

LDL-C, LDL cholesterol; SNP, single nucleotide polymorphism.
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1.8.8 Patient Impact of Genetic Testing for FH:
1.8.8.1 Potential Benefits of Genetic Testing for FH:
As outlined above (chapter 1.8.7), knowing the underlying genetics of hypercholesterolemia
can help tailor therapy most effectively to the individual patient It may also be necessary
to obtain a genetic diagnosis in order to procure funding or eligibility for newer therapies,
such as PCSK9 inhibitors. Some conditions can mimic HeFH, such as sitosterolemia, but
require very different management strategies (19, 351). . There is also a large potential
benefit to identifying and treating at-risk individuals aggressively as early as possible;
therefore in addition to allowing initiation of this treatment in the proband, genetic testing
may provide an opportunity for early detection and intervention for children or other family
members of identified individuals. There is therefore a compelling reason from the provider
perspective to offering genetic testing for suspected HeFH cases.
1.8.8.2 Past studies on patient impact of genetic testing in other conditions:
From the patient perspective, some studies have found a lack of retention or true
understanding when it comes to understanding genetic risk. For example, a study of
Alzheimer’s susceptibility testing found that only 27% of patients tested could accurately
recall their results a year later, whereas 23% were unable to recall any of the information
conveyed to them at the time of testing (352). Qualitative studies suggest a wide range of
individual responses to genetic information depending on a number of factors. These
include the strength of the genetic findings with penetrance of the disease, whether the
individual has witnessed family members express the disease in question, or whether active
disease symptoms are present (351, 353).
1.8.8.3 Past Studies on Provider Impact of Genetic Testing for FH:
The degree to which a genetic test alters management in the clinic can be variable. Some
studies have found that providing genetic test results to clinicians failed to result in
significant changes in clinical practice (28, 351, 354). A consistent belief was that the
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clinical diagnosis of FH was more important than the DNA testing results, and that a
negative genetic test did not rule out the disorder in patients with a strong clinical suspicion
(351). Many felt that monitoring and basing management on lipid levels alone was
sufficient and management was not often changed on the basis of a genetic test results
(351). Some responders suggested that the real impact is on the family members, especially
children, of the affected individuals, who could be diagnosed prior to developing any clinical
concerns (351). It is important to note that this study was conducted prior to the
introduction of PCSK9 inhibitors to the market for treatment of FH, and it is possible that a
genetic diagnosis of FH may now have more clinical impact.
1.8.8.4 Impact of genetic testing for FH:
A number of past studies have attempted to look at patient impact or attitudes towards
genetic testing, but often address only one aspect of testing impact, with small numbers of
responders, and no incorporation of polygenic hypercholesterolemia. Results of these
studies have also been mixed, highlighting the need for further investigation into these
areas. Some prior studies have suggested that undergoing genetic testing for FH when
offered is undertaken by a majority of individuals. One study showed that when
approached in a cascade screening program for FH, only 2% of individuals did not
participate, though 20% of respondents reported feeling social pressure to agree (355).
Impact of genetic testing on patients seems to be variable and dependent on a number of
factors, including those that are disease-related, past personal experiences, the method of
information delivery, and many individual patient factors (356). In FH testing in particular,
one study of newborn FH screening found that if the diagnosis was explained as made
based on an elevated cholesterol, it was interpreted as controllable and caused less distress
in parents than when the diagnosis was stated to have been made based on the discovery
of a mutation (357). However, when disclosure of FH status was delivered to an adult
population, it tended to be considered no more or less important than any other
cardiovascular risk factor (357), or had very little impact on beliefs and behaviors overall
(358, 359). One study found that patients with a diagnosis of FH felt less sense of

65

responsibility for their high cholesterol, and made a distinction between themselves and
other individuals who had high cholesterol associated with what they perceived to be
lifestyle (351, 359, 360). Some work has also been done on the potential negative impact of
a negative test for FH, when the individual was expecting a positive test. One qualitative
study suggested that failing to receive the expected diagnosis left patients feeling uncertain
about their risk and the risks to their offspring and left them confused about their own
contribution to their elevated cholesterol (361). Some felt that a genetic diagnosis was the
only explanation for their elevated cholesterol because their diet and lifestyle habits were
good, consequently these patients found the negative test difficult to accept (361). More
promising results were seen in a cohort of patients undergoing cardiovascular risk
stratification randomized to receive information on either their conventional risk factors
alone, or their conventional risk factors as well as their genetic risk profile. Those with high
genetic risk were more likely to remain on their statins than those at low genetic risk or
those who were not informed of their genetic profile (362). This mirrors the findings of
another study that suggested that those individuals with a genetic diagnosis of FH were less
likely to rely on the efficacy of diet in improving their cholesterol, and more likely to believe
in the efficacy of cholesterol-lowering medications (363). In a small qualitative study of 23
individuals, those with familial hypercholesterolemia reported increased guilt when not
compliant with their medication or treatment recommendations, and reported being more
attentive to their food choices but otherwise did not feel that the diagnosis significantly
impacted their lives (364). None of those questioned indicated that they would have
preferred to remain ignorant of their diagnosis (364). Further insight may also be derived
from the GenTLe-FH study (Trial registration number UMIN000029375). Recruitment is
underway for this study, in which patients will be randomized to either standard FH
counselling, without disclosure of genetic information, or to disclosure of genetic
information combined with genetic counselling regarding their diagnosis and will look at the
impact on LDL-C levels, smoking status, and medication use in individuals at 24 and 48
months following the intervention (365). Given the overall conflicting and inconsistent
results, it is clear that further study is needed in this area to clarify understanding. The
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GenTLe-FH study may complement the results of the study presented in this work (chapter
4.2), which aims to look at which factors may be helpful to address during genetic
counselling sessions about FH, and which behaviours may be impacted and to what degree.
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Chapter 2: Improving detection of Maturity Onset Diabetes of
the Young (MODY)
2.1 Overview:
Monogenic disorders that can be fully explained by the presence of a rare pathologic variant
are some of the most important clinical conditions to identify for a number of reasons.
Firstly, for many of these conditions optimal management may depend on establishing an
underlying genetic cause. Treatments or early interventions may be available that may
significantly improve outcomes or quality of life by making an early definitive diagnosis.
Secondly, these conditions will follow a consistent inheritance pattern within families so
identifying one family member may have benefits for other related individuals. By tracing
the mutation through the family it may allow for enhanced surveillance, early intervention,
and may assist in family planning discussions. Furthermore, providing a definitive diagnosis
for the patient often provides clarity and relief from uncertainty. It can also allow the
affected individual and his or her physician to make more informed health-related decisions
and have a better understanding of the expected disease course and prognosis. Patient
advocacy and support groups may be available for these conditions, allowing affected
individuals to seek information and access peer and community support.
One monogenic endocrine condition for which genetic testing may play a significant role is
in a group of monogenic diabetes syndromes, collectively termed Maturity onset Diabetes
of the Young (MODY) (see chapter 1.6 for background). MODY is inherited in an autosomal
dominant manner with the expressed phenotype largely dependent on the underlying
genotype. Optimal management of MODY depends on making the correct diagnosis and
tailoring management based on the specific subtype. As MODY can often be difficult to
clinically distinguish from more common forms of diabetes such as type 1 and type 2
diabetes, the ability to accurately identify mutations in those clinically suspected of MODY
is critical for establishing the correct diagnosis, and also for optimizing patient management.
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2.2 Genetic confirmation rate in clinically suspected maturityonset diabetes of the young.

The work presented in Chapter 2.2 has been edited from this original manuscript for brevity
and consistency throughout this dissertation.
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2.2.1 Background:
The best approach to genetic testing in MODY is controversial. Some argue for universal
testing in young individuals (<25 years of age) with diabetes and without evidence of
diabetes-associated antibodies; others suggest that it does not affect management or
patient outcomes sufficiently to justify the cost and inconvenience of widespread testing.
However, the cost of DNA sequencing has declined dramatically. Furthermore, the impact
of a definitive MODY diagnosis can be significant, especially for young individuals
misdiagnosed with type 1 diabetes. Many of these patients are able to stop insulin and
transition to SU therapy, with improved glycemic control (1, 2). Similarly, patients with SUsensitive MODY misdiagnosed with "garden variety" type 2 diabetes may also benefit from a
molecular diagnosis, since they are frequently well-maintained on SU monotherapy for
decades prior to advancing to additional treatment (1, 2). Also, GCK-MODY (MODY 2)
patients generally require less intensive treatment and have less risk of microvascular
complications, which may be reassuring to patients and families, and may reduce long term
monitoring and treatment costs (1). Finally, each first-degree relative of a mutation-positive
patient has a 50% chance of carrying the mutation, which opens the possibility of predictive
or pre-symptomatic screening for early intervention and counselling.
Who should be screened genetically for MODY? What type of testing should be conducted?
To answer this question in a Canadian context, we have informally offered research-grade
MODY genetic testing to colleagues since 1999, taking advantage of excess capacity on our
Sanger and next-generation sequencing platforms. Between 1999 and 2015, 96 samples
were received from unrelated patients for whom the referring endocrinologist had a high
index of clinical suspicion for MODY. The aim of this study was to determine the proportion
of suspected MODY cases submitted for analysis that resulted in a molecular diagnosis and
to assess whether high provider clinical suspicion is a sufficient criterion to proceed with
genetic testing.
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2.2.2 Methods
2.2.2.1 Patient samples
In 1999, research-based MODY gene sequencing was instituted at the Robarts Research
Institute in London, Ontario. Since that time, 25 Canadian physicians who suspected MODY
in patients based on clinical assessment have referred patient samples for DNA analysis,
with the caveat that the method was research-based and not clinically accredited. Referred
samples arrived in an ad hoc unsolicited manner, initiated at the discretion of the referring
physician. There was no cost to either referring physician or patient, except for the cost of
sample shipping. There were no specific inclusion or exclusion criteria. Informed consent
was obtained from patients prior to proceeding with DNA collection and analysis using a
protocol approved by the University of Western Ontario Ethics Review Board (#07920E)
(Appendix B).
2.2.2.2 DNA sequencing
DNA was extracted from whole blood. Samples received before 2012 were analyzed using
traditional Sanger sequencing to detect mutations in genes associated with MODY subtypes
1-6 (Table 1.3). If a causal mutation was detected, this was reported to the patient and
referring physician, with no further testing. All samples were retained for potential future
analysis.
More recently, we developed a targeted next generation sequencing (NGS) panel and
custom bioinformatic pipeline for metabolic disorders, known as LipidSeq (3) (Appendix C),
which has greatly enhanced our ability to detect clinically relevant mutations. LipidSeq is
high-throughput platform which has been designed to simultaneously screen for DNA
variants in dozens of genes linked to metabolic and dyslipidemia disorders, including 13
MODY subtypes (3). The coding region of each gene is sequenced, together with all intronexon boundaries, at least 150 bp of flanking intronic sequence and at least 500 bp of the
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promoter and 3'-untranslated region. Samples in which no MODY mutation was initially
found by Sanger sequencing were re-analyzed using the LipidSeq NGS panel. Samples
received after 2012 underwent processing directly on LipidSeq. When multiple samples
from affected individuals in the same kindred were received, the first tested affected
individual was considered as the index case and samples from other family members were
excluded from subsequent data analysis here.
Conventional prioritization criteria were applied to impute causality or potential clinical
relevance to a DNA variant (3). A variant was considered to be causative if it had been
previously reported in the literature and Human Genome Mutation Database (HGMD;
http://www.hgmd.cf.ac.uk/) as being causative for MODY. Rare variants detected in MODY
genes that had not previously been reported in HGMD were considered causal if: 1) their
reported frequency was < 1% in the general population; and 2) they was classified as having
a strong likelihood of being deleterious based on in silico prediction tools, such as sorting
intolerant from tolerant (SIFT) (4) and PolyPhen version 2.0 (5).

2.2.3 Results
In total, 96 index samples were received between 1999 and 2015. From 87 samples
received prior to 2012 that underwent Sanger sequencing, 20 had likely causative MODY
rare variants and 2 had non-MODY diabetes-related rare variants (Figure 2.1). The 65
mutation-negative samples were added to 9 samples received since 2012: 19 had likely
causative MODY rare variants and 6 had variants of uncertain significance in genes
associated with MODY (Figure 2.1). Thus, out of 96 samples, 39 had probable causative
variants in MODY genes, 6 had variants of uncertain significance in MODY genes, and 51 had
no likely causative variant detected in any MODY or other diabetes-related genes.
The overall genetic confirmation rate for patients with high clinical suspicion for MODY was
thus 40.6% in our sample set (39/96 patients). Of the 39 unique likely causative MODY
variants detected, 27 (71.1%) had been previously reported as being causative (Table 2.1)
whereas 12 (30.8%) were novel and had not previously been reported in the HGMD
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database (Table 2.2). The novel variants were all likely to be deleterious based on their very
low frequency in the general population and in silico bioinformatic prediction software
(Table 2.2). Furthermore, rare variants of uncertain significance for MODY or non-MODY
related diabetes were seen in 6.3% of samples (6/96 patients); the clinical relevance of
these will require additional genetic, clinical and biochemical studies to evaluate (Table 2.3)
Rare variants most frequently involved GCK (MODY2) and HNF1A (MODY3), with 14 and 15
mutations in each, accounting for a combined 74.4% of mutation-positive samples.
Mutations in other MODY genes were seen less frequently, including HNF4A, HNF1B, PDX1,
PAX4, BLK and INS. No mutations were seen in CEL, NEUROD, KLF11 or KCNJ11.
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N= 96
patients with clinically
suspected MODY

N= 39 (40.6%)

N = 51 (52.1%)

With genetic diagnosis
of MODY

With no causal MODY
mutations

N= 27

N= 12

Previously reported as
being causative of
MODY

Likely causal of MODY
based on in silico
prediction

N = 6 (6.25%)
With mutations in
MODY genes of
uncertain significance

Figure 2.1: Suspected MODY cases
A total of 96 index samples were received between 1999 and 2015. 87 samples underwent
Sanger sequencing, which identified 20 MODY mutations and 2 Non-MODY diabetes-related
mutations. The remaining 65 samples, along with 9 additional samples received after 2012,
were sequenced using targeted next generation sequencing (LipidSeq). An additional 19
MODY mutations (10 previously described, 9 novel but likely deleterious) were detected. 6
were found to have mutations of uncertain significance in MODY genes. MODY-related
mutations were not identified in 51 individuals.

104

Table 2.1: Previously reported rare MODY variants identified in referred Canadian
samples
Gene
GCK

HNF1A

Nucleotide
change

Mutation
name

In silico prediction

Detection
method

Previously
reported in:

SIFT

PolyPhen

SNV

c.T59C

p.L20P

Damaging

Probably
damaging

LipidSeq

MODY2

SNV

c.G128C

p.R43P

Damaging

Probably
damaging

LipidSeq

SNV

c.C175T

p.P59S

Damaging

Probably
damaging

Sanger

SNV

c.G214A

p.G72R

Damaging

Probably
damaging

Sanger

SNV

c.G386A

p.C129Y

Damaging

Probably
damaging

LipidSeq

SNV

c.C617G

p.T206R

Damaging

Probably
damaging

Sanger

SNV

c.G676A

p.V226M

Damaging

Probably
damaging

Sanger

SNV

c.G706A

p.E236K

Damaging

Possibly
damaging

Sanger

SNV

c.G766A

p.E256K

Damaging

Probably
damaging

Sanger

SNV

c.T787C

p.S263P

damaging

Benign

Sanger/LipidSeq

SNV

c.C834G

p.D278E

damaging

Probably
damaging

LipidSeq

SNV

c.T971C

p.L324P

Damaging

Probably
damaging

Sanger

SNV

c.C1148T

p.S383L

Damaging

FS
del

c.130delC

p.L44W fs
X110

NA

NA

Sanger

SNV

c.G392A

p.R131Q

Damaging

Probably
damaging

Sanger

SNV

c.C748T

p.Q250X

Damaging

NA

Sanger

SNV

c.T803C

p.F268S

Damaging

Probably
damaging

Sanger

FS
del

c.823_826 del
GAAG

p.E275P fs
X65

NA

NA

Sanger

FS
ins

c.872_873 ins
C

p.P291P fs
X25

NA

NA

Sanger

FS
del

c.1028_1029
del CA

p.T343S fs
X74

NA

NA

Sanger

Type
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LipidSeq
MODY3

FS
del

c.1054 del T

p.S352P fs
X11

NA

NA

Sanger

FS
del

c.1136_1137
del CT

p.P379R fs
X38

NA

NA

Sanger

FS
del

c.1268 del G

p.G423V fs
X33

NA

NA

LipidSeq

SNV

c.C1298T

p.T433I

Tolerated

Probably
damaging

LipidSeq

HNF1B

SNV

c.G244A

p.D82N

Tolerated

Possibly
damaging

LipidSeq

MODY5

PAX4

SNV

c.G575A

p.R192H

Damaging

Probably
damaging

LipidSeq

MODY9

INS

SNV

c.G94A

p.G32S

Damaging

Probably
damaging

LipidSeq

MODY10

FS del, frameshift mutation due to deletion; FS ins, frameshift mutation due to insertion; LipidSeq, targeted
next-generation sequencing; NA, not applicable; SIFT, sorting intolerant from tolerant software; SNV, single
nucleotide variant.
Note: Accession numbers for specific genes (National Center for Biotechnology Information,
www.ncbi.nlm.nih.gov/) as follows: HNF4A: NM_000457; GCK: NM_000162.3; HNF1A: NM_000545.5; HNF1B:
NM_000458.2; CEL: NM_001807.3; PAX4: NM_006193.2; BLK: NM001715.2.
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Table 2.2: Novel heterozygous rare variants in MODY genes likely to be clinically relevant
in study cohort
Gene

Mutation type

Nucleotide
change

Mutation
name

In silico prediction
SIFT

PolyPhen

Detection
method

HNF4A

SNV

c.G25A

p.D9N

Damaging

Probably
damaging

LipidSeq

GCK

Frameshift
deletion

c.1226 del A

p.D409V fs
X21

Damaging

Probably
damaging

Sanger

HNF1A

SNV

c.G707A

p.C236Y

Damaging

Probably
damaging

Sanger

Frameshift
insertion

c.137_138 ins G

p.K46K fs X13

NA

NA

LipidSeq

Frameshift
insertion

c.243_244 ins
AG

p.T82R fs X73

NA

NA

LipidSeq

Splicing

c.1108 -3 del
TAG

IVS5 3delTAG

NA

NA

Sanger

In-frame
insertion

c.713_714 ins
GCC

L238 ins P

NA

NA

LipidSeq

SNV

c.A571C

p.K191Q

Damaging

Probably
damaging

LipidSeq

SNV

c.G92T

p.R31L

Damaging

Probably
damaging

LipidSeq

SNV

c.G290A

p.R97H

Damaging

Benign

LipidSeq

INS

SNV

c.T89G

p.L30R

Damaging

Probably
damaging

LipidSeq

BLK

SNV

c.C809T

p.T270M

Damaging

Probably
damaging

LipidSeq

PDX1

PAX4

LipidSeq, targeted next generation sequencing; NA, not applicable; SIFT, sorting intolerant from tolerant
software; SNV, single nucleotide variant.
Note: Accession numbers for specific genes (National Center for Biotechnology Information,
www.ncbi.nlm.nih.gov/) as follows: HNF4A: NM_000457; GCK: NM_000162.3; HNF1A: NM_000545.5; PDX1:
NM_000209.3; PAX4: NM_006193.2; INS: NM_000207.2; BLK: NM001715.2.
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Table 2.3: Known and novel heterozygous rare variants in MODY genes of uncertain
clinical significance found in study cohort
Known rare variants in MODY genes, but not associated with MODY
Gene

Mutation
type

Mutation

In silico prediction
SIFT

Reported
in HGMD

Previously associated
with:

PolyPhen

HNF4A

SNV

p.T117I

tolerated

benign

Yes

Type 2 diabetes (not
MODY)

GCK

SNV

p.R36W

damaging

probably
damaging

Yes

Type 2 diabetes (not
MODY)

SNV

p.F150S

damaging

probably
damaging

Yes

Hyperglycemia

SNV

p.G32S

damaging

probably
damaging

Yes

Permanent neonatal
diabetes

Reported
in HGMD

Previously associated
with:

INS

Novel rare variants of uncertain clinical significance
Gene
ABCC8

Mutation
Type

Mutation

In Silico Prediction

SNV

p.G505S

damaging

probably
damaging

No

possibly MODY12; familial
hyperinsulinemic
hypoglycemia; non-MODY
type 2 diabetes

SNV

p.V560M

tolerated

benign

No

possibly MODY12; familial
hyperinsulinemic
hypoglycemia; non-MODY
type 2 diabetes

SIFT

PolyPhen

Abbreviations: SIFT, sorting intolerant from tolerant software; SNV, single nucleotide variant; prob., probably;
HGMD, Human Genetic Mutation Database
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2.2.4 Discussion
The relatively high genetic confirmation rate we observed (40.6% of samples with likely
causative variants in MODY-related genes suggests that among Canadian endocrinologists, a
high clinical suspicion for MODY provides a reasonable yield of positive genetic testing. We
did not systematically evaluate the clinical criteria considered by each referring physician
prior to requesting genetic testing. Similarly, we did not systematically collect the clinical
features of the patients. Nonetheless, while we performed the analyses as a collegial nocost service, with the caveats inherent to a research-based method, the relatively high
detection rate of known or likely disease-causing MODY variants is a testament to the
clinical acumen of the referring Canadian endocrinologists. But even without standardized
inclusion criteria, the nonspecific gestalt of "high suspicion for MODY" seems to be a
reasonable determinant of who should undergo genetic confirmatory testing. If such
testing was to be developed into a clinical service with formal laboratory accreditation and
proficiency testing, formal pre-test clinical criteria for MODY suspicion might further
increase the diagnostic yield.
MODY could be a consideration in all patients with new-onset diabetes, especially those
presenting under age 25. A key supporting feature is the presence of a strong family
history: autosomal dominant inheritance with vertical transmission from affected parent to
50% of offspring, with similar clinical course in affected individuals. Other factors that
would enhance suspicion for MODY include non-insulin requiring diabetes in a nonoverweight or obese young person, or a patient diagnosed with type 1 diabetes but with no
episodes of ketoacidosis, even years after diagnosis, and when insulin is withheld.
Observation of a robust response to SUs and minimal response to metformin, may further
increase suspicion of MODY. Evidence of preserved beta-cell function and negative
autoantibodies would also support the diagnosis. Factors that may prompt genetic
screening for MODY are summarized in Table 1.4. The use of a clinical prediction tool such
as that used by Shields et al (6) may also be useful; it is readily available online and
demonstrates a sensitivity of 91% and a specificity of 94% for predicting genetic
confirmation of MODY (6).
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Genetic confirmation of MODY may be valuable in clearly defining the primary mechanism
of hyperglycemia. This could permit tailored and possibly more effective management,
especially in patients with mutations in the most common causal genes, i.e. HNF4A-, GCKand HNF1A-MODYs which, together, constitute 70% to 90% of all patients with MODY.
Positive diagnoses can also allow for presymptomatic identification of at-risk family
members who may benefit from increased monitoring, early intervention and counselling or
reassurance if they are mutation negative.
As discussed above (chapter 1.6.4), management of HNF4A-MODY and HNF1A-MODY
includes consideration of low-dose SUs as a first-line medication, as response is often
robust, achieving 4-5% lowering of glycated hemoglobin (HbA1c) with monotherapy;
patients can be commonly maintained on this inexpensive and generally well-tolerated
monotherapy for decades (1, 7). Patients with GCK-MODY can generally be managed with
reassurance and lifestyle modifications only, and may benefit from reduced cost and effort
stemming from ongoing surveillance or monitoring (1, 7). Having a specific MODY diagnosis
may also permit more appropriate management during pregnancy, with frequent fetal
surveillance to guide therapy.
Assuming that genetic testing is appropriate when suspicion of MODY is high, what is the
best technology or system to use? The recent global experience for most diseases, also
reflected in our lab's study of patients with diabetes and dyslipidemia, is that nextgeneration sequencing technology (NGS) should be the standard diagnostic platform. NGS
has reduced costs and expanded the range of gene loci and sequences that can be
screened. For instance, cost recovery for DNA preparation and Sanger sequencing for only
MODY2 (GCK) and MODY3 (HNF1A), is ~ $600 CDN at our centre. The cost for Sanger
sequencing each additional MODY gene ranges from ~ $100 to ~1000 CDN, depending on
the size of the gene. Thus, comprehensive screening of all 14 MODY loci using Sanger
sequencing could total several thousand dollars per sample. This contrasts with the total
cost recovery of ~ $500 for targeted NGS sequencing of 13 MODY genes using LipidSeq,
which also captures several other inherited diabetes and dyslipidemia loci (3).
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Screening all MODY loci simultaneously with targeted NGS also improves diagnostic yield.
Although most MODY variants in our samples were found in GCK or HNF1A genes, about
30% of variants were scattered among other MODY genes. This emphasizes that NGS allows
for simultaneous screening of all known MODY loci. Including the minor MODY loci in
comprehensive screening process from the outset reduces the false negative detection rate.
LipidSeq was a valuable and cost-saving tool in identifying MODY mutations compared to
traditional Sanger sequencing, and was able to identify an additional 19 mutations in our
sample set (Figure 2.1).
Factors that may result in false negative results from standard NGS include the presence of
mutation types that escape detection by sequencing, such as large-scale copy number
variations or chromosomal rearrangements. Also, some mutations may lie deep within noncoding regions outside the range of the NGS capture reagents. We designed LipidSeq to
capture at least 150 base pairs at each intron-exon junction and up to 1000 base pairs in the
5' and 3' untranslated regions, so detection of potentially causative non-coding variants
should be reasonably good. However, we cannot exclude the presence of potential
causative variants deep within introns or within remote non-coding regions that may be
important in emerging pathogenic mechanisms, such as micro RNAs or long non-coding
RNAs, among others. Furthermore, there may still be unknown and undiscovered MODY
loci that may be relevant in some currently mutation-negative patients. Finally, we cannot
exclude undetected non-mendelian, mitochondrial, epigenetic, gene-gene interactions or
gene-environment interactions as being potentially causative for MODY in some mutationnegative patients studied here.
Our false positive rate is constrained in part because of our stringent criteria for defining a
detected variant as "likely causative" or clinically relevant, which include cross-checking
past publications and existing reports of variants in global disease databases. Because of
our overall caution when reporting findings, we are less concerned with reporting
potentially false positive results, although this remains possible, especially for rare variants
detected for the first time in this sample set. Sorting the wheat from the chaff is becoming
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a general concern for high-throughput NGS analysis of human disease samples. We use
state-of-the-art criteria, including stringent bioinformatic algorithms, to impute potential
causality or clinical relevance of newly detected variants reported here. However, we
realize that the ultimate proof of causality for many newly detected variants means further
studies, including expanded family studies showing co-segregation of the variant with the
MODY phenotype across generations. Also, each new variant can be studied functionally at
the laboratory bench in a range of experimental model systems to acquire more confidence
in their causative nature.
Recently, United States data were used to analyse cost-effectiveness of genetic screening
for MODY (8). The model estimated that indiscriminately testing all patients diagnosed with
type 2 diabetes only modestly improved quality adjusted life years (QALYs) by 0.012,
compared to no screening, at a cost for one QALY of > $200,000 US (8). The total cost
difference between testing and no testing scenarios on an individual patient basis was
$2400 US, accounted for by the costs of screening and treatment (8). Raising prevalence
(i.e. pre-test likelihood) of MODY to 6%, or reducing the cost of genetic testing to $700 UD
in the model, which is consistent with our cost, suggested a cost-effective strategy, with
$50,000 US per QALY. Actual cost savings were achieved at a MODY prevalence (i.e. pretest likelihood) of > 30% (9). This suggests that while indiscriminate testing of all type 2
diabetic patients is not reasonable, cost-effectiveness is improved as the cost of genetic
analysis decreases, or in subgroups with high suspicion who have an expected pre-test
prevalence > 6%, such as those patients meeting the criteria in Table 1.4. Prevalence of
mutation-positive samples in our data set – 40.6% - far exceeded the cost-saving threshold
of 30%, suggesting that testing patients with high pre-test clinical suspicion may actually
result in an overall cost benefit. As a result, identification of each MODY case that led to
initiation of SU treatment resulted in improved glycemic control, with reduced HbA1c by ~
1.5% (8).
The use of high-throughput targeted NGS techniques may further tip the cost-benefit
equation in favor of testing. LipidSeq also has the additional benefit of testing for mutations
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in genes causing non-MODY diabetes, dyslipidemias and related conditions such as
lipodystrophy (3). Communicating these results back to the referring physician may
perhaps prompt reassessment of the patient's clinical situation and adjustment of the short
and long-term treatment plans.
Another potential benefit of genetic testing is improved quality of life and cost reductions
when a patient misdiagnosed with type 1 diabetes is reclassified as having MODY. For
instance, in the SEARCH for Diabetes in Youth study, 586 patients with diabetes onset
before age 20, negative autoantibodies and C-peptide levels ≥ 0.8 ng/mL were genetically
tested for mutations HNF1A (MODY3), GCK (MODY2),and HNF4A (MODY1) (10). MODY
mutations were identified in 47 patients, or 8% of the participants, representing 1.2% of the
overall pediatric diabetes population studied (10). Of the 47 newly identified MODY
patients, all but three received insulin prior to reclassification (10); insulin was stopped or
postponed in most re-classified patients.
Our study has some important limitations. First, we have minimal data for patients
receiving genetic analysis, including the clinical factors that prompted genetic testing, and
no follow-up data on the impact of the diagnosis on their subsequent management or
outcomes. There were no defined inclusion or exclusion criteria applied to samples before
proceeding with genetic testing, and no data regarding those factors that prompted
physicians to send samples for analysis. Furthermore, we did not collect data related to
ethnicity, which may have influenced the prevalence of specific MODY mutations. Finally,
patients tended to be referred from tertiary care facilities, from providers with more
experience with MODY (and perhaps with genetic testing in general), and from providers
who may have believed that a positive diagnosis would change their management
approach.
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2.2.5 Conclusion
MODY generally presents in young individuals with a family history of diabetes. It might be
underdiagnosed based on the low volume of requests for confirmatory genetic testing. A
confirmatory molecular genetic diagnosis of MODY in patients who meet clinical criteria for
high suspicion can have significant benefits in terms of improving diabetes management
and control. It might even be cost-saving if diagnostic testing is confined to high risk groups
(i.e. high pre-test likelihood) with an expected confirmation rate of > 30% (8). Further study
is required to determine the precise criteria to select individuals for genetic testing. Newly
discovered MODY mutations can be studied functionally in basic research laboratories to
confirm their causal nature. However, even in the absence of such data, our findings
suggest that high provider suspicion of MODY among Canadian endocrinologists is a
reasonable first screen and may be sufficient in some cases to warrant consideration of
confirmatory genetic testing.
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2.3 Copy Number Variations in Patients With Maturity-Onset
Diabetes of the Young

The work presented in Chapter 2.3 has been edited from these original manuscripts for
brevity and consistency throughout this dissertation.

Berberich AJ, Huot C, Cao H, McIntyre AD, Robinson JF, Wang J, Hegele RA. Copy Number
Variation in GCK in Patients With Maturity-Onset Diabetes of the Young. J Clin Endocrinol
Metab. 2019 Aug 1;104(8):3428-3436. PMID: 30912798.

Berberich AJ, Mokashi A, McIntyre AD, Robinson JF, Cao H, Wang J, Hegele RA.
Bioinformatic detection of copy number variation in HNF4A causing maturity onset diabetes
of the young. Clin Genet. 2019 Oct;96(4):376-377. PMID: 31309534;

Berberich AJ, Wang J, Cao H, McIntyre AD, Spaic T, Miller DB, Stock S, Huot C, Stein R, Knoll
J, Yang P, Robinson JF, Hegele RA. Simplifying Detection of Copy-Number Variations in
Maturity-Onset Diabetes of the Young. Can J Diabetes. 2021 Feb;45(1):71-77. PMID:
33011132.
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2.3.1 Background:
Genetic testing for MODY is currently accomplished primarily using next generation
sequencing (NGS) techniques, which allow for the identification of single nucleotide variants
(SNVs), small-scale insertions or deletions, as well as small-scale frameshift and null
mutations (11-14) (see chapter 2.2). . However, copy number variations (CNVs), defined as
large-scale deletions or duplications in a genomic DNA region that can involve part of a
gene, a whole gene or multiple genes, have historically been missed using sequencing
techniques, while simultaneously being too small to be detected by traditional cytogenetic
methods. Specialized targeted probe-based analysis or genotyping techniques can be used
to assess for CNVs, but these add additional cost, and have not been incorporated into
routine diagnostic procedures (15). They are currently of uncertain value in MODY,
although a few gene deletions have detected this way (15, 16).
Affected sequences of duplicated or deleted genomic DNA in a CNV appears qualitatively
normal. Therefore without a robust quantitative analytical tool, even when there appears
to be an increase or decrease in the amount of genetic material replicated in certain DNA
sections, it is impossible to distinguish a true deletion or duplication from the natural
variability in chemical amplification of DNA that is used in most sequencing platforms
(Figure 1.2, Figure 1.3), which are optimized to detect small qualitative changes in the
genetic code.
Recently, new bioinformatic techniques have been developed to provide the robustness
needed to assess for CNVs using NGS output data, without requiring additional sequencing.
These methods take advantage of the fact that current NGS protocols generate large
numbers of short partially overlapping DNA fragments that are assembled computationally
to seamlessly reflect the genomic sequence of the source material (17). In addition, the
total number of these synthetically-generated DNA fragments reflects the amount of
starting material in the genome. This enabled the development of new algorithms that,
through tallying the numbers of chemically-generated DNA fragments, impute deviations of
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the amount of starting material from the normal diploid two copies (i.e. maternal and
paternal) for any particular chromosomal region using a depth of coverage (DOC) ratio.
This approach has successfully been applied to detect CNVs using NGS data for several
genes causing dyslipidemias (18-21). Here we describe the application of this technique to
identify novel heterozygous large-scale deletions in individuals with suspected MODY that
was not identified using traditional Sanger or targeted NGS-based sequencing.

2.3.2 Materials and Methods:
2.3.2.1 Subjects:
96 unselected individuals were suspected of having MODY by their individual clinicians and
were referred for research-based MODY genetic testing at our center (see chapter 2.2). No
specific inclusion or exclusion criteria were applied to individuals tested. The original
testing results from this cohort found likely causal variants found in 39 of the original 96
patient samples (see chapter 2.2). The original NGS output data for the remaining
undiagnosed 51 samples was re-analyzed for copy number variations using the CNV caller
tool in VarSeq v1.4.3.
We focused on these 51 individuals in whom our initial targeted NGS screening failed to
detect likely or definitely causative DNA variants in MODY genes (chapter 2.2). Patients and
family members provided informed consent for genetic testing and analysis and under a
protocol approved by the University of Western Ontario Ethics Review Board (#07920E)
(Appendix B).
2.3.2.2 Targeted NGS:
All individuals were assessed for mutations in known MODY-associated genes using the
targeted NGS panel and bioinformatics pipeline known as LipidSeq (3), designed to test for
clinically relevant mutations in 73 specific genes associated with metabolic disorders,
including those associated with MODY (Appendix C). Targeted NGS was performed using
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standard operating procedures of the London Regional Genomics Centre (LRGC;
www.lrgc.ca). Sequencing reactions were designed to include all coding regions, as well as
the flanking ~150 base pairs (bp) of intronic DNA for each exon and ~500 bp at the
promotor and 3’ untranslated regions. The average depth of coverage (DOC) generated
using this method is ~300-fold for each base, meaning that there are ~300 partially
overlapping, non-identical small generated DNA fragments covering all coding regions of
MODY-related genes; these can be quantified using bioinformatic analysis for CNVs.
2.3.2.3 Original variant calling:
A variant was considered causal if it had previously been reported as pathogenic in the
Human Genome Mutation Database (HGMD). A previously uncharacterized rare variant in a
MODY gene was considered pathogenic if the reported frequency was <1% in the general
population and if it was predicted to be deleterious using in silico prediction tools, i.e.
Sorting Intolerant from Tolerant (SIFT) (4), PolyPhen2 (5) and Combined Annotation
Dependent Depletion (CADD) (see chapter 2.2)(22).
2.3.2.4 Bioinformatic analysis:
Following library preparation and enrichment, .FASTQ files of sequence data were
generated using the MiSeq personal sequencer platform (Illumina) and sequence
alignments, variant calling (.VCF files) , and target region coverage statistics (.BAM files)
were generated using a custom automated workflow in CLC Genomics Workbench (CLC Bio,
Aarhus, Denmark). Using this method, a variant is considered causative if it had been
previously reported as causative in the Human Genome Mutation Database (HGMD) or if
present in <1% of general population and predicted to be pathologic using in-silico
prediction models. None of the individuals we report here were found to have causative
mutations for MODY using this method.
2.3.2.5 CNV detection using NGS data:
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LipidSeq data (in the form of .VCF and .BAM output files) was analyzed using the CNV caller
function in VarSeq v1.4.3 (Golden Helix, Bozeman MT). A .BED file defining the target
region and probes used in the NGS panel is also required. The algorithm uses a ratio of DOC
in each region compared to a healthy reference population of 73 samples that were
subjected to the same NGS sequencing panel as the sample being analyzed to identify
potential CNVs.
The CNV caller tool makes use of “depth of coverage” (DOC), which refers to the number of
amplification copies at a particular genomic location, to determine likely deletions or
duplications. This technique takes small segments of DNA of approximately 100 base pairs
(bps) in length, and determines the DOC at that location for that sample (23, 24). The DOC
in the region of interest is compared to the surrounding regions and to a population of
control genomes to determine if there in an unusual increase or decrease in DOC at that
location (23, 24). If there is a statistically significant change in DOC, it is considered
suspicious for a copy number change. This technique is based on the principle that the
number of amplification copies present will be directly related to the amount of starting
material, such that if there are fewer than expected DNA strands to begin with, there will be
fewer copies when it is amplified, with the opposite being true for a duplication (23, 24).
Using the CNV caller tool, a ratio is calculated for each segment of DNA by dividing the DOC
in the target sample by the mean DOC in a reference population as follows:
DOC target sample
DOC reference sample
The reference sample is derived from individuals who do not express the condition of
interest who were sequenced using the same targeted sequencing panel, chemistry and
conditions as the target sample. The reference sample used in our study was obtained from
a population of 73 individuals who did not have features of MODY. A deletion may be
suspected if the ratio is 0.75 or lower and duplication if the ratio is 1.25 or higher. A Z-score
is used to determine statistical significance, with a score 5 standard deviations away from

119

the mean reference population score considered significant. This corresponds to a Z-score
of 5 or -5.
2.3.2.6 Confirmation of CNV state using WES:
We confirmed each CNV call by next performing WES on samples of interest, using standard
operating methods and procedures at LRGC (www.lrgc.ca). The average DOC for WES in our
facility is ~100. We determined the extent of the deletions using the same CNV caller
analysis tool and procedure applied to WES-generated data. The ratio used for CNV
suspicion is the same as for the LipidSeq targeted NGS data, however since the reference
population for this analysis was derived using only 15 WES samples, the Z-score significance
threshold was decreased to 3 (or -3). CNVs were also considered significant for samples
with Z-scores between 2 to 3 (-2 to -3), if the p-value was strongly significant.
2.3.2.7 Cytoscan analysis:
Confirmation of the CNV state was conducted using a clinically validated single nucleotide
polymorphism (SNP) microarray to assess for CNVs utilizing 2.6 million probes to determine
gene dosage through the genome (CytoScan HD array analysis, Affymetrix/ThermoFisher
Scientific, Waltham, MA, USA).
2.3.2.8 Breakpoint analysis:
The CNV caller analysis results allow for strong suspicion of a CNV deletion using probe-level
data. These methods allow determination of the approximate size of the deletion and the
approximate breakpoints on either end of the deletion. To determine the exact breakpoint,
Sanger polymerase chain reaction (PCR)-based probe analysis is required. Probes were
designed to target either side of the suspected deletion in an attempt to identify the exact
start and stop position of the deletion. The span of the wild-type strand is too great to
amplify under the same conditions as the mutant allele that contains a deletion between
the primers; therefore if amplification occurs in the candidate sequence but not in the
control, it suggests the primers hybridize to DNA that is relatively close to each side of the
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breakpoint (Figure 2.2). PCR amplification and sequencing of the abnormal amplified
fragment using the identified primer pair is then completed. Sequence alignment between
the amplification product and the known reference sequence then allows for exact
identification of the start and stop points for the deletion.
2.3.2.9 Family member analysis:
Following breakpoint determination in the two probands, the designed primer pair was
used to conduct targeted assessment of available DNA for first-degree relatives of each
proband to detect either the presence or absence of the deletion.

2.3.3 Results:
Likely CNVs were seen in GCK in two male individuals with clinically suspected MODY using
CNV caller analysis of LipidSeq output data. These were confirmed by WES-generated data
in one of the two individuals (Table 2.4)
The two patients with CNVs affecting GCK (MODY2) were confirmed to have deletions at
precisely the same breakpoint, suggesting this may have been a single ancestral event. As
far as we are aware, there was no direct familial relationship between the two individuals.
The GCK deletions spanned the 5’UTR – altExon 1 in both individuals, affecting probes
7:44228257-44229272. In the first individual, the CNV average ratio for this deletion was
calculated at 0.575312 with Z-score of -7.69375 for the LipidSeq-generated data and an
average ratio of 0.581204 with a Z-score of -2.94078 for the whole exome sequencing data.
In the second individual, the CNV average ratio for this deletion was calculated at 0.57517
with Z-score -7.02283 for the LipidSeq-generated data. WES was not conducted in this
individual due to low volume of DNA. Breakpoint analysis confirmed the presence of a
4,763 bp deletion in both individuals spanning chr7: 44224750 – 44229512 (Figure 2.3).
Because the deletion encompasses the promoter region, initiation codon and all of exon 1,
neither transcription of RNA nor translation of mature enzyme are predicted from this
allele.
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Family analysis revealed the presence of the identical deletion in an affected mother of GCK
proband 1, while no deletion was detected in the unaffected father. Similarly, analysis from
the family of GCK proband 2 revealed the presence of the deletion in the affected mother
and sister, but not in the unaffected father (Figure 2.2)
The clinical presentation in the two GCK-MODY probands was similar (Table 2.5). Both were
of French Canadian descent and each presented in the ninth year of life. Both had fasting
hyperglycemia, mild elevations in glycated hemoglobin and negative auto-antibodies;
proband 1 was being treated with metformin and proband 2 was following a diabetic diet.
Both had an affected mother and genotypically and phenotypically normal father. Both
individuals presented with polyuria, which is atypical for GCK-MODY. The sister of proband
1 carried the same mutation but presented with a milder phenotype.
Disclosure of the GCK genetic results to the sending physician resulted in a significant
change to the management approach and recommendations were made to the affected
probands and family members that they could safely discontinue all therapeutic
interventions.
In an additional individual, a deletion was also detected affecting HNF4A (MODY1) that
appeared to span the entire gene from the 3’ to the 5’ untranslated regions, involving
consecutive probes 20:42835510 -43115348 from reference Human Genome build hg19
(Figure 2.4). The CNV average ratio for this deletion was calculated at 0.531123 with Zscore of -6.6691 for the targeted LipidSeq-generated data and an average ratio of 0.577031
with a Z-score of -2.94078 and a p-value of <1x10-30 for the WES data. CytoScan results also
demonstrated a large-scale deletion spanning this region (Figure 2.5). Breakpoint analysis
by Sanger sequencing confirmed the presence of a heterozygous 242,258 bp deletion
spanning chr20:42871409-43113666 (Figure 2.4, Table 2.6)
The proband carrying this mutation was a Caucasian female, who was diagnosed with
impaired glucose tolerance (2-hour oral glucose tolerance test (OGTT) blood sugar of
8.6mmol/L (N<7.8mmol/L)) in 2002 at age 13, after an incidental finding of elevated fasting
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blood glucose prompted testing and yearly follow-up. She developed symptoms of polyuria
and thirst 3 years later and was diagnosed with diabetes at that time with an HbA1c of 7.6%
and a random blood sugar of 12.9mmol/L. She was 50.3kg (normal BMI) at the time of
diagnosis with negative diabetes associated autoantibodies. She had a significant family
history of diabetes, with her brother diagnosed at age 14, a paternal aunt diagnosed with
diabetes at age 19, both paternal grandparents diagnosed >60 years of age, a mother
diagnosed with GDM with both pregnancies, maternal grandfather diagnosed with diabetes
in his sixties and several maternal and paternal aunts and uncles diagnosed with diabetes in
childhood or adolescence. Initial genetic testing for MODY done at that time (2005) did not
identify any mutations. She was initially managed with gliclazide 30mg daily, but
experienced hypoglycemia with increase to 60mg with an HbA1c of 5.1%. She was trialed
on a long acting insulin analogue. Her HbA1c rose to 7.5% on Levemir and a rapid acting
insulin analogue was added without significant HbA1c benefit (7.2%). She was then
switched to glimiperide (a SU) at 2mg daily with significant improvement in HbA1c to 5.6%.
She was managed effectively with SU therapy for several years, but this eventually became
ineffective and she was switched to multiple daily injections of insulin and then a
continuous insulin infusion pump.
Three more CNVs, namely three distinct chromosome 17q12 deletions, ranging in size from
1.4-1.9 million base pairs, and all spanning HNF1B (MODY5) were also detected (Table 2.7,
Figure 2.5).
To confirm the three CNV calls for the chromosome 17q12 deletions, which all extended
into regions not covered by the targeted NGS panel, WES sequencing was performed.
Results of WES were concordant with those of targeted NGS (Table 2.7, Figure 2.5).
Clinical genotyping using CytoScan HD array analysis (Affymetrix/ThermoFisher Scientific,
Waltham, MA, USA) confirmed the presence of a chromosome 17q12 deletion at the
predicted location for all three individuals tested (Table 2.7, Figure 2.5). Family studies of
two probands found to have chromosome 17q12 HNF1B deletions suggested de novo
mutations in both, as neither parent was found to carry the mutation. Adding this new
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information to the findings of the original MODY cohort (chapter 2.2), CNVs accounted for 3
out of 4 (75%) of the HNF1B mutations found.
Following confirmation of the validity of CNV calling added to variant calling for MODY, this
analysis was incorporated routinely for all new samples received with clinical suspicion for
MODY. This allowed for the detection of two additional CNVs causing whole-gene deletions
of HNF1B in two further individuals, unrelated to each other or the original probands.
Clinical information for the five probands found to have heterozygous HNF1B gene
deletions on chromosome 17q12 is summarized in Table 2.8. All five probands initially
presented with symptoms in adolescence, between ages 12 and 18 years. All were of
Caucasian ethnicity. Four had a normal body-mass index (BMI), while the fifth had a BMI
that just met the threshold for overweight (25.1 kg/m2). Four of these five subjects were
negative for anti-GAD antibodies (Table 2.8). Glycosylated hemoglobin (HbA1c) during
available follow-up period ranged between 5.0-8.1% (Table 2.8). Four of these five subjects
were known to have additional manifestations related to the HNF1B deletion, including
congenital uterine or renal malformations, renal cysts, hypomagnesemia and
hyperparathyroidism (Table 2.8).
The positive antibody status in proband 2 is unusual for MODY. It is possible these are
elevated due to the presence of other autoimmune conditions (ie thyroid autoimmunity
(25)) or other conditions (ie cerebellar ataxia (26), which have both been linked to anti-GAD
positivity. Furthermore, previous studies (27) have also shown anti-GAD positivity in 1.7%
of non-diabetic adults, so it may be an incidental finding. Additionally, the HLA-DQA1/DQB1
risk haplotype for autoimmunity is also associated with anti-GAD positivity, even in the
absence of diabetes (27, 28), and she may carry this risk haplotype given that she has had
multiple family members diagnosed with T1DM. It is also possible that she may have a
combined type 1 and MODY phenotype.
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Figure 2.2: PCR amplification of DNA subjected to primers designed on either side of
suspected breakpoint in both probands and family members.
The top section shows the GCK gene and location of primers used to confirm and sequence
across the breakpoint. The normal sequence distance between primer pair F4 and R4 is
10,655 base pairs (bp), however PCR amplification in probands using primer pair F4 and R4
generated a product size of 5,893 bp, suggesting a 4,763 bp deletion.
In the pedigree charts for proband 1 and 2, affected status is indicated by solid color and
probands are indicated by arrows as shown. Gels show PCR amplified fragments aligned
beneath each individual.
The top gel shows amplification products generated using primers P1 located on the
proximal side of the suspected breakpoint, and P2, within the deleted fragment. The
middle gel contains amplification products generated using primers P4, located on the distal
side of the suspected breakpoint, and P3 within the deleted fragment. All subjects
demonstrated amplification for both the proximal (636 bp) and distal (288 bp) primer pairs.
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The bottom gel shows amplification products generated using primers P1 and P4 (581 bp).
In individuals without the deletion, the span between these two primers would be too great
to amplify under standard conditions; therefore if amplification occurs, it confirms the
presence of a large deletion between the two primers. Amplification between P1 and P4 is
seen in both probands and all affected family members, but not in unaffected family
members, confirming the presence of a deletion in these individuals.
The normal amplification products generated in individuals carrying the deletion with both
the proximal (P1 and P2) and distal (P3 and P4) primer pairs confirms these individuals carry
one normal copy of the gene and are heterozygous for the deletion. Thus, the mother and
both children in Family 1, and the mother and proband in Family 2 are all heterozygous for
the normal and deleted GCK alleles.
Primer (P) design: F4 (GTTCAGCCTCAGGTGTAGAAGCAG); R4
(AGGAACAGGACAGGAGTATACGTGG); P1 (TGAGTCAGTGGCTCCTGGAAAGG); P2
(CTGTCATTCCTCAGCTGAGCCAG); P3 (CTAGGGCTGTAAACTCTCCAGAG); P4
(AGGCTGAAGCTTCCTGAGCAGG). All PCR reactions used an annealing temperature of 60
degrees Celsius and a 5% DMSO solution. bp= base pair;
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Figure 2.3 Determination of deletion breakpoint for GCK
A) Screen capture of targeted NGS-generated data from Proband 1 processed by the CNV
caller tool identifies a potential deletion (shown by the star), as indicated by a significant
drop in DOC ratio to less than 0.75 and a Z-score less than -5, when compared to DOC in a
reference population. The bottom section maps the extent of involvement of GCK coding
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sequence, which is oriented 5' to 3' left-to-right, indicating that exon 1 is involved; B) WESgenerated data from the same sample using the same tool to confirm and also determine
the approximate extent of the deletion involving exon 1 and the 5'-flanking region of GCK
but not neighboring genes; C) Sanger sequencing electropherogram tracings showing
normal DNA sequences in the vicinity of the 3' (left side; letter codes shaded blue) and 5'
(right side; letter codes shaded yellow) breakpoints of the deletion. Internal sequence that
is missing in the deleted allele is shaded grey; D) Sanger sequencing electropherogram
tracings mutated DNA sequence in which the 3' (shaded blue) and 5' (shaded yellow)
regions flanking the deletion breakpoint, with absence of the intervening 4763 nucleotides.
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Table 2.4: Suspected MODY patients with Confirmed GCK CNVs
MODY
Subtype

Gene

Affected
Exons

Probes Affected
Chr:positionrange

CNV
State

VarSeq
Avg
Ratio

VarSeq
Avg Zscore

WES Avg
Ratio

WES Avg
Z-Score

Deletion
Size

Breakpoint

MODY 2

GCK

5UTR
– altExon 1

7:44228257
-44229272

Del,
het

0.575312

-7.69375

0.581204

-2.94078

4,763 bp

chr7: 44224750 –
44229512

MODY 2

GCK

5UTR –
altExon 1

7:4422825744229272

Del,
het

0.57517

-7.02283

N/A

N/A

4,763 bp

chr7: 44224750 –
44229512
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Table 2.5: Clinical Features of GCK-MODY Probands
GCK Proband 1:

Sister of GCK Proband 1:

GCK Proband 2:

Gender

Male

Female

Male

Age at diagnosis

8.5 years

11.8 years

8.9 years

Duration of
Symptoms PreDiagnosis

Longstanding polydipsia

Asymptomatic

9-12 months of polyuria,
polydipsia

Presentation

Fasting hyperglycemia
and abnormal OGTT

Elevated fasting BG (6-7
mmol/L)

Polyuria, polydipsia
Fasting BG 7 mmol/L

Family history

Mother: impaired glucose
tolerance
Paternal grandmother:
T2DM

Mother: impaired glucose
tolerance
Paternal grandmother:
T2DM

Mother: impaired glucose
tolerance
Maternal aunts: DM early
adulthood

Ethnic background

French Canadian

French Canadian

French Canadian

Weight at diagnosis

Weight 95th percentile
Height 75th percentile

Weight 95th percentile
Height 50th percentile

23 kg (25th percentile)

Anti-GAD antibodies

<1

N/A

<

Evolution

Fasting BG 6-9 mmol/L

Fasting BG 5-7 mmol/L

No decompensation

OGTT (at 120 mins)

BG 11.1 mmol/L

BG 10.0 mmol/L

BG 7.4 mmol/L
Peak insulin 149 pmol/L

Treatment

Metformin

Metformin

Diet only

Autoimmunity

No thyroid antibodies

No thyroid antibodies

No thyroid antibodies

HbA1c

6.4-6.9%

6.0-6.2%

5.9-7.0

Family

M: positive for mutation
F: negative for mutation
S: positive for mutation

M: positive for mutation.
F: negative for mutation
B: positive for mutation

M: positive for mutation.
F: negative for mutation

M: mother; F: Father; S: Sister; B: Brother; OGTT: oral glucose tolerance test; BG: Blood glucose; DM, diabetes;
T2DM: type 2 diabetes; GAD, glutamic acid decarboxylase; HbA1c, glycosylated hemoglobin
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Table 2.6: Summary of findings for HNF4A deletion
Gene

Affected
Exons

Probes
Affected
Chr:position

CNV
State

VarSeq
Avg
Ratio

VarSeq
Avg Zscore

WES Avg
Ratio

WES
Avg ZScore

PValue

CytoScan
Results

Deletion
Size

Breakpoint

HNF4A

5UTR
– 3UTR

20:42835510
-43115348

Del,
het

0.531123

6.6691

0.577031

2.5639

<1x10-

Positive

242,258
bp

chr20:4287140943113666

MODY
Subtype
MODY 1

30

Del: deletion; het: heterozygote; UTR: untranslated region; NA: not available; WES: Whole exome sequencing; CNV: copy number
variation; bp: base pair; Avg: average;
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Figure 2.4: Confirmation of CNV detection using NGS output data in HNF4A
A CytoScan genotyping output showing loss of zygosity on chromosome 20q13 spanning the HNF4A gene, with reduced intensity
of probe signals, shown on an expanded scale in panel B. Panel C shows the corresponding region with the same deletion
detected using depth-of-coverage analysis from NGS and WES output data. Panel D shows the genes that map within the
deleted region, which includes the entire HNF4A gene. Panel E shows Sanger sequencing electropherogram tracings that
demonstrate normal DNA sequences in the vicinity of the proximal 3' (left side) and distal 5' (right side) breakpoints of the
deletion. Internal sequence that is missing in the deleted allele is shaded grey. In the bottom center is the Sanger sequencing
electropherogram tracing from the proband, showing the deletion junction, with absence of the intervening 242,258
nucleotides. Amplification primer locations relative to the deletion are indicated on the CNV state output in panel C. The normal
sequence distance between primer pair PF and PR is 246,593 base pairs (bp), and PCR amplification between them would not be
possible, however PCR amplification in the proband, but not the normal control, using primer pair PF and PR generated a product
size of 4,335 bp, suggesting a 242,258 bp deletion. Amplification is also seen in the proband using primer pair P1 and P2 on the
proximal end of the breakpoint, and primer pair P3 and P4 on the distal end of the breakpoint, confirming the presence of at
least one normal gene copy. Thus a heterozygous deletion spanning the entire HNF4A gene is confirmed in the proband.
Primer (P) design: PF (GTCAGCCATGTGTCCTAGCCATGTTCAGG ); PR (CTGAGTAGTGGAGACTACAGACATGTG); P1
(TCCAGAAGTGCTGGGATTACAGGTG); P2 (GATCTGTCACGTTGCTTCACTGTGG); P3 (CACTTGAGGTCAGGAGTTTGAGACCAG); P4
(AGTTTTGCTGTTCTCACCCAGGCTG); PCR reactions for P1-P4 used an annealing temperature of 60 degrees Celsius and reactions
for PF/PR used annealing temperature of 63 degrees Celsius. All PCR reactions used a 5% DMSO solution. bp= base pair.
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Table 2.7: CNV Caller Summary HNF1B deletions
Type

TNGS Probes
Affected

TNGS
Ratio
0.581791

TNGS Zscore

WES Ratio

WES Zscore

Cytoscan

Probes Affected

Size

Del,
17:3604618317q12
17:34455782-5.5768
0.579920
-2.13712
1.852 million bp
het
36105346
Deletion
36307773
Del,
17:3604618317q12
17:348224650.540671
-9.32017
0.521851
-3.89335
1.582 million bp
het
36105346
Deletion
36404138
Del,
17:3604618317q12
17:348224650.539208
-12.4028
0.535156
-2.27315
1.461 million bp
het
36105346
Deletion
36283612
Abbreviations: Del, deletion; Het, heterozygous; TNGS, Targeted Next Generation Sequencing, WES, Whole Exome Sequencing; bp, base pairs
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Table 2.8: Clinical Characteristics of Probands carrying HNF1B mutations
HNF1B
Proband 1
Female

HNF1B
Proband 2
Female

HNF1B
Proband 3
Female

HNF1B
Proband 4
Male

HNF1B
Proband 5
Female

Age at
diagnosis
Duration and
Symptoms
Pre-Diagnosis

12.2 years

15 years

17.6 years

18 years

15 years

Polyuria,
polydipsia for
few months

Polyuria,
polydipsia

Weight loss

8 months of
fatigue, trouble
focusing

Presentation

BG 19
mmol/L;
urinary
ketones 1+;
no acidosis
Mother: GDM
Mat GM:
T2DM

BG 32;
No ketones

1 month of
fatigue,
anorexia, slight
weight loss
2 days nausea +
vomiting
BG 24 without
acidosis

Elevated BG; no
ketones

IGT on OGTT

Mat GM:
T2DM
Siblings: T1DM
Uncle T1DM

None

Father: T2DM
Sister: GDM

Caucasian,
French
Canadian
18.7

Caucasian

Caucasian

Caucasian

Mother: GDM x3
 T2DM
Mat GM: T2DM
Mat uncle:
T2DM
Italian

23.3

21.6

25.1

Normal

Anti-GAD
antibodies

<1

>250

Negative

Negative

Negative

Treatment

Insulin 0.87
U/kg/day

Insulin
Failed
Metformin

Metformin
Insulin
0.1U/kg/day

Metformin
Gliclazide

Autoimmunity

No thyroid
antibodies

-

No other
Autoimmune
disease

HbA1c

6.1-6.7%

5.0-6.9%

TTG neg
TSH normal
TPO AB
negative
<6%

Insulin 
metformin 
insulin +
metformin
No other
Autoimmune
disease

6.2-8.6%

max 8.1%

Other
manifestations

Uterine
agenesis;
Renal cysts

Left partial UPJ
obstruction

Hypomag /
Gittelman’s
Normocalcemic
hyperPTH
M: negative for
mutation

Congenital
renal
malformation

None Known

Gender

Family history

Ethnic
background
BMI

Family

M: Negative
ND
ND
ND
for mutation
F: Negative
for mutation
Abbreviations: BG: blood glucose in mmol/L; F: father; GDM: gestational diabetes; GM: grandmother; HbA1c:
hemoglobin A1c; hyperPTH: hyperparathyroidism; IGT: impaired glucose tolerance; M: mother; Mat: maternal;
Max: maximum; ND: not done; OGTT: oral glucose tolerance test; T2DM: type 2 diabetes; TPO AB: thyroid
peroxidase antibody; TSH: thyroid stimulating hormone; TTG: tissue transglutaminase; UPJ: ureteropelvic
junction
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Figure 2.5: Identification and confirmation of 17q12 deletion

Figure 2.5A: Screen capture showing data generated using the CNV caller tool applied to targeted NGS-generated output. Ratio
is approximately 0.5 throughout with an average Z-score of -9.32017. The potential deletion spanning the entire HNF1B gene is
shown by the large red box.
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Figure 2.5B: The deletion was predicted to span approximately 1.6 million base pairs by the CNV caller tool using WES-generated
data. The span of the deletion is shown by the large red box, with an average ratio of approximately 0.5 throughout and an
average Z-score of -3.89335.
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Figure 2.5C: Results of a CytoScanTM HD Array, visualized using Chromosome Analysis Suite identifies the region containing the
CNV, on chromosome 17 as shown in the top panel. The middle panel shows a drop in signal, indicating a decrease in copy
number at that position. The bottom panels shows an expanded view of the deleted region, which includes the HNF1B gene, as
indicated
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2.3.4 Discussion:
The work outlined above has expanded the available knowledge on MODY in a number of
important ways. Firstly, novel mutations, including CNVs, were identified as likely causal for
MODY through investigation into clinically suspected MODY cases. Additionally, while
further investigation is needed, this work established that clinical suspicion of MODY can be
a reasonable screening tool on its own to help select appropriate candidates for genetic
testing.
These investigations also demonstrated that the use of gene panels incorporating all MODY
genes, along with routine CNV testing is a beneficial and cost effective way to screen for
MODY in suspected cases. This work suggests that incorporating these methods into
routine screening may significantly improve genetic confirmation rate and maximize genetic
testing utility, and would be recommended
Furthermore, these studies also highlight the benefits of reclassifying individuals who have
been presumptively diagnosed with other diabetes phenotypes as having MODY. Changes
in management were recommended not only for the probands, but also for other affected
family members in the majority of cases.
As previously discussed, optimal management of MODY diabetes is highly dependent on the
underlying genotype. For example, as seen in the proband diagnosed with HNF4A -MODY
(MODY1), this form of MODY may be optimally treated with low-dose oral sulfonylurea
therapy for many years, although insulin therapy may eventually be required (2, 12, 29).
Three individuals in this series were diagnosed with HNF1B deletions. Mutations in HNF1B
lead to MODY5, also known as renal cysts and diabetes syndrome (30, 31). Whole gene
deletions of one copy of HNF1B are responsible for up to 50% of cases of MODY5, with
virtually all of these being chromosome 17q12 deletions of varying magnitude (30-33). The
majority (~70%) of these deletions arise de novo (33). The "17q12 deletion syndrome" is a
term that refers to more extensive deletions of ~1.4 Mbps that encompass HNF1B and
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several surrounding genes (32-34). Clinical manifestations of 17q12 deletion syndrome
include a mild to moderate, progressive diabetes with a mean onset of age 24, but which
can present from the neonatal period up to middle age (31, 33). Individuals with the
condition can have congenital or later-onset urogenital malformations, and also have
frequent renal, pancreatic or hepatic complications, including cysts, hypomagnesemia,
hyperuricemia, or exocrine pancreatic deficiencies (31-33). Primary hyperparathyroidism
also appears with higher prevalence (31). Cognitive impairment and/or developmental
delay is common, presenting in 50% of those with 17q12 deletion syndrome (31-33).
Individuals with impaired function of HNF1B may respond to low-dose oral sulfonylurea
therapy but insulin is often required (31, 35). They may also warrant periodic monitoring
for genitourinary, parathyroid, hepatic or other manifestations.
Generally, GCK-MODY (MODY2) is benign and non-progressive and can be managed without
medication, or other therapeutic measures, including diet, with the exception of special
monitoring during pregnancy (12, 36, 37). However, it is important to distinguish it from
other forms of MODY and from type 1 or type 2 diabetes in order to optimize management
decisions (38). A recent study from the United States found that 49% of patients with GCKMODY were unnecessarily being treated with glucose-lowering agents (38). As patients
with MODY often present at a young age and with a normal BMI they are frequently
misdiagnosed as having type 1 diabetes and are started on multiple daily injections of
insulin (6, 10, 39). For example, two recent large cohort studies identified MODY, mutations
in up to 6.5% of children with diabetes, many of whom had not previously been identified
(40, 41). Re-classifying some of these patients as GCK-MODY could allow for safe
discontinuation of insulin, and generally all other treatments, which can have a profound
impact on quality of life as well as healthcare costs and burden.
Clinically, there is also some suggestion that large-scale deletions may present with a
slightly more severe phenotype than in other forms of MODY. For example, both probands
with GCK deletions experienced polyuria, a symptom not generally associated with GCKMODY, which is usually asymptomatic. GCK proband 1 also had higher than expected
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fasting blood glucose, up to 9 mmol/L. However, both affected mothers and the sister of
GCK proband 1 appeared to have only mild phenotypes, with the mother of GCK proband 1
was diagnosed with only impaired glucose tolerance and the mother of GCK proband 2 with
isolated gestational diabetes. The sister of GCK proband 1 presented with features more
classically consistent with GCK-MODY, being asymptomatic, with lower fasting BG (5-7).
Both families were also French Canadian, and may have shared a common ancestor. The
milder phenotype in the females harboring the deletion raises the possibility that there may
be gender differences associated with phenotype expression, or this difference could be
related to other factors, such as variable penetrance, environmental or lifestyle influence or
simple chance. Further work to investigate whether other CNVs support a distinctive
clinical phenotype may help clarify the importance of these observations.
While CNVs have not traditionally been screened for or reported as causal mutations for
MODY, our findings here, as well as other emerging work, suggests CNVs may be a more
significant contributor to MODY than previously thought (6, 12, 38, 39). One report
identified deletions causing MODY in GCK and HNF1A using a dedicated multiplex ligationdependent probe amplification (MLPA) assay (16). Another reported large-scale CNVs in
HNF1B make up a significant proportion of causative mutations for MODY5 (15). Case
reports of partial gene deletions in GCK have also been reported in the literature (42, 43).
Our data provide further support the presence of CNVs in at least 3-4% of previously
undiagnosed MODY patients, while demonstrating a simpler, more cost-effective approach
to make this molecular diagnosis. The overall proportion of MODY cases that can be
attributed to CNVs may become more apparent as CNV analysis is incorporated routinely
when assessing for MODY via NGS.
In total, we now have identified heterozygous CNVs in 8 individuals with MODY,
representing ~13% of those with a clear molecular diagnosis. For those who could be reclassified from "mutation-negative" to "CNV positive", quality of life and management
decisions were impacted, allowing for more personalized and effective treatment. Our
approach can effectively detect CNVs in MODY genes from NGS data. It seems to be
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important to seek CNVs when performing molecular testing for MODY using NGS to avoid
false negative results, which occurred in ~6% of our original cohort using NGS alone without
CNV detection. This is accomplished by incorporating CNV detection routinely during NGS
variant calling, without significantly adding to the cost of sequencing. As shown, the routine
use of this method helped to diagnose two additional cases subsequent to our initial cohort,
which would otherwise have been missed using standard NGS sequencing.
Seeking CNVs may be of particular importance when HNF1B mutations are suspected. This
was supported by our data, which showed that five of the 8 detected cases of CNVs causing
MODY in our series were caused by deletions in HNF1B. Furthermore, prior work suggests
that deletions comprise ~50% of all HNF1B mutations (32). At a minimum, if MODY is
suspected and there are any signs of urogenital malformations, exocrine pancreatic
dysfunction, hypomagnesaemia, hypercalcemia, or other features associated with HNF1BMODY or 17q12 deletion syndrome, and no variants are detected using bioinformatic calling
algorithms for small mutations in NGS output, effort should be made to extend the
investigation to include CNVs to avoid missing cases and making false negative diagnoses.
Detected deletions of HNF1B appear to be distinct in different families and vary notably in
size, ranging from 1.4-1.9 million base pairs. Exact breakpoint determination was
attempted in the individuals studied here but this proved to be unsuccessful due to
technical challenges related to the high degree of DNA sequence homology involving the
surrounding genomic region. It may be that sequence homology, which made primer-based
breakpoint analysis impossible, causes a tendency for misreads during DNA duplication in
vivo, which may account for the relatively high frequency of deletions and duplications that
occur in this region. This is also supported by the fact that most detected cases of deletions
in this region arise de novo (32-34, 44). This also suggests that a lack of family history
should not be a reason to refrain from genetic testing for HNF1B-MODY if clinical suspicion
is otherwise present.
Overall, by reclassifying these new mutation-positive cases, the genetic confirmation rate
we originally reported in chapter 2.2 would increase from ~40% to close to 50% (45/96 =
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47%), which strengthens the argument that clinical suspicion for MODY by a specialist may
be sufficient on its own, without additional selection criteria, to recommend referral for
genetic testing.
Our results have some limitations. While these large deletions would be expected to have
deleterious effects, and they seem to segregate with phenotype in family members, no
functional studies were conducted to directly confirm lack of in vivo activity. Also, while
the CNV caller tool was validated using our specific NGS panel and reference population,
this may not be universally applicable. Also, given our small sample size, generalizations
about any phenotype differences with this large-scale deletion compared to causes related
to pathogenic SNPs or small inserts/deletions is limited.
Future work is still needed to better refine the strategies for suspecting and identifying
MODY clinically and selecting the most appropriate candidates for genetic testing.
Establishing an estimate of the unrecognized MODY burden may also provide valuable
information, and may be obtained by systematically assessing the local diabetes database to
identify those who may be most likely to benefit from genetic testing. Additionally, the
standard incorporation of NGS-based CNV testing for MODY may help to more accurately
determine the prevalence of CNVs amongst MODY genes. Furthermore, systematically
screening populations with higher potential for MODY burden, such as newly diagnosed
patients under the age of 35 with negative autoantibodies or atypical features, or those
diagnosed with hyperglycemia in pregnancy, may also help establish the best methods for
case detection and more accurately determine the prevalence of MODY subtypes in these
populations.

2.3.5 Conclusion:
These findings confirm the utility of applying the CNV caller tool to screen for CNVs in MODY
genes from NGS data. In doing so, we have identified novel deletions in two MODY genes
and confirmed the presence of CNVs causal for MODY in 8 individuals with consistent
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clinical features. Our data suggests that routinely incorporating CNV analysis of NGS data
may increase diagnostic yield when investigating a suspected MODY case.
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2.4 Chapter Conclusions:
Establishing a MODY diagnosis can have a significant impact on optimal management,
quality of life and disease course in individuals misclassified with other diabetes subtypes,
as well as for their family members. CNVs may be an under-recognized cause of MODY, and
may be overlooked with standard genetic testing. The use of panel-bases NGS sequencing
with incorporated CNV analysis improved genetic confirmation rates in a cost-effective
manner, and should be considered as a standard testing method when evaluating an
individual clinically suspected of MODY.
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Chapter 3: Improve counselling and management of genetic
triglyceride disorders

3.1 Overview:
Unlike MODY, which has monogenic origins, many endocrine conditions have more complex
genetic determinants, and are largely polygenic in nature. For most of these conditions
there may be a very small fraction of the population that expresses the phenotype due to
large effect mutations, but the majority of individuals will have a high burden of smaller
effect changes that lead to expression of the phenotype.
The expression of these conditions tends to be more variable than in monogenic conditions,
and, while there is often a family history present, there is not a clearly predictable pattern
of inheritance like that seen in monogenic traits. Clinical assessment, therefore, plays an
important role in the evaluation of these disorders.
For most polygenic conditions, the genetic background of an individual may predispose to a
certain phenotype but environmental factors may also play a significant role. For many of
these, it may be possible to modify expression and ameliorate risk by adjusting these
environmental influences. It is therefore important to identify which factors are most likely
to lead to expression of these conditions to achieve best possible control and prevention.
One endocrine condition with complex molecular genetics is hypertriglyceridemia. There
are very rare, autosomal recessive monogenic forms of hypertriglyceridemia that are
important to identify and treat accordingly. Understanding how to differentiate these
individuals from the more common individual with polygenic basis is important clinically for
optimal management.
The first study in this section (chapter 3.2) investigates the phenotypes seen in the rare
monogenic forms of hypertriglyceridemia that lead to familial chylomicronemia syndrome
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(FCS) to identify the clinical features that may help predict the underlying genotype, and
may distinguish them from other more common HTG phenotypes.
While understanding these rare monogenic forms is important, most individuals with
hypertriglyceridemia will have polygenic susceptibility. Therefore, counselling and
management for most individuals with HTG will focus on addressing modifiable risk factors
and optimally managing complications, which are the focus of the second (chapter 3.3) and
third (chapter 3.4) study presented here.
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3.2 Clinical and biochemical features of different molecular
etiologies of familial chylomicronemia

The work presented in Chapter 3.2 has been edited from this original manuscript for brevity
and consistency throughout this dissertation:

Hegele RA, Berberich AJ, Ban MR, Wang J, Digenio A, Alexander VJ, D'Erasmo L, Arca M,
Jones A, Bruckert E, Stroes ES, Bergeron J, Civeira F, Witztum JL, Gaudet D. Clinical and
biochemical features of different molecular etiologies of familial chylomicronemia. J Clin
Lipidol. 2018 Jul-Aug;12(4):920-927.e4. doi: 10.1016/j.jacl.2018.03.093. Epub 2018 Apr 4.
PMID: 29748148.
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3.2.1 Background:
Familial chylomicronemia syndrome (FCS) is the rare monogenic form of
hypertriglyceridemia, affecting between 1 and 10 per million individuals (1-3). While severe
hypertriglyceridemia (TG > 10 mmol/L or 880 mg/dL) is relatively common with a prevalence
of ~ 1 in 600 in North America, only a small fraction of these individuals have FCS (1, 4, 5)
(see chapter 1.7 for additional background).
FCS follows an autosomal recessive pattern of inheritance and results predominantly (>90%)
from bi-allelic mutations in the LPL gene encoding lipoprotein lipase (LPL) (2, 3, 6-15); this
form we abbreviate herein as LPL-FCS. The remainder are caused by bi-allelic mutations in
four additional genes involved in supporting or enabling LPL function, namely APOC2,
APOA5, LMF1 and GPIHBP1, which encode, respectively, apolipoprotein (apo) C-II and A-V,
lipase maturation factor 1 (LMF1) and glycosylphosphatidylinositol-anchored high density
lipoprotein-binding protein 1 (GPIHBP1) (16-18), and we abbreviate this group of patients as
non-LPL-FCS. The role of each of these gene products in lipolysis of TG is discussed in
chapter 1.7.5 (4, 5).
Given the extreme rarity of these conditions, especially of non-LPL-FCS, no prior studies
have directly compared clinical and biochemical features of the different monogenic causes
of FCS. Here, we evaluate phenotypic differences between LPL-FCS and non-LPL-FCS
patients.

3.2.2 Methods
3.2.2.1 Participants
The study included data from clinically identified FCS participants who were screened and
included in a phase 3 randomized placebo-controlled trial of volanesorsen (NCT02211209).
Briefly, the trial duration was 52 weeks, and subjects were randomized 1:1 to receive either
volanesorsen 300 mg SC or placebo injections. The primary outcome was percent change in
triglyceride levels at 13 weeks. Inclusion criteria for the clinical trial included a personal
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history of pancreatitis and with documented chylomicronemia or triglyceride values
exceeding 10 mmol/L and genetic testing or post-heparin lipolytic assay consistent with FCS.
Patients without pancreatitis could be eligible up to a maximum of 28% of all patients. The
study enrolled adult patients (age ≥18 years) with history of chylomicronemia as evidenced
by: 1) documentation of lactescent serum in the fasting state; or fasting triglyceride
measurement ≥ 10 mmol/L (880 mg/dL). The diagnosis of FCS required documentation of at
least one of the following: 1) known bi-allelic loss-of-function mutations in LPL, APOC2,
APOA5, GPIHBP1 or LMF1 genes; 2) post-heparin plasma LPL activity of ≤20% of normal;
plus 3) fasting TG ≥ 8.4 mmol/L (750 mg/dL) at screening. Patients were willing to follow a
restrictive diet (≤20 g fat per day). The patients included for analysis here were derived from
screening the confirmatory testing on referred samples from study subjects in the clinical
trial. Subjects gave informed consent for DNA sequencing, which was performed under
Western University Research Ethics protocol 07920E (Appendix B).
3.2.2.2 Clinical and biochemical assessments
Baseline lipids, lipoproteins, apolipoproteins and metabolic assays were performed on
fasting plasma as described in the trial protocol (19, 20). Fasting venous blood samples
were taken 10 minutes pre- and post-intravenous infusion of heparin (50 U/kg), and total
post-heparin lipolytic activity was determined as described (21, 22). A subset of markers
was also examined 4 hours post liquid-formulated high fat-test meal (4800 kJ, 130 g of fat,
17 g of protein and 21 g of carbohydrate).
3.2.2.3 Molecular analysis
Genomic DNA was isolated from whole blood as described (23). Genomic libraries of
indexed and pooled patient samples were generated for target candidate genes in lipid
metabolism. These included the coding regions, > 150 base pairs (bp) at intron-exon
boundaries and > 1000 bp of the 5' untranslated region of the known causative genes for
monogenic chylomicronemia, including LPL, APOC2, APOA5, LMF1 and GPIHBP1. The
targeted next-generation DNA sequencing and custom bioinformatic pipeline are known
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collectively as "LipidSeq" (23, 24) (Appendix C). Prepared DNA libraries from each patient
sample were assayed using the MiSeq personal sequencer (Illumina, San Diego CA). The
method has mean > 300-fold coverage for each base. Sanger sequencing was used to
confirm all variants.
3.2.2.4 Annotation and evaluation of observed variants
FASTQ files derived from the MiSeq output were processed individually using a custom
automated workflow in CLC Genomics Workbench version 8.5.1 (CLCbio, Aarhus, Denmark)
for sequence alignment, variant calling, producing a variant call format (vcf) file, and target
region coverage statistics. Variant annotation was performed using ANNOVAR (25, 26) using
customized scripts (http://annovar.openbioinformatics.org/en/latest/).
There is no consensus on the procedure to attribute causality or pathogenicity to FCS
variants detected by NGS. Fortunately, many variants detected in monogenic
chylomicronemia genes have had a long history of archiving and annotation, as well as
abundant publications of functional consequences. For instance, > 150 individual variants
previously reported as being causative in LPL deficiency are reported in the Human Gene
Mutation Database (HGMD; HGMD; http://www.biobase-international.com/product/hgmd)
(27-29).
Annotated coding and noncoding (± 10 base pairs from adjacent exon) variants in vcfs were
first filtered to select the rare variants according to minor allele frequencies (MAF) <1% in
1000 Genomes Project (1KG) (30), Exome Variant Server (EVS) (31) or Exome Aggregation
Consortium (ExAC) (32) databases. Polymorphism Phenotype Version 2 (PolyPhen2) (33),
Sorting Intolerant from Tolerant (SIFT) (34, 35) and Combined Annotation Dependent
Depletion (CADD) (36) scores were used to evaluate the deleteriousness of the filtered
coding variants. Splicing Based Analysis of Variants (SPANR) (37) and Automated Splice Site
and Exon Definition Analyses (ASSEDA) (38) were used to identify rare deleterious splicing
variants.
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Novel variants found in this study were determined to be likely causative when: 1) they had
no listed allele frequencies in 1KG, EVS or ExAC databases, no reference SNP indentification
number (rsID) in the dbSNP database, and/or were not reported in the HGMD database; 2)
for coding variants, a deleterious score for > 2 in silico algorithms; and 3) for non-coding
variants, a deleterious score for > 1 in silico algorithm. Copy number variants (CNVs),
sometimes referred to as "del-dup" mutations, were determined using a custom
bioinformatics approach.
As controls for our annotation pipeline, we used sequence data from the 1KG database.
Standard criteria based on standards of the American College of Medical Genetics, and also
on published functional studies where available, were used to assess the potential
pathogenicity of identified mutations. Individuals with bi-allelic pathogenic mutations in
LPL were classified as "LPL-FCS" while those with pathogenic mutations in the other genes
were classified as "non-LPL-FCS". Simple heterozygotes for loss-of-function mutations were
excluded from the analysis.
3.2.2.5 Statistical analysis
Statistical analyses were conducted using SAS v9.3 (SAS Institute, Cary NC). Between-group
differences for mean quantitative traits were evaluated with Wilcoxon signed-rank test for
non-parametric sample distribution, while differences in discrete traits were evaluated
using chi-square analysis with Fisher's exact test. Statistical significance was defined as
P<0.05 for all comparisons. Our study sample afforded 84% power to detect a 50%
difference in a quantitative trait whose standard deviation was 20% of the mean with 2sided alpha = 0.05.

3.2.3 Results
3.2.3.1 Classification and mutation distribution
Of 67 individuals with phenotypic data who underwent targeted next generation
sequencing, 41 had likely or definitely pathogenic bi-allelic LPL gene mutations: of these
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82%, 7% and 11% were missense, nonsense and splicing variants, respectively (Table 3.1)
DNA quality for one patient from Québec was inadequate for LipidSeq; in this case we made
an exception and accepted results from the certified provincial DNA testing facility, which
diagnosed homozygosity for the founder LPL p.P234L loss of function variant. An additional
11 individuals had non-LPL FCS, of whom 2 (22%) had bi-allelic mutations in APOA5, 5 (45%)
had bi-allelic mutations in GPIHBP1, 1 (11%) had bi-allelic mutations in LMF1, 1 (11%) had
bi-allelic mutations in APOC2 and 2 were compound heterozygotes for mutations in LPL and
either APOA5 (11%) or LMF1 (11%). The remainder of individuals, with a clinical FCS
phenotype, but in whom genetic testing was not fully confirmatory, were excluded from this
analysis. The mutations detected in study subjects are shown in Tables 3.1 and 3.2
3.2.3.2 Clinical and biochemical features
Numerous clinical, demographic and biochemical features were determined from studied
individuals (Table 3.3). Non-LPL-FCS individuals were younger at screening than LPL-FCS
cases (38.3 + 12.3 vs. 47.1+ 12.8 years, P=0.075). As expected compared to LPL-FCS
individuals, non-LPL-FCS individuals had significantly higher post-heparin LPL activity
(39.7+29.8 vs. 6.3+5.8 U, P=0.0028). Also, low density lipoprotein (LDL) cholesterol,
determined directly by ultracentrifugation, was significantly higher in individuals with nonLPL-FCS compared to LPL-FCS (0.57 +0.27 vs 0.75 +0.21 mmol/L (28.9 + 8.1 vs. 22.1 + 10.4
mg/dl) P=0.027), although levels in both subgroups were very low. Apo B levels were not
significantly different. Finally, compared to LPL-FCS individuals, non-LPL-FCS individuals had
higher postprandial insulin (302.7+159.3 vs 97.0 +137.1 u/L; P= 0.0089) and higher
postprandial C-peptide levels (32.5 + 12.3 vs 20.7 + 6.2, P=0.0492).
Compared to LPL-FCS individuals, non-LPL-FCS individuals had a non-significant trend
towards lower total triglycerides (TG) (20.79 +10.6 vs 29.5 +14.8 mmol/L (1840+ 938 vs
2613 + 1307 mg/dL) P=0.091), chylomicron TG (16.52 + 10.1 vs 25.94 +14.7 mmol/L (1462 +
894 vs 2296+1298 mg/dL) P=0.060), 4-hour post prandial chylomicron triglycerides
(68.3+51.1 vs 104.3 + 56.1 mmol/L (6045 + 4525 vs 9229 + 4973 mg/dL) P=0.082) and higher

157

VLDL triglycerides (3.68 + 1.65 vs 2.76 + 1.63 mmol/L (325.9 + 145.7 vs 244.4 + 144.2 mg/dL)
P= 0.059).
There were no significant differences in other measured biochemical variables, including
traditional and non-traditional lipid, lipoprotein and apolipoprotein variables. Furthermore,
most variables from advanced lipoprotein analysis and from post-prandial studies were
similar between groups. There was no significant difference in acute pancreatitis history
between non-LPL-FCS and LPL-FCS groups (72.7% vs. 85.4%, respectively) or age of first
episode of pancreatitis (27.8±8.5 vs. 25.6±16.5, respectively). We repeated these analyses
post hoc, excluding the LPL p.P234L homozygote whose diagnosis was determined by
traditional sequencing only; all statistical comparisons and interpretation of results
remained the same.
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Table 3.1: Lipoprotein lipase gene (LPL) mutation status and LPL activity
Patient mutation
status

Type

Mutation name and zygosity

Number
of
patients

LPL activity
pretreatment*
(umol/L/min)

LPL activity
posttreatment*

CNV state

Previously
reported
(reference
numbers)

Homozygous

SNV

p.P234L homozygote

8

7.4

8.7

-

(39, 40)

p.G215E homozygote

3

7.4

8.7

-

(41-43)

p.D277N homozygote

2

3.6

3

-

(44)

p.Y329X homozygote

2

6.45

3.85

-

(37, 45)

p.I221T homozygote

2

18.9

11.8

-

(46, 47)

p.G166S homozygote

2

3.1

3.2

-

(48)

p.W113R homozygote

1

1.8

1.8

-

(44)

p.V206A homozygote

1

7.4

4.8

-

(49)

p.R270H homozygote

1

4.9

1.8

-

(50, 51)

p.L330P homozygote

1

5.9

9.6

-

(52)

p.H210R homozygote

1

2.6

ND

-

No

p.D277D fs X4 homozygote

2

ND

11.2

-

No

p.A61A fs X28 homozygote

1

6.1

5.2

-

No

intron 6 -2A>T homozygote

2

2.9

3.6

-

(53)

intron 7 +7A>G homozygote

1

6.9

1.8

-

No

p.P234L heterozygote; GPIHBP1,
intron 1 +4C>T heterozygote

1

7.5

8

-

(39, 40)

nonsense/
frameshift
intronic SNV

Double
heterozygote (LPL

SNV/
intronic SNV
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and GPIHBP1
genes)
Homozygous and
CNV in additional
geneb(GPIHBP1)

SNV/CNV

p.A185T homozygote

1

19.2

ND

GPIHBP1, exon
3-4 deletion,
heterozygote

(52)

Compound
heterozygous

SNV/
SNV

p.G215E heterozygote and
p.R270C heterozygote

2

3.15

2.6

-

(41-43)

p.W113R heterozygote and
p.H163R heterozygote

1

3.6

3.4

-

(44)
(54)

p.G81D heterozygote and
p.F212L heterozygote

1

2.3

ND

-

(9)
No

p.G215E heterozygote and
p.P234L heterozygote

1

2.1

ND

-

(41-43)

p.G215E heterozygote and
p.V96L heterozygote

1

14.8

11.6

-

(41-43)
(55)

p.G215E heterozygote and
p.I221T heterozygote

1

3.4

3.5

-

(41-43)
(46, 47)

p.A61V and intron 2 -1G>C
homozygote

1

6.2

1.8

-

(41-43)

p.G215E heterozygote, and
intron 1 +5G>C

1

3.5

2.4

-

(41-43)

SNV/
intronic SNV

*average taken if data available for more than one patient with mutation
abbreviations: LPL, lipoprotein lipase; SNV, single nucleotide variant; CNV, copy number variant; ND, not determined; "-" absent
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Table 3.2: Non-Lipoprotein lipase gene (non-LPL) mutation status and LPL activity
Gene

Mutation

CNV state

LPL activity
pretreatment*
(umol/L/min)

LPL activity
posttreatment*

Previously
reported?

APOA5

p.Q330Q fs X6
homozygote

-

37

4

No

p.L253P
homozygote

-

56.4

-

(56, 57)

APOC2

intron 3 +1G>C
homozygote

APOC2, exon 1
deletion
(noncoding),
homozygote

80

.

No

LMF1

p.P248S
homozygote

-

31.7

13.5

No

GPIHBP1

p.A6D
homozygote

-

16.1

14.6

No

p.Q132X
homozygote

-

-

4.6

No

LPL p.G215E
heterozygote;
APOA5 p.A315V
heterozygote

-

80

-

(41-43)

LPL p.R116Q
heterozygote;
LMF1 p.R233X
heterozygote

-

-

GPIHBP1, exon 1-4
deletion,
homozygote

1.8

.

No

-

GPIHBP1, exon 3-4
deletion,
homozygote

14.9

17.3

(58)

-

GPIHBP1, exon 3-4
deletion,
homozygote

.

3.9

(58)

Double
heterozygote
LPL + other

CNV

No
-

-

(53)
No

abbreviations: as in Table 3.2
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Table 3.3: Characteristics of molecularly characterized familial chylomicronemia subjects
LPL vs non-LPL FCS
p-value
(Wilcoxon)

LPL-FCS

non-LPL-FCS

Number of individuals

41

11

Sex (% female)

61.0

72.7

NS

Age at screening

47.1 ± 12.8

38.3 ± 12.3

NS (0.075)

Body mass index (kg/m2)

24.0 ± 5.6

24.6 ± 6.7

NS

History of acute pancreatitis (%)

85.4

72.7

NS

Age of onset of pancreatitis (years)

25.6 ± 16.5

27.8 ± 8.5

NS

Post heparin LPL activity at baseline (mol/L/min)

6.3 ± 5.8

39.7 ± 29.8

0.0028

Total cholesterol (mg/dL)
(mmol/L)

300.9 ± 125.4
7.78 ± 3.24

242.5 ± 86.2
6.27 ± 2.23

NS

Triglycerides (mg/dL)
(mmol/L)

2613 ± 1307
29.5 ± 14.8

1840 ± 938
20.79 ± 10.6

NS (0.091)

LDL cholesterol (mg/dL; by ultracentrifuge)
(mmol/L)

22.1 ± 10.4
0.57 ± 0.27

28.9 ± 8.1
0.75 ± 0.21

0.027

HDL cholesterol (mg/dL; by precipitation)
(mmol/L)

15.2 ± 4.1
0.39 ± 0.11

15.7 ± 3.3
0.41 ± 0.09

NS

Non-HDL cholesterol (mg/dL)
(mmol/L)

284.9 ± 124.5
7.36 ± 3.22

226.8 ± 87.1
5.86 ± 2.25

NS

Apo A-I (mg/dL)

92.6 ±13.8

99.2 ± 26.0

NS

Apo B-100 (mg/dL)

59.5 ± 18.0

60.3 ± 13.6

NS

Apo B-48 (mg/dL)

11.4 ± 7.11

10.1 ± 7.97

NS

Apo C-III (mg/dL)

27.4 ± 12.1

28.4 ± 12.7

NS

Chylomicron triglycerides (mg/dL)
(mmol/L)

2296 ± 1298
25.94 ± 14.7

1462 ± 894
16.52 ± 10.1

NS (0.060)

VLDL cholesterol (mg/dL)
(mmol/L)

31.3 ± 26.0
0.81 ± 0.67

40.4 ± 23.2
1.04 ± 0.60

NS

VLDL triglycerides (mg/dL)
(mmol/L)

244.4 ± 144.2
2.76 ± 1.63

325.9 ± 145.7
3.68 ± 1.65

NS (0.059)

Chylomicron plus VLDL apo C-III content (mg/dL)

26.7 ± 12.6

25.6 ± 14.2

NS

HDL apo C-III content (mg/dL)

1.26 ± 0.56

1.11 ± 0.39

NS

Glucose (mg/dL)
(mmol/L)

93.7 ± 13.8
5.21 ± 0.77

99.4 ± 23.9
5.52 ± 1.33

NS

Triglycerides 4 h post-prandial (mg/dL)
(mmol/L)

10031 ± 5125
113.3 ± 57.9

7467 ± 4844
84.4 ± 54.7

NS

Apo B-48 4 h post-prandial (mg/dL)

41.08 ± 23.09

36.51 ± 31.79

NS

Chylomicron triglycerides 4 h post-prandial (mg/dL)

9229 ± 4973

6045 ± 4525

NS (0.082)
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(mmol/L)
104.3 ± 56.1

68.3 ± 51.1

Glucose 4 h post-prandial (mg/dL)
(mmol/L)

408.7 ± 92.8
22.7 ± 5.16

531.6 ± 244.1
29.5 ± 13.6

NS

Insulin 4 h post-prandial (U/L)

97.0 ± 137.1

302.7 ± 159.3

0.0089

C-peptide 4 h post-prandial (U/L)

20.7 ± 6.2

32.5 ± 12.3

0.0492

Abbreviations: apo, apolipoprotein; HDL, high density lipoprotein; LDL, low density lipoprotein; LPL-FCS,
familial chylomicronemia syndrome due to bi-allelic mutations in the LPL gene encoding lipoprotein lipase;
non-LPL-FCS, familial chylomicronemia syndrome due to bi-allelic mutations in the either the APOC2, APOA5,
LMF1 or GPIHBP1, which encode, respectively, apo C-II, apo A-V, lipase maturation factor 1, or
glycosylphosphatidylinositol-anchored HDL-binding protein 1; NS, not significant; VLDL, very-low density
lipoprotein
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Table 3.4: Characteristics of molecularly characterized familial chylomicronemia subjects by gene
LPL

APOC2

APOA5

LMF1

GPIHBP1

Compound
Heterozygote

Number of individuals

41

1

2

1

5

2

-

Sex (% female)

61.0

100.0

100.0

100.0

60.0

50.0

NS

47.1 ± 12.8

56

46.5 ± 6.4

39

33.8 ± 11.9

32.0 ± 17.0

NS

Body mass index (kg/m )

24.0 ± 5.6

20.5

23.6 ± 1.98

17.9

22.4 ± 4.21

36.2 ± 3.39

0.045

History of acute pancreatitis (%)

85.4

100.0

50.0

100.0

60.0

100.0

NS

Age of onset of pancreatitis (years)

25.6 ± 16.5

41

26.0

24.0

24.3 ± 6.03

29.0 ± 14.1

NS

Post heparin LPL activity at baseline (mol/L/min)

6.3 ± 5.8

80.0

46.7 ± 13.7

31.7

10.9 ± 7.93

80.0

<.0001

Total cholesterol (mg/dL)

300.9 ± 125.4

188

362

254.8 ± 53.9

175.5 ± 122.3

NS

(mmol/L)

7.78 ± 3.24

4.86

246.5 ±
143.5

9.36

6.59 ± 1.39

4.53 ± 3.16

Triglycerides (mg/dL)

2613 ± 1307

1254

1969 ± 1790

2683

2096 ± 627.3

944 ± 1001

(mmol/L)

29.5 ± 14.8

14.2

22.2 ± 20.2

30.3

23.7 ± 7.08

10.7 ± 11.3

LDL cholesterol (mg/dL; by ultracentrifuge)

22.1 ± 10.2

28

30.5 ± 10.6

20

27 ± 7.81

37 ± 8.49

(mmol/L)

0.57 ± 0.26

0.72

0.79 ± 0.27

0.52

0.70 ± 0.20

0.96 ± 0.22

HDL cholesterol (mg/dL; by precipitation)

15.2 ± 4.1

14

18

18

13.6 ± 1.67

18.5 ± 6.36

(mmol/L)

0.39 ± 0.11

0.36

0.47

0.47

0.35 ± 0.043

0.48 ± 0.16

Non-HDL cholesterol (mg/dL)

284.9 ± 124.6

174

344

241.2 ± 53.4

157 ± 128.7

(mmol/L)

7.36 ± 3.22

4.50

228.5 ±
143.5

8.90

6.24 ± 1.38

4.06 ± 3.33

Apo A-I (mg/dL)

92.6 ±13.8

79

136 ± 11.3

140

85.8 ± 12.3

85.5 ± 0.71

<0.0001

Apo B-100 (mg/dL)

59.5 ± 18.0

55

69.15 ± 2.62

66.3

52.6 ± 13.2

70.6 ± 20.3

NS

Apo B-48 (mg/dL)

11.4 ± 7.11

4.88

3.62 ± 2.73

18.1

14.3 ± 8.21

4.5 ± 5.62

NS

Apo C-III (mg/dL)

27.4 ± 12.1

19.39

31.9 ± 11.8

38.6

25.9 ± 11.1

30.6 ± 27.1

NS

Chylomicron triglycerides (mg/dL)

2296 ± 1298

959

1551 ± 1730

2123

1780 ± 624.2

501.5 ± 623

NS

(mmol/L)

25.94 ± 14.7

10.8

17.5 ± 19.5

24.0

20.1 ± 7.05

5.66 ± 7.03

VLDL cholesterol (mg/dL)

31.3 ± 26.0

28

36.5 ± 3.54

67

34.2 ± 10.4

49.5 ± 57.3

(mmol/L)

0.81 ± 0.67

0.72

0.94 ± 0.092

0.76

0.88 ± 0.27

1.28 ± 1.48

Age at screening
2
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6.37 ± 3.71

5.91 ± 3.71

P-value
(overall)

NS
NS
NS
NS

NS

VLDL triglycerides (mg/dL)

244.4 ± 144.2

238

312 ± 1.41

449

290 ± 95.5

394 ± 355

(mmol/L)

2.76 ± 1.63

2.69

3.52 ± 0.016

5.07

3.27 ± 1.08

4.45 ± 4.01

Chylomicron plus VLDL apo C-III content (mg/dL)

26.7 ± 12.6

.

.

.

24.4 ± 11.05

28.5 ± 26.5

NS

HDL apo C-III content (mg/dL)

1.26 ± 0.56

0.92

.

.

1.15 ± 0.50

1.09 ± 0.071

NS

Glucose (mg/dL)

93.7 ± 13.8

79.0

93.5 ± 3.54
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90.0 ± 5.5

105 ± 4.24

<0.0001

(mmol/L)

5.21 ± 0.77

4.39

5.19 ± 0.20

9.28

5 ± 0.31

5.83 ± 0.24

Triglycerides 4 h post-prandial (mg/dL)

10031 ± 5125

7706

6124 ± 4019

18173

7042 ± 3090

1331

(mmol/L)

113.3 ± 57.9

87.0

69.1 ± 45.4

205.2

79.5 ± 34.9

15.0

Apo B-48 4 h post-prandial (mg/dL)

41.08 ± 23.09

42.1

29.4 ± 28.1

114.52

29.2 ± 13.7

3.87

0.021

Chylomicron triglycerides 4 h post-prandial (mg/dL)

9229 ± 4973

6473.5

4396 ± 3650

15685

5784 ± 3250

583.5

NS

(mmol/L)

104.3 ± 56.1

73.09

49.6 ± 41.2

177.1

65.3 ± 36.7

6.59

Glucose 4 h post-prandial (mg/dL)

408.7 ± 92.8

.

420.5

943

365 ± 15.6

564.5

(mmol/L)

22.7 ± 5.16

23.4

52.4

20.3 ± 0.87

31.4

Insulin 4 h post-prandial (U/L)

97.0 ± 137.1

.

413.2

527.4

177.9 ± 16.1

216.8

0.022

C-peptide 4 h post-prandial (U/L)

20.7 ± 6.1

.

38.1

49.1

27.7 ± 9.95

20.0

0.0015

NS

NS

0.0003

Abbreviations: apo, apolipoprotein; HDL, high density lipoprotein; LDL, low density lipoprotein; LPL-FCS, familial chylomicronemia syndrome due to biallelic mutations in the LPL gene encoding lipoprotein lipase; non-LPL-FCS, familial chylomicronemia syndrome due to bi-allelic mutations in the either the
APOC2, APOA5, LMF1 or GPIHBP1, which encode, respectively, apo C-II, apo A-V, lipase maturation factor 1, or glycosylphosphatidylinositol-anchored HDLbinding protein 1; NS, not significant; VLDL, very-low density lipoprotein; P-values calculated from analysis of variance and indicates an overall difference
between classes. Pairwise comparisons between individual classes were not performed
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3.2.4 Discussion
While most patients with monogenic chylomicronemia have bi-allelic, loss-of-function
variants in LPL, a substantial minority has the phenotype due to mutations in the four
remaining minor genes. A direct head-to-head comparison of clinical and biochemical
features among individuals with LPL-related and non-LPL related monogenic
chylomicronemia has not yet been reported, generally because these patents are so rare
and consistent harmonized methods have not been used in a larger cohort of individuals.
Here, because of the comprehensive assessments of these individuals due to their
involvement in a clinical trial, we had a unique collection of phenotypically and
genotypically well-characterized individuals with monogenic chylomicronemia to allow for a
detailed assessment of phenotypic differences according to the main underlying molecular
classes.
Our findings primarily indicate that for most fasting and dynamic metabolic measures,
individuals with monogenic chylomicronemia are phenotypically similar whether the
underlying cause is bi-allelic mutations in LPL or one of the other four genes. The difference
in post-heparin LPL activity was expected based on our understanding of the biochemistry
and genetic basis of the different forms of the condition. Individuals with mutations in nonLPL genes, by definition, had normal lipoprotein lipase enzyme, and thus there would be
less expected lipolytic compromise under the conditions of the ex vivo lipolytic assay. We
note in Table 3.4 that ex vivo lipolysis is lower in patients with LMF1 and GPIHBP1 mutations
than in the other non-LPL-FCS genetic subgroups, but not as low as for LPL-FCS patients.
Under in vitro conditions, the deficiencies resulting from LMF1 and GPIHBP1 mutations that
would otherwise impair in vivo function become less relevant. Similarly, the deficiencies
resulting from mutations in APOA5 and APOC2 can be rescued since the in vitro test
substrate contains some normal apolipoproteins. Thus, on balance, non-LPL mutation
patients had higher LPL activity. The trend towards significantly higher levels of
chylomicrons and triglycerides seen in LPL-mutation positive patients suggests that LPL
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deficiency may manifest with somewhat more severe chylomicronemia than FCS resulting
from mutations in non-LPL genes.
Of particular note, total cholesterol values were high in both groups, while LDL-C, HDL-C,
VLDL-C levels were all low in both LPL-FCS and non-LPL-FCS groups. This highlights a
fundamental feature of the metabolic defect in FCS. With absent or minimal LPL activity,
there is a significant impairment in conversion of triglyceride-rich particles to their remnant
lipoproteins, which generates a cascading impairment in production of subsequent smaller
lipoprotein sub-fractions, for which these remnants are the initial substrate. Each step of
the lipoprotein metabolism pathway involves lipolysis of triglyceride via LPL for conversion
to a smaller lipoprotein species (i.e. from chylomicrons to chylomicron remnants to VLDL to
VLDL remnants and IDL to LDL). Though LPL deficient individuals commonly exhibit
elevated total cholesterol values, the cholesterol measured is predominantly present within
chylomicrons, with a triglyceride to cholesterol ratio of ~20:1, with very-low density
lipoprotein (VLDL), intermediate density lipoprotein (IDL) and low-density lipoprotein (LDL)
cholesterol all typically at very low levels. HDL cholesterol is similarly low due to a decrease
in available cholesterol from its primary sources: VLDL, LDL and peripheral tissues. This
does not hold true, however, for individuals with other secondary or polygenic causes of
elevated triglycerides, in which LPL is generally functional, and all lipoproteins and their
remnants can be present and elevated to varying degrees, along with an increase in
cardiovascular risk. This key concept has significant implications when selecting appropriate
therapy. While secondary and polygenic (type V) hypertriglyceridemia patients who have
some residual LPL activity can often be effectively managed with fibrates or other oral
agents, this is not expected to be effective in patients with LPL deficiency, who require more
targeted triglyceride-specific therapy.
Further subdividing the non-LPL-FCS subgroup by genotype allows for some additional
anecdotal observations (Table 3.4). For instance, in the LMF1 deficient patient, plasma apo
A-I is very high, consistent with a concomitant low hepatic lipase activity affecting apo A-Icontaining particles, as would be expected given the role of LMF1 in maturation of both
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lipases. Although in this patient, there is no obvious difference in baseline LDL and HDL
cholesterol levels, it is notable that total and especially post prandial triglycerides are very
high. Furthermore, the triglyceride levels in the APOC2 and APOA5 deficient patients appear
somewhat lower than in the LPL-FCS group, as might be expected. Finally, the double
heterozygotes who each have one normal functioning LPL allele have, as expected, the
lowest triglyceride levels at baseline and especially post-prandially.
The significantly higher level of LDL cholesterol seen in patients with non-LPL-FCS compared
to the LPL-FCS population has not been previously described. It may reflect a less severe
impairment of LPL activity in these patients, or the presence of concomitant secondary
causes, compared to the LPL-FCS group. It may also suggest a minor or indirect role of
APOC2, APOA5, LMF1 or GPIHBP1 in LDL processing or clearance, or potentially the
clustering of other unmeasured risk genes in this subgroup compared to those with LPL-FCS.
Some support for this may come from studies that have shown an association between
mutations in APOA5 and APOC2 and hypercholesterolemia (59). Environmental, or geneenvironment interactions, may also be playing a role. Interestingly apo B levels were not
significantly different between the two groups, although specific B-100 and B-48 assays
were not performed. Further investigation is required to fully mechanistically define such
potential differences.
The tendency of non-LPL mutation carriers to have somewhat worse indices of insulin
resistance suggests that this secondary factor may be playing an underlying role in this
subgroup. Alternatively, perhaps the LPL defect leads to greater requirements for glucose
in peripheral tissues with improved insulin sensitivity and lower glucose levels, assuming the
islets are functioning normally. Also, some of the non-LPL gene product mechanisms may
be predisposing to somewhat compromised insulin sensitivity, in addition to their major
effects on chylomicron and lipoprotein metabolism. However, the similarity of the
remainder of the phenotypes suggests that regardless of etiology, large effect mutations
directly affecting LPL or one of its critical interacting factors results in a severe phenotype
that is clinically and biochemically similar irrespective of the molecular etiology. It would be
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important to rigorously evaluate insulin sensitivity in individuals subdivided according to FCS
genotype class to confirm our observations here.
The pancreatitis rates were high in both groups (75% and 85% respectively), however it is
important to note that this was as a result of the clinical trial selection criteria, which
included a personal history of pancreatitis, and should not be misinterpreted as prevalence
rates for pancreatitis in either genotype.
3.2.4.1 Limitations
Even though we have collected a unique and relatively large group of these extremely rare
individuals, the sample size is small, and it is possible that more subtle differences in some
of these variables would be apparent with a larger number of subjects, particularly those
with non-LPL monogenic chylomicronemia. Furthermore, we did not have sufficient
numbers of individuals to further subdivide according to minor gene etiology or mutation
type. Because these individuals were studied in a trial of an inhibitor of apo C-III, it would
have been informative to have collected not just apo C-III content in subfractions but also
apo E and apo A-V, however these were not available. We note that apo C-III content was
available in TG-rich particles (chylomicrons plus VLDL) and also in HDL: overall, these were
not statistically different between the genotypic classes.
Additionally, it is important to note that the trial inclusion criteria limited this data analysis
to relatively severe cases of chylomicronemia. This has the potential to miss important
differences between LPL and non-LPL FCS that may have been seen if those with milder
phenotypes were included. Furthermore, different mutations in both LPL and non-LPL
genes could present with a wide phenotypic spectrum based on the severity of functional
compromise that results from a given mutation. We also excluded heterozygous LPL
mutation-positive patients from analysis, however it is possible that heterozygous null
mutation carriers may present with a phenotype that overlaps with milder homozygous or
compound heterozygous mutation-positive individuals and further analysis based on degree
of functional compromise could be informative. Finally, it might also have been
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informative to examine the individuals with a clinical FCS phenotype but in whom genetic
testing or LPL activity were not fully confirmatory, although such patients would not be
easily classified in this experimental design.
3.2.4.2 Future directions
This study compared phenotypes of the individuals tested who presented with a clinical FCS
phenotype and had a confirmed genetic basis for their severe chylomicronemia. It is
possible that the remaining individuals have as-yet unidentified mutations causing true FCS,
or they may simply have severe secondary or polygenic (type V) chylomicronemia. The
features of these 15 individuals were not compared to those who had confirmatory genetic
testing in our study. For some lipidologists, the diagnosis of FCS should include genetic
testing, although the ability to make a diagnosis based on predictive clinical features alone
is highly attractive. It is beyond the scope of this study to recommend the necessity for
genetic testing to diagnose patients with true bi-allelic FCS from among the multitude of
those with severe HTG. However, once genetic testing has been performed, and individuals
with FCS are subdivided between bi-allelic LPL and non-LPL subgroups, the betweengenotype clinical and biochemical differences are subtle. A comparison between individuals
with a clinical FCS phenotype but no genetic diagnosis to those who have identified
mutations could be informative. Some preliminary work suggests that some predictive
features may include a personal history of pancreatitis, low BMI and low apo B levels.

3.2.5 Conclusions
In summary, we found that patients with LPL-related and non-LPL-related monogenic
chylomicronemia are largely phenotypically similar, but that LPL-FCS has lower post-heparin
LPL activity and a trend towards somewhat higher chylomicrons and triglycerides, while LDL
cholesterol and markers of insulin resistance were higher in non-LPL-FCS. It remains to be
determined whether these two subgroups of patients differ with respect to other
attributes, including the response to interventions.
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3.3 Incidence, Predictors and Patterns of Care of Patients with
Very Severe Hypertriglyceridemia in Ontario, Canada: A
Population-Based Cohort Study
The work presented in Chapter 3.3 has been edited from this original manuscript for brevity
and consistency throughout this dissertation

Berberich AJ, Ouédraogo AM, Shariff SZ, Hegele RA, Clemens KK. Incidence, predictors and
patterns of care of patients with very severe hypertriglyceridemia in Ontario, Canada: a
population-based cohort study. Lipids Health Dis. 2021 Sep 3;20(1):98. doi: 10.1186/s12944021-01517-6. PMID: 34479547.
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3.3.1 Background:
Triglyceride (TG) values >20 mmol/L can have significant consequences. One of the most
detrimental outcomes is pancreatitis, which often requires hospitalization or admission to
intensive care, and associated mortality. In clinical practice, very severe
hypertriglyceridemia (VS-HTG), defined in this study as triglyceride (TG) levels that exceed
20 mmol/L, is captured through routine lipid testing and commonly misattributed to an
exclusive genetic etiology. A minority of cases of VS-HTG (~1 in 1 million) arise from a
primary TG disorder, as reviewed in chapter 3.2. Most cases result from secondary causes,
often in conjunction with inherited partial impairment in TG metabolism (1, 60-63). These
cases may only manifest under conditions that increase TG production or impair clearance.
Previous studies conducted elsewhere have suggested that secondary causes of VS-HTG,
include obesity and metabolic syndrome, poorly controlled diabetes, nephrotic syndrome,
severe hypothyroidism, oral estrogen or tamoxifen, glucocorticoids, beta blockers, retinoids
and HIV antiretroviral regimens (64-66). Irrespective of the underlying cause, VS-HTG is of
clinical concern due to the risk of HTG-associated pancreatitis. Thus, it remains important
to understand and manage the secondary risk factors associated with this condition (67).
Studies conducted in other regions, such as Norway and the United States, have suggested
the prevalence of S-HTG (TG > 10mmol/L) to be between 0.13-0.4% (68, 69) and VS-HTG to
be 0.05-0.1% (70, 71), there is minimal documentation of the epidemiology of S-HTG or VSHTG in Canada. In this study we examined the incidence of S-HTG and VS-HTG in Canada’s
most populous province (Ontario), which is ethnically and socially distinct from populations
studied previously (68, 70). We also determined the demographic distribution, laboratory
features and co-morbidities associated with VS-HTG in Ontario. Further, as studies
conducted in regions without universal health care coverage (70) suggest a significant care
gap for patients with VS-HTG, we examined the care patterns of Ontario residents with VSHTG to determine whether a similar care gaps exist.
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3.3.2 Methods:
3.3.2.1 Design and setting:
This was a population-based retrospective cohort study of adults ≥18 years in Ontario,
Canada between 2010 and 2015. Ontario's approximately 13.5 million residents have
universal healthcare through the Ontario Health Insurance Program (OHIP), with
comprehensive medication coverage provided to those ≥65 years or using social assistance.
Information on the use of these health services is maintained at ICES (formerly The Institute
for Clinical Evaluative Sciences). ICES is an independent, non-profit research institute whose
legal status under Ontario’s health information privacy law allows it to collect and analyze
health care and demographic data, for health system evaluation and improvement.
3.3.2.2 Participants:
All individuals aged ≥18 years with at least one TG value in the Ontario Laboratories
Information System (OLIS) between September 1, 2010 and September 1, 2015 were
included. This study period was selected to allow for a 2-year follow up for care patterns
and outcomes of interest following identification of an incident case (OLIS laboratory data
available until the end of 2017). Standard data cleaning excluded those with invalid health
card numbers, age ≥105 years, missing sex, and non-Ontario residents. Three patient
cohorts were then created. Individuals who had TG levels >20 mmol/L were included in the
VS-HTG cohort (cohort 1) and individuals who had TG levels >10-20 mmol/L were included
in the S-HTG cohort (cohort 2). Those with prior evidence of TG >20 or >10 mmol/L
between September 1 2007-August 31, 2010 were excluded to define new evidence of VSHTG or S-HTG respectively.
A third cohort (cohort 3) was used to contrast characteristics of those with VS-HTG and with
no HTG and establish predictors for VS-HTG. This comparator group included all Ontario
residents ages ≥18 years with at least one TG value in OLIS during the study period, no
evidence of TG value >3 mmol/L and who were not already in the S-HTG or VS-HTG cohort.
In all cohorts, those who died within two years after a TG test were excluded to limit to
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those in whom we could establish follow up care patterns. If individuals had more than one
TG test >20mmol/L during the study period, the first TG test was selected (Figure 3.1).
3.3.2.3 Sources of data:
Data were drawn from a number of ICES databases (Appendix D). Datasets were linked
using unique encoded identifiers and analyzed at ICES. Demographic data were obtained
from the Registered Persons Database (RPDB), which includes all individuals who have been
issued an Ontario health card. The Client Agency Program Enrolment (CAPE) database was
used to determine patients who were rostered to a family physician. The Canadian
Institutes for Health Information’s Discharge Abstract Database (CIHI-DAD) and the National
Ambulatory Care Reporting System (NACRS) contain diagnostic and procedural information
captured during hospitalizations and emergency department visits, respectively, using
International Classification of Diseases 10th Revision (ICD-10) (72) and Canadian
Classification of Health Interventions (CCI) (73) codes. Additional comorbidities and
healthcare services use was captured through OHIP, which contains billing and diagnostic
codes (Appendix D). Hypertension and diabetes status were determined from the
hypertension database (HYPER) (74) and Ontario Diabetes Database (ODD) (75) ,
respectively. For individuals ≥65 years, use of medications that can be associated with or
used to treat HTG was captured using the Ontario Drug Benefit (ODB) and Drug
Identification Number (DIN) database. Laboratory data were obtained through OLIS. The
OLIS database holds laboratory data from both community and hospital laboratories with
good catchment across Ontario (76). As of 2016, 95% of community lab volume and over
80% of total provincial lab volume were recorded in OLIS (77). Appendix D includes full
details on variable definitions.
3.3.2.4 Incidence of VS-HTG:
The primary aim was to calculate the incidence of S-HTG and VS-HTG over the 5 year period.
This was done using two denominators: the mean number of Ontarians ≥18 years between
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2010-2015, and the number of adults ≥18 years who had a measured TG level over the
study period.
3.3.2.5 Outcomes:
The 2-year patterns of care of those with VS-HTG were examined, including contacts with
family physicians, internists and endocrinologists, repeat TG testing, new prescriptions for
fibrates, statins and niacin, and minimum and last follow-up TG values. The secondary
exploratory outcomes of interest included hospital encounters for pancreatitis, acute
myocardial infarction or ischemic stroke over the 2-year follow up period.
3.3.2.6 Statistical analysis:
The incidence of S-HTG and VS-HTG was provided as a rate per 100,000. Descriptive
statistics were used to capture baseline differences between the VS-HTG cohort 1 and the
comparator cohort 3. Continuous variables were reported as mean +/- standard deviation
(SD) and median with interquartile range (IQR). Binary variables were reported as
percentages. Differences between cohorts were evaluated using standardized differences
(StDiff), with a value of >0.1 considered significant (78). One-way ANOVA or Chi Square
tests were also used to compare the means and medians of continuous variables and the
proportions of categorical variables, respectively. P-values < 0.05 were considered
statistically significant. Variables that were hypothesized to affect TG levels, co-exist with
HTG or related complications from HTG were included in the analysis. To identify predictors
of VS-HTG, both univariable and multivariable logistic regression were used (nominal Pvalue for significance <0.05) and reported results as odds ratios (OR) and 95% confidence
intervals (CI). Descriptive statistics were used to report crude rates of secondary outcomes
of interest.
3.3.2.7 Ethics Approval:
The use of data in this project was authorized under section 45 of Ontario’s Personal Health
Information Protection Act, which does not require review by a Research Ethics Board.
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Guidelines for reporting of studies outlined by routine collected healthcare data (RECORD)
were used (Addendix E) (79), as well as STrengthening the Reporting of OBservational
studies in Epidemiology (STROBE) cohort reporting guidelines for observational studies (80).

3.3.3 Results:
There were 22,745,387 TG tests performed in Ontario between 2010-2015 in those ≥18
years (7,047,586 unique individuals). A total of 17,615 and 2,869 people had S-HTG and VSHTG respectively. The comparison cohort included 6,742,506 individuals (Figure 3.1).
Baseline differences considered between the VS-HTG cohort 1 and the comparison cohort 3
are shown in Table 3.5. In general, those with VS-HTG were more often male (78.0% vs
45.6%; StDiff 0.71, P-value <0.001), had diabetes (44.0% vs 13.9%; StDiff 0.7, P-value
<0.001), chronic liver disease (7.9% vs 3.4%; StDiff 0.19, P-value <0.001), alcohol abuse
(2.3% vs 0.4%; StDiff 0.17; P-value <0.001), obesity (1.8% vs 0.6%; StDiff 0.12; P-value
<0.001) and HbA1c >8.5% (13.8% vs 1.5%; StDiff 0.48; P-value <0.001). Significantly more
individuals in the VS-HTG cohort had a baseline history of pancreatitis (6.2% vs 0.3%; StDiff
0.34; P-value <0.001) (Table 3.5). All measured components of metabolic syndrome
appeared higher in the VS-HTG cohort: (HTN (43.4% vs 33.1%; StDiff 0.21; P-value <0.001),
low HDL cholesterol (C) (mean 0.97 vs 1.27 mmol/L; StDiff 0.79; P-value <0.001), elevated
HbA1c (mean 7.88% vs 6.63%; StDiff 0.67; P-value <0.001) and obesity (1.8% vs 0.6%; StDiff
0.12; P-value <0.001).
Incidence of S-HTG and VS-HTG in Ontario adults between 2010 and 2015 was 163.61 and
26.65 per 100,000 (~1 in 615 and 1 in 3750) adults overall, and 250.18 and 40.75 per
100,000 (~1 in 400 and 1 in 2500) adults who had at least one TG test (Table 3.6).
Combined incidence rate of TG >10 mmol/L was ~1 in 344 adults who had at least one TG
value and ~1 in 526 adults overall (Table 3.6, Figure 3.2). The highest incidence of S-HTG
and VS-HTG appeared between ages 31-45 (315.17 and 63.07/100,000 with a TG test;
197.12 and 39.45/100,000 population) and 46-65 (324.86 and 48.21/100,000 with a TG test;

176

266.40 and 39.54/100,000 population) (Table 3.6). Overall, incidence was higher in men
(Table 3.7).
Medication use was only available for individuals ≥65 years (N=136 in the VS-HTG cohort)
(Table 3.8) At baseline, a higher proportion of VS-HTG patients used a fibrate (18.4% vs
1.6%; SD 0.58) and a lower proportion used statins (40.4% vs 45.7%; StDiff 0.11) compared
to the comparison cohort (N=1,392,795). A higher proportion of VS-HTG patients also
appeared to use other lipid-lowering agents (11.8% vs 4.2%; StDiff 0.28), oral furosemide
(16.2% vs 6.3%; StDiff 0.32) chlorthalidone (<5% vs 0.6%; StDiff 0.14) and salicylates (5.9%
vs 3.5%; StDiff 0.11) (Table 3.8).
Results of univariable and multivariable analysis are presented in Table 3.9. In
multivariable analysis, significant predictors of VS-HTG were diabetes (OR 5.38, CI 4.935.88), male sex (OR 3.83, CI 3.50-4.18), alcohol abuse (OR 2.47, CI 1.90-3.19), chronic liver
disease (OR 1.71, CI 1.48-1.97), hypertension (OR 1.69, CI 1.54-1.86), obesity (OR 1.49, CI
1.13-1.98), and chronic kidney disease (OR 1.39, CI 1.19-1.63). Older age was associated
with reduced risk of VS-HTG (OR 0.64/decade, CI 0.62-0.66). Higher income quintiles (4 and
5) were associated with lower odds of having VS-HTG in both univariable and multivariable
analysis (0.78, CI 0.70-0.88 for quintile 4 and 0.72, CI 0.63-0.81 for quintile 5). In univariable
analysis, lowest income quintile was associated with VS-HTG (OR 1.21, CI 1.09- 1.35) but this
did not remain significant in the multivariate analysis. Likewise, higher Charlson
comorbidity scores (moderate to high) were associated with VS-HTG in the univariate
analysis. A Charlson index of 3+ was no longer significantly associated with VS-HTG in
multivariable analysis (Table 3.9).
3.3.3.1 Outcome measures:
The majority of individuals with VS-HTG received follow-up healthcare within two years of
their TG test (Table 3.10); 98.4% had at least one follow up visit to a family physician (FP),
32.8% had at least one visit to an endocrinologist and 56.7% had at least one visit to a
general internist. The majority achieved TG reduction below the high-risk pancreatitis
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threshold of 10 mmol/L, with 89.3% having a repeat TG test. The last TG measured had a
median TG value of 4.7 mmol/L (IQR 2.7-9.1) and lowest TG value had a median TG value of
3.3 mmol/L (IQR 2.0-5.9). For individuals >65 years of age, new prescriptions for statins
were provided in 32.4% and for fibrates, in 19.9% (Table 3.8).
Following detection of VS-HTG, pancreatitis occurred in 4.1% and 6.0% of individuals in the
VS-HTG cohort within one and two years, respectively (Table 3.10). Within two years, 1.4%
and 0.8% of individuals in the VS-HTG cohort had at least one hospital encounter for acute
myocardial infarction and ischemic stroke, respectively (Table 3.10).
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Figure 3.1: Flowchart of study participants.
After removal of duplicate and invalid data, the final cohorts included 2,869 individuals in
VS-HTG cohort 1 (TG >20mmol/L), 17,615 in S-HTG cohort 2 (TG >10-20mmol/L) and
6,742,506 in the comparison cohort 3 (no TG >3.0mmol/L).
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DISTRIBUTION OF MEASURED TRIGLYCERIDE LEVELS
AMONG INDIVIDUALS ≥18 IN ONTARIO 2010-2015
Consistently <3mmol/L

>3-10mmolL

>10-20mmol/L

>20mmol/L

0.25%

96%

4%
0.29%

0.04%

Figure 3.2: Summary of measured triglyceride (TG) values in Ontario from 2010-2015.
Among 7,040,865 individuals ≥18 years with measured TG in Ontario between 2010 and
2015: 6,742,506 (96%) had no TG value measured above 3 mmol/L; 21,484 individuals in
Ontario (0.29%) had at least one TG value >10 mmol/L, with 0.25% (n=17,615) having severe
hypertriglyceridemia (TG>10-20 mmol/L) and 0.04% (n=2,869) having very severe
hypertriglyceridemia (TG>10 mmol/L). 277,875 (4%) individuals were not included in the
other three cohorts and were assumed to have at least one measured TG value within the
range of >3-10 mmol/L.

180

Table 3.5: Baseline characteristics of VS-HTG and comparison cohorts
VS-HTG Cohort
N=2,869

Comparison Cohort
N=6,742,506

Standardized
differences

P-value

Mean (SD)

47.28 ± 10.87

51.74 ± 16.21

0.32

<0.001

Median (IQR)

47.0 (40.00-54.00)

52.0 (40.00-63.00)

0.35

<0.001

18-30 yrs

174 (6.1%)

744,062 (11.0%)

0.18

<0.001

31-45 yrs

1,078 (37.6%)

1,642,193 (24.4%)

0.29

46-65 yrs

1,481 (51.6%)

2,963,456 (44.0%)

0.15

66+ yrs

136 (4.7%)

1,392,795 (20.7%)

0.49

Sex, female

630 (22.0%)

3,667,595 (54.4%)

0.71

<0.001

1 - lowest

690 (24.1%)

1,231,411 (18.3%)

0.14

<0.001

2

649 (22.6%)

1,323,360 (19.6%)

0.07

3

635 (22.1%)

1,371,761 (20.3%)

0.04

4

493 (17.2%)

1,432,535 (21.2%)

0.1

5 - highest

402 (14.0%)

1,383,439 (20.5%)

0.17

Rostered to a GP

2,346 (81.8%)

5,619,709 (83.3%)

0.04

0.023

Diabetes (Type 1 and Type 2)

1,262 (44.0%)

940,151 (13.9%)

0.70

<0.001

Hypertension

1,244 (43.4%)

2,232,885 (33.1%)

0.21

<0.001

Coronary artery disease
(excluding angina)

339 (11.8%)

600,499 (8.9%)

0.10

<0.001

Cardiovascular disease

87 (3.0%)

218,670 (3.2%)

0.01

0.524

Peripheral vascular disease

18 (0.6%)

21,539 (0.3%)

0.04

0.003

Chronic liver disease

226 (7.9%)

230,046 (3.4%)

0.19

<0.001

Alcohol

66 (2.3%)

24,957 (0.4%)

0.17

<0.001

Obesity

53 (1.8%)

38,645 (0.6%)

0.12

<0.001

Hypothyroidism

15 (0.5%)

24,618 (0.4%)

0.02

0.161

Multiple myeloma

0

1,060 (0.0%)

0.02

0.502

Nephrotic syndrome

29 (1.0%)

14,392 (0.2%)

0.10

<0.001

Chronic kidney disease

199 (6.9%)

209,348 (3.1%)

0.18

<0.001

Acute Pancreatitis

177 (6.2%)

19,602 (0.3%)

0.34

<0.001

Gallstone disease

212 (7.4%)

114,035 (1.7%)

0.28

<0.001

Current pregnancy in women

47 (1.6%)

385,120 (5.7%)

0.22

<0.001

Mean (SD)

0.92 ± 1.38

0.44 ± 1.05

0.39

<0.001

Median (IQR)

0.00 (0.00-1.00)

0.00 (0.00-0.00)

0.52

<0.001

0

2,241 (78.1%)

6,104,946 (90.5%)

0.35

<0.001

1

331 (11.5%)

302,652 (4.5%)

0.26

Age at index date, years

Income quintile*

Comorbidities

Charlson comorbidity index
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2

142 (4.9%)

193,468 (2.9%)

0.11

3+

155 (5.4%)

141,440 (2.1%)

0.17

Mean (SD)

6.87 ± 8.85

5.24 ± 6.45

0.21

<0.001

Median (IQR)

5.00 (2.00-8.00)

4.00 (2.00-7.00)

0.21

<0.001

0.23 ± 0.93

0.06 ± 0.48

0.22

<0.001

1.03 ± 2.90

0.62 ± 2.36

0.15

<0.001

HbA1c

1,083 (37.7%)

929,242 (13.8%)

0.57

<0.001

HbA1c >8.5%

397 (13.8%)

100,258 (1.5%)

0.48

<0.001

Mean (SD)

7.88 ± 2.29

6.63 ± 1.37

0.67

<0.001

Median (IQR)

7.30 (6.00-9.40)

6.20 (5.80-7.10)

0.53

<0.001

LDL cholesterol

485 (16.9%)

955,143 (14.2%)

0.08

<0.001

Mean (SD) mmol/L

2.52 ± 1.49

2.71 ± 1.02

0.15

<0.001

Median (IQR) mmol/L

2.31 (1.49-3.26)

2.58 (1.93-3.38)

0.25

<0.001

HDL cholesterol

1,202 (41.9%)

986,111 (14.6%)

0.64

<0.001

Mean (SD) mmol/L

0.97 ± 0.38

1.27 ± 0.38

0.79

<0.001

Median (IQR) mmol/L

0.91 (0.76-1.11)

1.21 (1.00-1.47)

0.93

<0.001

non-HDL cholesterol

327 (11.4%)

18,595 (0.3%)

0.49

<0.001

Mean (SD) mmol/L

5.14 ± 2.27

4.58 ± 1.38

0.30

<0.001

Median (IQR) mmol/L

4.68 (3.75-5.98)

4.52 (3.64-5.40)

0.17

0.001

Total cholesterol

1,206 (42.0%)

994,409 (14.7%)

0.63

<0.001

Mean (SD) mmol/L

6.41 ± 2.75

4.78 ± 1.25

0.76

<0.001

Median (IQR) mmol/L

5.79 (4.71-7.33)

4.66 (3.85-5.57)

0.74

<0.001

ALT

1,282 (44.7%)

1,384,012 (20.5%)

0.53

<0.001

Mean (SD) U/L

40.99 ± 39.83

27.36 ± 29.50

0.39

<0.001

Median (IQR)

31.00 (21.00-46.00)

22.00 (17.00-31.00)

0.58

<0.001

Corrected calcium

210 (7.3%)

166,005 (2.5%)

0.23

<0.001

Mean (SD) mmol/L

2.30 ± 0.15

2.31 ± 0.11

0.12

0.045

Median (IQR) mmol/L

2.29 (2.23-2.37)

2.31 (2.24-2.37)

0.10

0.127

Health care utilization
Primary care (FP/GP) visits

Endocrinologist visits
Mean (SD)
Internal medicine visits
Mean (SD)
Laboratory measurements

Standardized difference > 10% are considered statistically significant; <1% of income quintiles were missing
and were re-coded as ‘3’; Small cells (<6) are suppressed as per ICES privacy policy; Comorbidities were
obtained in the 5 years prior to the index date; Health care utilization measures were obtained in the 1 year
prior to index date; Health care utilization measures were obtained in the 1 year prior to index date;
Laboratory measurements were obtained in the 1 year prior to index prescription date; Evidence of pregnancy
in women was obtained in the 1 year prior and within 9 month after to index date. Please refer to
supplementary table 1 for further information on coded data included for each variable. * Missing income
(<1%) was recoded as '3'. Missing Charlson (~50%) was due to patients having no hospitalizations for relevant
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comorbidities found during the 5 year lookback period; they were recoded as '0'; ^P-value for variable as a
whole.
Abbreviations: VS-HTG: very severe hypertriglyceridemia (TG>20mmol/L); yrs: years; SD: Standard deviation;
IQR: Interquartile range; GP: General Practitioner; HTN: hypertension; CAD: coronary artery disease; PVD:
peripheral vascular disease; CVD: cerebrovascular disease; CKD: chronic kidney disease; FP: family practitioner;
HbA1c: hemoglobin A1c; LDL: low-density lipoprotein; HDL: high density lipoprotein; ALT: alanine
aminotransferase.
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Table 3.6:
Ages 18-30

Ages 31-45

Ages 46-65

Ages 66+

Total

Number of individuals with at
least one TG test

761,224

1,709,237

3,071,797

1,498,607

7,040,865

Mean Ontario population
between 2010-2015

2,412,041

2,732,915

3,745,940

1,875,874

10,766,770

n

835

5,387

9,979

1,414

17,615

Incidence in those with at least
one TG test (per 100,000)

109.69

315.17

324.86

94.35

250.18

Incidence in Ontario population
(per 100,000)

34.62

197.12

266.40

75.38

163.61

n

174

1,078

1,481

136

2,869

Incidence in those with at least
one TG test (per 100,000)

22.86

63.07

48.21

9.08

40.75

Incidence in Ontario population
(per 100,000)

7.21

39.45

39.54

7.25

26.65

S-HTG

VS-HTG

Abbreviations: S-HTG: severe hypertriglyceridemia (TG >10-20 mmol/L); VS-HTG: very severe
hypertriglyceridemia (TG >20mmol/L); ON: Ontario; pop: population; n: number of individuals;
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Table 3.7: Incidence of severe (S-HTG; TG >10-20mmol/L) and very severe (VS-HTG;
TG>20mmol/L) hypertriglyceridemia in Ontario by age group and gender
Ages 1830
Number of individuals with at
least one TG test
Mean Ontario population
between 2010-2015
S-HTG
n
Incidence in those with at
least one TG test (per 100,000)
Incidence in Ontario
population (per 100,000)
VS-HTG
n
Incidence in those with at
least one TG test (per 100,000)
Incidence in Ontario
population (per 100,000)

Ages 31-45

Ages 46-65

Ages 66+

Total

424,465

Women
933,287

1,604,830

817,872

3,780,454

1,201,563

1,392,309

1,895,645

1,047,061

5,536,578

206
49

1043
112

2387
149

564
69

4,200
111

17

75

126

54

76

39
9.19

211
22.61

322
20.06

58
7.09

630
16.66

3.25

15.15

16.99

5.54

11.38

Men
775,950

Number of individuals with at
336,759
1,466,967
680,735
least one TG test
Mean Ontario population
1,210,478 1,340,606
1,850,295
828,813
between 2010-2015
S-HTG
n
629
4,344
7,592
850
Incidence in those with at
187
560
518
125
least one TG test (per 100,000)
Incidence in Ontario
52
324
410
103
population (per 100,000)
VS-HTG
n
135
867
1,159
78
Incidence in those with at
40.09
111.73
79.01
11.46
least one TG test (per 100,000)
Incidence in Ontario
11.15
64.67
62.64
9.41
population (per 100,000)
Abbreviations: S-HTG: severe hypertriglyceridemia (TG >10-20 mmol/L); VS-HTG: very severe
hypertriglyceridemia (TG >20mmol/L); ON: Ontario; pop: population; n: number of individuals;
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3,260,411
5,230,192
13,415
411
256
2,239
68.67
42.81

Table 3.8: Prescription characteristics of VS-HTG and comparison cohorts
VS-HTG cohor N=136

Comparison cohort
N=1,392,795

<6

8,741 (0.6%)

0.01

Statin

55 (40.4%)

636,487 (45.7%)

0.11

Fibrate

25 (18.4%)

22,422 (1.6%)

0.58

Niacin

0 (0.0%)

147 (0.0%)

0.01

16 (11.8%)

57,839 (4.2%)

0.28

Lipid combination (e.g. with blood
pressure medication)

0

13,984 (1.0%)

0.14

Metronidazole

<6

15,899 (1.1%)

0.03

0 (0.0%)

2,287 (0.2%)

0.06

Oral furosemide

22 (16.2%)

87,477 (6.3%)

0.32

Hydrochlorothiazide

32 (23.5%)

315,376 (22.6%)

0.02

Chlorthalidone

<6

8,525 (0.6%)

0.14

Indapamide

<6

47,567 (3.4%)

0.01

Sulphasalazine

0

13 (0.0%)

0

Azathioprine

0

1,912 (0.1%)

0.05

Valproic acid

0

908 (0.1%)

0.04

Sulindac

0

2,665 (0.2%)

0.06

8 (5.9%)

48,599 (3.5%)

0.11

0

128 (0.0%)

0.01

ACE/ARB

38 (27.9%)

396,107 (28.4%)

0.01

Beta blocker

54 (39.7%)

320,828 (23.0%)

0.37

Characteristics in ages 66+
Oral glucocorticoid

Other lipid

Tetracycline

Salicylates
HIV/AIDS specific meds

Standardized difference > 10% are considered statistically significant; <1% of income quintiles were missing and were re-coded as ‘3’;
Small cells (<6) are suppressed as per ICES privacy policy; Medication use were obtained in the 1 year prior to index date; A few other
medications of interest (e.g. oral estrogen, pentamidine, 5-ASA, L-asparaginase, didanosine) were not found.

186

Table 3.9 Predictors of VS-HTG, ranked by odds ratio
Univariable analysis

Multivariable analysis

Odds
Ratio

LCL

UCL

P-value

Odds
Ratio

LCL

UCL

P-value

4.85

4.50

5.22

<0.0001

5.38

4.93

5.88

<0.0001

Male

4.24

3.88

4.63

<0.0001

3.83

3.50

4.18

<0.0001

Female

REF

REF

REF

REF

REF

REF

Alcohol

6.34

4.96

8.09

<0.0001

2.47

1.90

3.19

<0.0001

Chronic liver
disease

2.42

2.11

2.77

<0.0001

1.71

1.48

1.97

<0.0001

HTN

1.55

1.44

1.67

<0.0001

1.69

1.54

1.86

<0.0001

Obesity

3.27

2.49

4.29

<0.0001

1.49

1.13

1.98

0.0049

CKD

2.33

2.01

2.69

<0.0001

1.39

1.19

1.63

<0.0001

1 - lowest

1.21

1.09

1.35

0.0005

1.09

0.98

1.22

0.1134

2

1.06

0.95

1.18

0.3011

1.02

0.92

1.14

0.6747

3

REF

REF

REF

REF

REF

REF

4

0.74

0.66

0.84

<0.0001

0.78

0.70

0.88

<0.0001

5 - highest

0.63

0.55

0.71

<0.0001

0.72

0.63

0.81

<0.0001

Age (per decade)

0.84

0.82

0.86

<0.0001

0.64

0.62

0.66

<0.0001

0

REF

REF

REF

REF

REF

REF

1

2.98

2.66

3.34

<0.0001

1.61

1.42

1.82

<0.0001

2

2.00

1.69

2.37

<0.0001

1.26

1.05

1.50

0.0137

3+

2.99

2.54

3.51

<0.0001

1.15

0.95

1.38

0.1504

Diabetes
Sex

Income quintile

Charlson
comorbidity
index*

Sample size is the full cohort (N= 6,745,375); Exposed (n= 2,869); Unexposed (n= 6,742,506)All predictors
were associated with the odds of having hypertriglyceridemia. Diabetes includes both type 1 and type 2.
Abbreviations: LCL: lower confidence limit; UCL: upper confidence limit; HTN: hypertension; CKD: chronic
kidney disease; REF: used as reference
* Missing income (<1%) was recoded as '3'. Missing charlson (~50%) was due to patients having no
hospitalizations for relevant comorbidities found during the 5 year lookback period; they were recoded as '0'
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Table 3.10: Healthcare Patterns and Events of Interest in patients with VS-HTG
Within 1 year

Within 2 years

General practitioner visit

2,786 (97.1%)

2,822 (98.4%)

Endocrinologist visit

775 (27.0%)

941 (32.8%)

Internist visit*

1,279 (44.6%)

1,628 (56.7%)

TG test

2,218 (77.3%)

2,561 (89.3%)

Mean (SD) (mmol/L)

7.66 ± 8.29

7.68 ± 8.35

Median (IQR) (mmol/L)

4.7 (2.7-9.1)

4.7 (2.7-9.1)

Mean (SD) (mmol/L)

6.09 ± 6.74

5.30 ± 6.05

Median (IQR) (mmol/L)

3.8 (2.2-7.1)

3.3 (2.0-5.9)

Statin

35 (25.7%)

44 (32.4%)

Fibrate

25 (18.4%)

27 (19.9%)

Niacin

0

0

Events

Within 1 year

Within 2 years

At least one hospital encounter for pancreatitis

118 (4.1%)

171 (6.0%)

At least one hospital encounter for acute myocardial
infarction

22 (0.8%)

39 (1.4%)

At least one hospital encounter for Ischemic stroke

12 (0.4%)

24 (0.8%)

Healthcare patterns (N= 2,869)

Last TG value

Lowest TG value

New prescriptions (restricted to ages 66+, N=136)

* For the purposes of this data ‘internal medicine’ refers specifically to the subspecialty of general internal
medicine and does not include other internal medicine subspecialties.
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3.3.4 Discussion:
The incidence of TG >10-20 (S-HTG) and >20 mmol/L (VS-HTG) between 2010 and 2015 was
approximately 1 in 400 (0.25%) and 1 in 2500 (0.04%) among adults in Ontario with
measured TG, and 1 in 613 (0.16%) and 1 in 3750 (0.27%) of the adult population,
respectively. These numbers align with prevalence rates reported in other studies (68, 70,
71). Peak age of incidence was 31-65 years, which may correspond to the age at which a
screening lipid profile may first be conducted, or the age at which related chronic conditions
start to manifest. While the Endocrine Society defines severe hypertriglyceridemia as a
serum TG level >1000 mg/dL (11.3 mmol/L) and very severe as >3000 mg/dL (22.6 mmol/L)
(81), the approximations of 10 and 20 mmol/L, respectively, are more practical for a
Canadian population.
Significant predictors of VS-HTG in Ontario included male sex, as well as known risk factors
for HTG, including diabetes, chronic liver disease, alcohol abuse, obesity and chronic kidney
disease. Hypertension was likely a predictor given its association with metabolic syndrome.
The two most significant controllable predictors were diabetes and alcohol abuse. The
definition used for alcohol abuse in this study was broad to allow for increased sensitivity,
but included any complication that stemmed from chronic or acute alcohol ingestion (see
Appendix D). It is thus difficult to determine which specific alcohol-related behaviors or
patterns of intake may be most contributory.
The VS-HTG cohort had more contacts with healthcare providers, which may relate to more
associated chronic diseases. This may have predisposed individuals to having had a
screening lipid test. Patients in the VS-HTG group were also more likely to have had HbA1c
testing, and to have an HbA1c >8.5%, likely relating to the higher prevalence of metabolic
syndrome and diabetes in the VS-HTG cohort. Mean LDL-C was minimally but significantly
higher in the VS-HTG. Mean HDL-C was significantly lower in the VS-HTG cohort, reflecting
the inverse relationship between TG and HDL-C. Non-HDL and total cholesterol were higher
in the VS-HTG cohort, likely driven by elevated TG-rich lipoproteins and remnant particles.
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While other studies showed poor follow up care following identification of HTG, in this
Ontario cohort, no significant gaps in appropriate care were identified. This may be due to
universal healthcare access in Ontario, which was not a feature of other populations studied
(70). Within the 2 year follow-up period, 98.4% of individuals in the VS-HTG cohort were
seen by a FP and 89.3% had a repeat TG test. One-third were seen by an endocrinologist
and over half by an internist. Follow-up TG tests showed significant reductions in TG levels,
with the median TG level falling below the threshold for pancreatitis risk (4.7 mmol/L; IQR
2.7-9.1). The median of the lowest recorded TG values remained elevated at 3.3 mmol/L
(IQR 2.0-5.9) (normal <1.7 mmol/L), likely reflecting the limitations of currently available
pharmacological and lifestyle interventions to fully correct TG to a normal range,
particularly in those with underlying inherited metabolic defects. Discussions of current
management recommendations for HTG and options are beyond the scope of this work, but
are discussed in detail elsewhere (67). In the subset of the VS-HTG cohort that were over
the age of 65, most were on, or were placed on, a statin (40.4% at baseline, 32.4% with new
prescriptions following identification of VS-HTG) and a third were on a fibrate (18.4% at
baseline, 19.9% with new prescriptions). The substantial reduction in TG levels, despite
only a third of patients with medication information available being placed on a fibrate,
suggests that control of contributory secondary factors, such as diabetes, obesity or lifestyle
may have played a considerable role in the improvements in TG levels.
Pancreatitis rates in individuals with VS-HTG (4.1% within 1 year, 6% within 2 years) were
within the range of expectation based on other reports (82). There was no apparent excess
risk of ASCVD within the VS-HTG cohort at baseline or within the year follow up period.
However, this study was not designed to examine these outcomes. A separate study
focusing on the risk of ASCVD and ischemic stroke in the VS-HTG population that accounts
for potential confounders may provide further support for the findings observed.
Future studies that evaluate TG as a continuous variable would help define the risk of acute
pancreatitis associated with a given degree of HTG. Further investigations that focus on
outcomes in VS-HTG patients is another avenue of investigation, including prevalence and
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predictors of pancreatitis and its complications. Genetic investigation into a subset of this
cohort may also help define the spectrum of genetic variation that may underlie a
presentation of VS-HTG.
3.3.4.1 Comparison with other provinces in Canada and European Union (EU)
countries:
All Canadian provinces have universal healthcare coverage, however there are differences
across the Canadian provinces in terms of risk factors for VS-HTG (e.g. obesity and type 2
diabetes). For example, provinces such as Saskatchewan, New Brunswick, Nova Scotia and
Newfoundland and Labrador have higher rates of obesity (35-38%) compared to Ontario
(26%), which is just below the national average of 27% (range of all provinces 22-38%) (28).
Approximately 30% of Ontarians live with diabetes or prediabetes, which is slightly higher
than the national average of 29% (range of all province 25 - 35%) (29). There is also ethnic
variation between the provinces, with Ontario and British Columbia having the highest rates
of ethnic diversity (29.3 and 30.3% of adult population identifying as visible minorities,
respectively, national average 22.3%, range for all provinces 2.3%-30.3%) (30).
Most EU countries are similar to Ontario in that they have universal access to healthcare,
but may differ in other ways that could affect prevalence and predictors of VS-HTG.
Obesity rates are overall lower in the EU compared to Ontario (17%; range 10.7-30.6%) (31),
as are rates of type 2 diabetes (~10%) (32). There may also be differences in ethnic
diversity.
3.3.4.2 Study strengths and limitations:
Strengths of this study include access to province-wide laboratory data, the large study
cohort with access to universal health services and the use of well-defined coding
algorithms used to investigate patient characteristics. It is also, to our knowledge, the first
study to systematically assess incidence and characteristics associated with HTG in a
Canadian population.
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While this study provides useful province-wide information on incidence of S- and VS-HTG,
there are some limitations. Prevalence was not examined and information was only
gathered over a 5-year time frame with the study collection period ending in 2015, limiting
capture of more recent trends. Furthermore, not all laboratory data were available for all
individuals (e.g. HbA1c), potentially creating bias. Additionally, not all laboratories
submitted data to OLIS simultaneously and data may be less complete for earlier time
points (76). Inclusion in the VS-HTG or S-HTG cohort were also based upon a single TG
measurement, which could have allowed for inclusion of individuals in these cohorts who
had only transiently elevated TG levels. However, TG levels in this range, even transiently
can expose an individual to the risk of pancreatitis. Furthermore, literature supports day-today variability in TG of approximately 20% (83), therefore even accounting for maximal
variability, TG levels are likely to remain elevated on subsequent tests. Information on
pharmacological treatment was limited to a subset of the VS-HTG cohort, limiting the
usefulness and generalizability of this data. The use of over the counter supplements could
not be captured with our data sources. Certain susceptibility states, such as obesity and
alcohol abuse, may be underestimated in the administrative data due to low coding
sensitivity, which may have underestimated their contribution to HTG. Individuals with
poor access to healthcare may be under-represented in the study sample as they would be
less likely to obtain a lipid profile. Similarly, it is possible that including these patients with
undetected VS-HTG may have resulted in lower follow-up rates than seen in this VS-HTG
cohort. Additionally, data regarding visits to some specialists that may be involved in the
management of VS-HTG, such as cardiologists or gastroenterologists, was not captured.
While it was concluded that there was no significant care gap, it could be argued that
specialist referral would be most appropriate for anyone with a history of VS-HTG, given it is
a rare condition with potentially serious side effects, suggesting that there may still be a gap
in appropriate care within Ontario. There were overall low numbers in the VS-HTG cohort,
but only 10 predictors were chosen and there should have had sufficient statistical power.
Additionally, the baseline rates of pancreatitis and use of fibrates were high in those with
VS-HTG, suggesting that these may not have all been incident cases. Finally, given the
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observational nature of the data set, causality cannot be determined, and the findings may
not be generalizable outside Ontario.

3.3.5 Conclusions:
In conclusion, this study shows that ~1/400 adults in Ontario have S-HTG and ~1/2500 had
new evidence of VS-HTG from 2010-2015. Peak incidence occurs between the ages of 31
and 65 years. Conditions that are most strongly associated with VS-HTG include diabetes,
male sex, alcohol, chronic liver disease, hypertension, obesity and chronic kidney disease.
No significant care gap was identified for individuals in Ontario with identified VS-HTG and
the majority had repeat TG below the threshold for pancreatitis risk.
These findings may assist clinicians in recognizing individuals at heightened risk for VS-HTG,
who may benefit from increased surveillance. Male patients with diabetes, obesity and
alcohol abuse are at the highest risk; early attention to these patients may assist in
developing an individualized treatment plan to monitor for HTG and prevent associated
adverse outcomes.
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3.4 Conservative management in hypertriglyceridemiaassociated pancreatitis

The work presented in Chapter 3.4 has been edited from this original manuscript for brevity
and consistency throughout this dissertation.

Berberich AJ, Ziada A, Zou GY, Hegele RA. Conservative management in
hypertriglyceridemia-associated pancreatitis. J Intern Med. 2019 Dec;286(6):644-650. doi:
10.1111/joim.12925. Epub 2019 Jun 6. PMID: 31077464.
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3.4.1 Background:
Acute pancreatitis can result from severe elevations in TG in both monogenic and polygenic
forms of hypertriglyceridemia. Despite absence of high-quality evidence, acute pancreatitis
with severe HTG (TG >20 mmol/L) has been listed as a category 3 indication for
plasmapheresis (84). However, plasmapheresis risks include those associated with central
line placement, potential allergic or transfusion reactions, bleeding and possible infection.
Plasmapheresis is also costly, requires specialized staff and infrastructure, and only
temporarily lowers TG levels without addressing underlying causes (85). We followed TG
levels in patients with HTG-associated pancreatitis managed conservatively with
discontinuation of oral intake and without plasmapheresis in order to determine the safety
and effectiveness of this approach.

3.4.2 Methods
We conducted an observational, retrospective review of the medical records for patients
with HTG-associated pancreatitis admitted to our institution between 2002 and 2018,
approved by the University of Western Ontario Ethics Review Board (#07920E) (Appendix
B). A diagnosis of pancreatitis was based on at least two of: 1) medical history and clinical
examination confirming the presence of abdominal pain; 2) serum lipase elevations greater
than three times the upper limit of normal; and 3) CT abdominal imaging studies consistent
with pancreatitis.
Demographic and clinical data were extracted from retrospective chart review, including
identified secondary factors for HTG such as alcohol intake, diabetes, related medications
and elevated body-mass index (BMI), history of past pancreatitis or dyslipidemia, treatment
with cessation of oral intake (NPO) and/or insulin acutely and TG levels measured over the
course of hospital admission (Table 3.11, Figure 3.3). All patients were managed with
supportive measures, including withholding of all oral intake (NPO), intravenous fluid
replacement, pain management, frequent monitoring of TG and pancreatic lipase levels and
surveillance for complications such as pancreatic necrosis and pseudocyst. Insulin infusion
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(INS IV) was used in 12 patients for the purpose of treating hyperglycemia; heparin was not
used in any patient. Duration of NPO status and implementation of other supportive
measures was determined at the discretion of the treating physician.
All statistical analyses were performed using Stata Statistical Software: Release 15
(StataCorp LLC, College Station, TX). Data were analyzed using a mixed effects model
approach to account for repeated measurements and inconsistent time points. Any TG
value above the detection limit of the laboratory assay was assigned the maximum
measured value of 62.2 mmol/L. Model selection was done by a backward procedure.
Specifically, a model with a quadratic effect of time and interactions with treatment
modality (NPO versus INS IV/NPO) was first considered, followed by a model omitting the
interaction terms if p-values > 0.05, and finally by a model with linear effect of time if the pvalue for the quadratic term > 0.05. Normality of residues for the final model was assessed.
The Kenward-Rogers method was applied to adjust degree-of-freedom in the analyses. The
mixed statistical model procedure permitted use of all TG values from all time points in all
patients to estimate the mean absolute value and mean percentage decline at 48 hours
post-admission. We also estimated the half-life for TG in this conservatively managed
cohort.

3.4.3 Results
Our sample included 20 patients who sustained 22 separate episodes of HTG-associated
pancreatitis. Mean patient age was 37 (range 22 to 60 years) and 13 patients (65%) were
male. All but two cases had at least one identified secondary cause for HTG, with 9 having
more than one identified secondary factor (Table 3.11). Nine individuals had type 2
diabetes, two had type 1 diabetes; 9 had a history of chronic alcohol misuse; 10 had obesity
(defined as BMI > 30 kg/m2); two were taking oral contraceptive pills and one was taking
glucocorticoids. Eight individuals had a history of recurrent pancreatitis. Seven patients
had severe pancreatitis, defined as requiring admission to the intensive care unit. One
patient died as a result of complications from severe necrotizing pancreatitis, despite his TG
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levels decreasing by 87%, from 31.4 to 4.10 mmol/L, within 49 hours. Two additional
patients developed pancreatic necrosis and abscess formation. One patient developed a
pseudocyst, which did not require drainage and one patient developed a splenic vein
thrombosis.
Among 14 individuals who consented to genetic testing, we found similar complex genetic
influences as we observed previously in other severe HTG cohorts (86): 0/14 had bi-allelic
large-effect mutations in LPL or related genes (87) (see chapter 3.2) while 2/14 had
heterozygous mutations in these genes (APOA5 p.G185C and LPL p.G300R) and 7/14 had a
polygenic risk score (PRS) for HTG in the top 75th percentile or higher (Table 3.12). An
additional 2/14 had PRS scores at the 65th percentile, suggesting a possible contribution to
the HTG phenotype. A high PRS for HTG is the most common genetic profile seen in adults
with TG >10 mmol/L (88).
The mean baseline TG level was 45.4 mmol/L (range 11.2 to 91.1 mmol/L). This mean value
is certainly an underestimate, since four patients had TG levels exceeding the laboratory's
limit of detection for TG. Nonetheless, we took the value of this upper detection limit (i.e.
62.2 mmol/L) as the baseline TG measurement for these four patients. Because there was
no standardized protocol for blood sampling, we tabulated the TG value obtained closest to
the 48 hour mark from admission (Table 3.11).
Individual plasma TG profiles during admission are shown in Figure 3.3. The mixed effects
statistical model determined that mean TG level at 48 hours was 13.3 mmol/L, which
represented a mean decrease of 67.8%. Regression analysis using the mixed effects model
was used to generate a predicted rate of TG decline based on all available data. The final
model of fixed effects that fits the data is given by the equation: TG = 43.0097 – 0.8367
hours + 0.0044 hours2. Using this equation, the predicted estimated TG half-life was 30.6
hours in patients managed supportively, with predicted TG reductions of 40.8%, 69.8% and
87.0% at 24, 48 and 72 hours respectively (Figure 3.4).
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To account for a possible confounding effect of insulin infusion on the decline in TG levels,
data were also analyzed separately for the supportively managed patients only (“NPO”;
N=10) and those who concurrently received insulin infusion for management of their
hyperglycemia (“NPO/INS IV”; N=12). Results for these sub-groups were similar to the
overall group; treatment modality was not associated with rate of TG decline. The average
baseline TG level in the NPO group was 45.7 mmol/L (range 13.8 - 87.9 mmol/L). At 48
hours, this had decreased to 13.1 mmol/L (range 1.75 - 28.0 mmol/L), which represented a
mean decrease of 71.4%. For the NPO/INS IV group, the average baseline TG level was 40.9
mmol/L (range 11.2 - 91.1 mmol/L), which declined to 13.5 mmol/L (range 1.03 - 28.7
mmol/L) at 48 hours, which represented a mean decrease of 67.8%. These values did not
differ between groups.
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Figure 3.3: Predicted individual trajectories of triglyceride levels (in mmol/L) over time for
patients presenting with severe hypertriglyceridemia and pancreatitis.
Dark black line shows mean trend curve incorporating all available data. Dotted blue line
indicates highest risk threshold for pancreatitis; solid blue line indicates triglyceride
threshold below which there is minimal risk of pancreatitis.
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Table 3.11: Demographic and clinical data on admission of patients with severe HTG and pancreatitis
Sex

Age
(years)

Initial TG
(mmol/L)

Follow-up TG
(mmol/L)/
elapsed time
(hours)

% decrease
at 48
hours‡

DM

EtOH

Obesity

Peak
serum
lipase

Other
Risk
Factors

Recurrent
Pancreatitis

ICU

Complications
:

NPO1

M

27

36.6

12.2 / 32

80.5%

N

Y

N

1492

-

Y

N

-

NPO2

M

40

>62.2

20.4 / 38

66.9%

N

Y

Y

1702

-

N

Y

-

NPO3

M

45

>62.2

23.8 / 30

68.4%

N

Y

N

2407

-

Y

N

-

NPO4

F

26

29.6

4.28 / 55

79.5%

N

N

N

771

OCP, GC

Y

N

-

NPO5

M

39

45.3

29.5 / 20.5

63.5%

N

Y

Y

2015

-

N

N

-

NPO6

M

46

87.9

14.4 / 52

81.4%

N

Y

N

2558

-

N

N

-

NPO7

F

38

58.5

11.7 / 40

77.4%

N

N

N

2186

-

N

N

-

NPO8

F

26

13.8

7.35 / 14.5

87.3%

N

Y

Y

>600

-

N

N

-

NPO9

F

38

45.2

16.5 / 28

72.6%

Y

N

Y

232

-

N

N

-

NPO10

M

50

54.5

27.1 /46

46.4%

Y

Y

Y

265

-

N

N

Pseudocyst~

NPO
/INS IV1

M

49

11.2

4.31 /106

35.1%

Y

N

N

492

-

Y

Y

-

NPO/
INS IV2

M

39

>62.2

19.5 / 48

73.9%

Y

N

N

>600

-

Y

N

-

NPO/
INS IV3

M

36

31.4

4.10 / 49

86.9%

Y

N

Y

14447

-

N

Y

Necrosis/
Death

NPO/
INS IV4

F

43

28.7

18.7 / 47

38.1%

Y (1)

N

N

N/A

-

Y

Y

-

NPO/
INS IV5

F

38

91.1

15.9 / 44

77.4%

Y (1)

N

N

1039

-

Y

Y

-

NPO/
INS IV6

M

52

49.0

31.9 /3)

41.0%

N

N

N/A
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-

N

N

Necrosis/
Abscess
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NPO/
INS IV7

F

27

23.5

14.9 / 25

48.9%

Y

N

Y

491

-

N

Y

Splenic vein
thrombosis

NPO/
INS IV8

M

22

33.6

3.26 / 32

96.8%

Y

N

Y

218

-

Y

N

-

NPO/
INS iV9

M

23

31.8

6.15 / 43

75.1%

Y

N/A

Y

>599

-

Y

N

-

NPO/
INS IV10

M

60

41.4

2.68 / 29

98.9%

N

Y

Y

290†

-

N

N

-

NPO/
INS IV11

F

43

50.0

26.5 / 40

46.4%

Y

N

N

>599

OCP

Y

N

-

NPO/
INS IV12

M

26

>49.9

15.58 / 47

73.3%

Y

Y

Y

>599

N

Y

Necrosis/
Abscess

Abbreviations: TG: serum triglycerides (mmol/L), DM: diabetes mellitus; (1) type 1; EtOH: alcohol intake> 3/day; ICU: Required ICU admission; NPO: managed by
withholding oral intake only; NPO/INS IV: managed by withholding oral intake in addition to insulin infusion; M: Male; F: Female; Y: Yes; N: No; OCP: Oral
contraceptive pill; GC: glucocorticoids; ~ no drainage required, *died,†pancreatic amylase; ‡When actual measurement of 48 hour triglycerides were unavailable,
percentage decrease was based on projected 48 hour triglycerides calculated using a line of best fit for individual triglyceride trajectory. NPO/INS IV4 and
NPO/INSIV5 were the same individual; NPO/INS IV8 and NPO/INS IV9 were the same individual.
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Table 3:12 Contributing genetic profiles in HTG pancreatitis patients
Monogenic mutation

Polygenic risk
score

Percentile

Phenotype contribution*

NPO2

APOA5 G185C

16/28

82nd

Likely

NPO3

None

15/28

65th

Possible

NPO4

None

14/28

50th

Not Identified

NPO5

None

18/28

99th

Likely

NPO6

None

13/28

35th

Not Identified

NPO7

LPL G300R

11/28

5th

Likely

NPO10

None

15/28

65th

Possible

NPO/INS IV1

None

18/28

99th

Likely

NPO/INS IV2

None

16/28

82nd

Likely

NPO/INS
IV4/5

None

19/28

>99th

Likely

NPO/INS IV6

None

19/28

>99th

Likely

NPO/INS IV7

None

18/28

99th

Likely

NPO/INS IV10

None

13/28

35th

Not Identified

NPO/INS IV12

None

11/28

5th

Not Identified

All monogenic mutations are heterozygous unless otherwise stated; ~unlikely causal mutation but possibly
contributory; `predicted benign; *Phenotype contribution of genetic findings was considered likely if there was
a) presence of homozygous rare, predicted or known pathogenic mutations in a gene known to be associated
with hypertriglyceridemia; b) a polygenic risk score >75th percentile or c) presence of a single, rare, predicted
or known pathogenic mutations in a gene known to be associated with hypertriglyceridemia AND a polygenic
risk score greater than or equal to the 65th percentile; phenotype contribution was considered possible if 1)
there was there is a polygenic risk score greater than or equal to the 65th percentile.
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Percentage Decline in Triglycerides over Time
100.00%
87.03%

90.00%
80.00%

69.81%
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40.80%

30.00%
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0.00%

24 hours

48 hours
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Figure 3.4 Predicted decrease in triglycerides at 24, 48 and 72 hours in patients managed
supportively
Predicted percentages of triglyceride decline were determined using the equation derived
from regression analysis of available data. These compare favourably with reports of
triglyceride decline from a single plasmapheresis session (49-80%) (85, 89-102).
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3.4.4 Discussion
This case series highlights the natural trajectory of serum TG in patients managed
conservatively with fasting, hydration, pain management and alleviation of underlying
contributing factors. The 22 episodes of HTG-associated pancreatitis in our series had a
calculated fall in serum TG of 69.8% by 48 hours. This rate of decline is similar to those
reported in plasmapheresis case series, which demonstrated 49-80% reductions in serum
TG after a single session (85, 89-102). These findings are also consistent with other
observational reports that showed no difference in the rate of TG decline between patients
managed with or without plasmapheresis (103). Furthermore, our observed plasma TG
half-life of 30.6 hours is an expected physiologic response to the elimination of oral fat in
patients who do not have complete LPL deficiency. By removing the metabolic source, i.e.
dietary fat or alcohol, the persisting chylomicrons can be cleared through residual LPL
activity.
There has been no randomized, controlled head-to-head comparison of plasmapheresis
versus supportive measures alone in severe HTG evaluating clinical outcomes, or comparing
TG trajectories. One study compared use of plasmapheresis in 10 individuals versus
conservative management in 19 retrospective controls and showed no differences in
morbidity and mortality (104). Another retrospective study that evaluated 30 patients with
HTG-associated pancreatitis, of whom 10 and 20 were managed, respectively, with
plasmapheresis and conservatively, found no differences in either TG trajectory or clinical
outcomes (103). However, there is no evidence for incremental short or long term clinical
benefit with plasmapheresis.
Interestingly, the 8 patients with positive genetic findings were found to have polygenic
susceptibility rather than monogenic HTG. 90% of patients also had secondary factors.
Thus, supporting the assertion that polygenic susceptibility plus non-genetic stressors is
required to express the severe HTG phenotype in most affected adults. Proposed
mechanisms underlying HTG-associated pancreatitis include obstruction of the local
capillary bed by circulating chylomicrons, leading to ischemia (85, 89, 93, 99, 105, 106).
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Further, pancreatic lipase that mislocalizes to plasma might partially hydrolyze TG in
chylomicrons to free fatty acids, leading to cytotoxic injury and release of inflammatory
cytokines (85, 89, 93, 99, 105, 106).
Prophylaxis of future pancreatitis episodes requires managing secondary factors (see
chapter 3.3), including eliminating alcohol, attaining good glycemic control, weight
reduction, improved physical activity, dietary reduction of simple sugars and high fat foods,
and review of any contributing medications. Pharmacotherapies include fibrates, high dose
omega-3 fatty acids and possibly niacin (5). Experimental biological agents, such as
volanesorsen (Akcea Therapeutics) an antisense oligonucleotide inhibitor of apolipoprotein
C-III (APOC3) or evinacumab (Regeneron Therapeutics), a monoclonal antibody against
angiopoietin-like 3 (ANGPTL3), may also find future utility in patients with recurrent HTGassociated pancreatitis (107-110).
Our report has some limitations. First, we could not control for all possible confounding
factors. Data were obtained from chart review and not all relevant information was
available for all patients included in the series, including TG values at all time points.
Additionally, we had no corresponding plasmapheresis-treated group to provide direct
comparison. Nonetheless, we show that supportive measures alone excluding
plasmapheresis are effective in a relatively large cohort of patients with HTG-associated
pancreatitis.

3.4.5 Conclusion:
Plasmapheresis has been suggested as a consideration for the management of HTGassociated pancreatitis, despite the lack of well-designed trials confirming its benefit. While
plasmapheresis may hasten the TG decline, this was not observed in a recent comparison
series (103). Furthermore, TG levels fall rapidly without any intervention other than
supportive management and withholding oral intake. Finally, there is no evidence that a
more rapid decline in TG levels, or that plasmapheresis itself, results in superior clinical
outcomes in HTG-associated pancreatitis. Given the lack of evidence to suggest benefit of
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plasmapheresis, we feel there is insufficient justification for plasmapheresis in the
treatment of HTG-associated pancreatitis, except perhaps during pregnancy (111) . We
suggest that supportive management is relatively easy, safe and effective, and further that
outcomes appear no worse compared to literature references of patients who undergo
plasmapheresis for severe HTG-associated pancreatitis.
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3.5 Chapter Conclusions:
The findings of these three studies collectively will help inform the clinical evaluation,
assessment, counselling and management of individuals who present with severe
hypertriglyceridemia.
For those who present young, with a strong family history, low BMI and a severe
phenotype, FCS may be suspected. The study in chapter 3.2 suggests that there is no clear
way to distinguish the molecular etiologies of FCS based on clinical presentation,
highlighting the importance of genetic confirmation in suspected FCS cases in order to
establish a clear diagnosis.
For those with a polygenic pattern of inheritance, risk of expression was most strongly
associated with the modifiable risk factors of diabetes, obesity and alcohol abuse,
suggesting that these may be important to address when counselling individuals with
hypertriglyceridemia.
Furthermore, of those who present with hypertriglyceridemia of either monogenic or
polygenic etiology who present with pancreatitis, conservative management seems safe and
appropriate for most individuals.
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Chapter 4: Assessing the personal impact of genetic testing
results on individuals with hypercholesterolemia
4.1 Overview:
An important consideration when attempting to establish the role of genetic testing in the
clinical setting is to evaluate the indirect effects it may have on the individuals tested.
While there can be many potential benefits to establishing a genetic diagnosis, as seen in
chapter 2 above, there is also the potential for unintended harm. Benefits to patients
could include the ability to receive personalized care, allow for early intervention, for more
informed decision-making, as well as provide the opportunity for screening at-risk family
members. A genetic diagnosis may also alleviate a sense of responsibility for a certain
health condition, or motivate an individual to attain a healthy lifestyle. However, there can
also be valid concerns about the potential negative impacts. Some individuals may be
concerned about the possibility of genetic discrimination from insurance agencies or
employers, a genetic diagnosis may also cause undue worry about health and long-term
risk, or may lead to guilt about passing the condition to offspring.
One of the most common inherited endocrine disorders to be confirmed genetically is
familial hypercholesterolemia (FH) (see chapter 1.8 for additional background). The
heterozygous form (HeFH) affects 1 in ~250 individuals, and establishing a genetic diagnosis
is becoming more common as a clinical tool. Genetic screening for FH is currently
recommended by many clinical guideline committees when it is suspected clinically.
Establishing the impact of this testing on patients may help to better guide the use of
genetic testing in the clinic and improve counselling around testing by increasing awareness
of the potential benefits or harms.
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4.2 Patient impact of genetic testing for familial
hypercholesterolemia
4.2.1 Background:
Heterozygous familial hypercholesterolemia (HeFH) can have significant health implications,
with patients harbouring the mutation at greatly increased risk of premature ASCVD and
death (1-3). Compared to patients with a similar LDL-C level, patients with a genetic
diagnosis of FH have a significantly greater risk and often warrant earlier treatment and
closer monitoring to prevent these possible complications (4, 5). Early intervention with
effective medications, such as statins, has been shown to greatly attenuate the risk of
cardiovascular events in these individuals, highlighting the need to identify these patients
and begin treatment as early as possible (5).
Genetic testing for familial hypercholesterolemia (FH) is becoming more common as a
clinical tool and is currently used to help guide eligibility for funding for certain medications,
such as PCSK9 inhibitors. Clinicians may find the genetic diagnosis of HeFH helpful in
recommending treatments and management strategies, selecting the most suitable
pharmacological agent and providing a better estimate of prognosis (see chapter 1.8.7).
The impact of this diagnosis on the patients themselves is less certain.
Results of studies addressing this issue in the past have been mixed, with some studies
suggesting a genetic diagnosis had very little impact on patient behavior or sense of health
burden, but perhaps contributed to a decreased sense of responsibility for their health
concerns (6, 7), and others suggesting improved medication compliance in those with a
genetic diagnosis (8) (see chapter 1.8.8.3). This study aims to address the question of
whether a genetically confirmed diagnosis of HeFH, or high polygenic risk for
hypercholesterolemia (PHC), rather than just elevated cholesterol, changes perceptions of
health, motivation to achieve a healthy lifestyle or adhere to prescribed medications, or
perception of disease burden and level of anxiety.
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This was done using a survey-based method of assessing these outcomes in patients who
have been diagnosed with HeFH based on a genetic test positive for a pathologic mutation,
compared to those with high polygenic risk for hypercholesterolemia based on a 10-SNP
score (polygenic hypercholesterolemia (PHC)), and compared to responses from patients
with high levels of LDL-C (>5.0mmol/L) who underwent genetic testing but were not found
to have a pathogenic mutation (mutation negative (Mut Neg)).
It is hoped that this information may help to better guide the use of genetic testing in the
clinic by increasing awareness of the potential patient benefits or harms. Additionally, this
study aims to identify any potential areas of concern to address with individuals during pretest and post-test counselling sessions.

4.2.2 Methods:
4.2.2.1 Study subjects:
Study subjects were recruited from general endocrine and lipid specialty clinics. Eligible
individuals were greater than 18 years of age, found to have an off-treatment LDL-C above
4.9 mmol/L and subsequently underwent genetic testing to look for a genetic cause for their
elevated cholesterol. Results must have been disclosed to the individual at least one year
prior to the date of screening for inclusion eligibility. Those unable to provide consent or
unable to complete English-language surveys were excluded. Attempts were made to
contact all patients attending the specialty lipid clinic at our center who met eligibility
criteria for study inclusion through in-person, email or telephone recruitment, to assess for
willingness to participate. All interested individuals who provided informed consent were
invited to complete the surveys. The protocol was approved by the University of Western
Ontario Ethics Review Board (#113228) (Appendix B).
4.2.2.2 Comparison Groups:
Participating individuals were divided into three groups for analysis, and compared
independently for each aim.
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Group 1 Familial hypercholesterolemia (HeFH): This group consists of individuals found to
be positive for a pathogenic heterozygous mutation in one of the canonical HeFH genes:
LDLR, ApoB or PCSK9. They may or may not have additional high polygenic risk.
Group 2 Polygenic hypercholesterolemia (PHC): This group consists of individuals
ascertained to be at high polygenic risk, defined as a 10-SNP polygenic risk score that falls
above the 75th percentile for the general population.
Group 3 Mutation negative hypercholesterolemia (Mut Neg): This group consists of
individuals with untreated LDL-C levels 5.0 mmol/L or above who are not found to have a
genetic cause for their hypercholesterolemia.
4.2.2.3 Polygenic Risk Score:
For determination of polygenic hypercholesterolemia, a set of 10 genetic markers (SNPs)
most strongly associated with raising plasma LDL cholesterol were used to generate a
weighted and unweighted polygenic risk score (PRS). The 75th percentile for the
unweighted PRS corresponds to an unweighted PRS of 14/20 risk alleles present. A
weighted score for each SNP is generated by multiplying the number of alleles associated
with the risk trait levels at each SNP locus (0, 1, or 2) by the reported effect size of the risk
allele (beta coefficient) (see chapter 1.4.6). The weighted scores for each SNP locus are then
totaled to generate the overall weighted PRS for an individual. Higher scores indicate that
individuals carry a greater number of risk alleles, with presumed additive effect on raising
cholesterol levels, while lower scores indicate that individuals carry fewer risk alleles.
Included SNPs and beta coefficients for weighted scores are listed in Table 1.12.
4.2.2.4 Chart Review:
Chart review was conducted on all consenting patients who agreed to participate in the
study and completed the surveys. Extracted data included information on personal
demographics, genetic statis and results of genetic testing, relevant laboratory tests,
physical exam finding, family history and cardiovascular medical history.
220

4.2.2.5 Surveys:
Survey Completion: Participants were offered the opportunity to complete surveys in one
of four ways, selected based on patient preference: a) in-person paper-based survey
conducted in clinic; b) in-person online-based survey conducted in clinic; c) mailed out
paper-based survey, completed at home, returned by pre-paid mail; d) online survey
conducted at home, with a link provided by mail, telephone or email. Participants were
provided with as much time as they required to complete the survey and completed the
survey on their own outside the presence of any study personnel.
Paper-Based Survey: The paper based survey is attached in the supplemental material
(Appendix F) and consists of 9 pages of 46 multiple-choice style questions, and also offers
an opportunity to provide qualitative statements at the end. Paper surveys were labelled
with an anonymized patient study reference number in order to be linked to chart review
data but did not contain participant name. Data from the paper-based surveys was then
entered manually into the REDCap database to aid in generation of a complete data set.
Online Survey: The online survey followed the same structure as the paper-based survey,
displaying the same questions in the same order as the paper-based version. Participants
were provided with a anonymized study reference number to complete the online surveys.
The electronic survey was hosted on the Personal Information Protection and Electronic
Documents Act (PIPEDA) and Health Information Patient Protection Act (HIPPA)-compliant
online version of REDCap (Research Electronic Data Capture) (9) hosted at the Lawson
Health Research Institute in London, Ontario.
Survey Content: Survey questions are formatted according to the original validated surveys.
Health Related Quality of Life Measure (12 questions) (10, 11):
The Health Related Quality of Life measure, short form 12 (SF-12), is a 12-item
questionnaire designed to assess quality of life for individuals with chronic conditions. It is
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subdivided into a Physical Component and Mental Component summary, and has been
validated in a number of populations and for a number of chronic diseases (10, 11).
Medication Adherence Measure (8 questions) (12, 13):
The Eight-Item Morisky Medication Adherence Scale (MMAS-8) is an 8-question version of
the more simple medication adherence questionnaire (MAQ) that has been validated in a
broad range of diseases and patient populations (13). It allows for disclosures of nonadherence by using a “yes-saying” bias and explores some of the contributors to medication
non-compliance (13). Previous studies have shown good concordance of the MMAS-8 with
pill counting for patients taking statins (14). Results are reported as an overall score and
divided into low, intermediate and high adherence. License is required for use and scoring
in proprietary (Appendix A).
Simple Lifestyle Indicator Measure (10 questions)(15, 16):
The simple lifestyle indicator questionnaire (SLIQ) is an 8 question survey consisting of
questions designed to ascertain patterns of behavior in various lifestyle components that
affect cardiovascular disease, including diet, activity level, stress, smoking and alcohol
consumption. Each category is scored separately and the results are combined to generate
the overall finding. It has been validated previously in a Canadian population at elevated
cardiovascular risk administered in a clinical research setting (15, 16). Scores from 0-4 are
considered ‘unhealthy’, 5-7 are ‘intermediate’, and 8-10 are ‘healthy’.
Generalized Anxiety Measure (8 questions) (17):
Receiving a genetic diagnoses of FH may contribute to heightened levels of anxiety. This
has been seen in other conditions that receive a genetic diagnosis, such as in inherited
cancer syndromes, along with feelings of guilt about potentially having passed the condition
to offspring (18). The generalized anxiety disorder screener (GAD-7) is a 7 item
questionnaire validated in the general population to assess for anxiety (17). The GAD-7 has
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been used in other cardiovascular disease populations to clinically assess for anxiety and
been shown to perform well (19).
Perceived Cardiovascular Risk (1 question):
This was addressed by a single item question in which the respondent was asked to rate his
or her own risk of having a heart attack or stroke as low, moderate, high or very high over
the next ten years.
Perceived Impact (7 questions):
These 7 items directly asked the respondent to address their own perceptions of their
experience with genetic testing. Using a 5-point Likert scale ranging from strongly negative
to strongly positive they rated their own perceived impact of genetic testing for FH. They
were also asked how likely they would be to recommend testing to family members.
Additionally, they were asked to respond to questions commenting on any lifestyle or
medication adherence changes they may have made in response to the genetic testing
results, as well as perceptions of health and level of worry about health.
4.2.2.6 REDCap Database:
REDCap (Research Electronic Data Capture) (9) is a PIPEDA and HIPPA compliant secure
server that is encrypted, has user authentication, data logging with mechanisms in place to
ensure confidentiality. All data entered online or in the study database was de-identified.
Data was available from the online REDCap system to study personnel only through secure
log-in, user authentication and site encryption.
4.2.2.7 Statistical Analysis:
For each survey outcome, differences between any two groups were evaluated with twotailed unpaired t-tests and are reported as mean difference + standard deviation. With the
three groups (Group1: patients who diagnosed with FH by a single genetic mutation, Group
2: those who have polygenic scores greater than 75 percentile, and Group 3: those who
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have no pathogenic mutations), comparisons were made between Group1 vs. Group2,
Group 1 vs. Group3, Group 2 vs. Group 3 and pooled results from Group 1 and 2 (genetic
hypercholesterolemia) vs. Group 3). For outcome variables measured by categories, or
Likert scale, such as perceived cardiovascular risk by very high, high, mod, low, KruskalWallis test was used. Alpha level for significance was set at P < .05.

4.2.3 Results:
4.2.3.1 Responders:
A total of 139 individuals completed the survey. Of the respondents, 63 (45.3%) were
diagnosed with heterozygous FH (HeFH - group 1), 48 (34.5%) were diagnosed with
polygenic hypercholesterolemia (PHC – group 2) and 28 (20.1%) had mutation negative
hypercholesterolemia (Mut Neg – group 3) (Table 4.1).
4.2.3.2 The Health Related Quality of Life:
There were no significant differences in health related quality of life, as assessed by the SF12 score between the study groups, and none differed significantly from the literature
reported average (50 ± 10) , for either physical or mental quality of life scores (Table 4.2).
Average physical scores were 51.58 ± 8.54, 48.91 ± 7.92 and 47.73 ± 10.44 and average
mental scores were 52.14 ± 7.92, 51.51 ± 9.27 and 50.30 ± 8.48 for HeFH, PHC and Mut Neg
groups respectively (Table 4.2).
4.2.3.3 Medication Adherence Measure:
Respondents not taking medications did not complete this section of the survey. Average
scores for the MASS-8 were 6.41 ± 1.84, 7.20 ± 0.84 and 6.36 ± 1.88 for HeFH (n=60), PHC
(n= 46) and Mut Neg (n=26) groups respectively (Table 4.3). Average scores were
significantly higher for PHC compared to the other two groups (p = .0105 (v HeFH) and
.00841 (v Mut Neg)) by paired T-test. Low adherence was found in 32% of the HeFH group,
9% in the PHC group and 31% in the Mut Neg group, compared to the literature average of
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32%. Medium adherence was seen in 32% of the HeFH group, 54% of the PHC group and
35% of the Mut Neg group, with a literature average of 52%. High adherence was seen in
37% of the HeFH group, 37% of the PHC group and 35% of the Mut Neg group, compared to
the literature average of 16% (Table 4.3).
In the analysis of categorical data, the mean ranks were 63.21, 73.01 and 62.56, for HeFH,
PHC and Mut Neg groups respectively. From Kruskal-Wallis rank-sum test, the difference in
rank was not found to be statistically significant (Kruskal-Wallis chi-squared = 2.0512,
degrees of freedom = 2, p-value = 0.35858) (Table 4.3). For the pooled HeFH/PHC vs Mut
Neg comparison, mean ranks were 67.47 and 62.56, the difference in rank was not found to
be statistically significant (Kruskal-Wallis chi-squared = 0.344, degrees of freedom = 1, pvalue = 0.55756) (Table 4.3).
4.2.3.4 Simple Lifestyle Indicator Measure:
No significant differences were noted between groups in terms of the SLIQ mean scores
(7.36 ± 1.38, 6.98 ± 1.4 and 6.79 ± 1.99 for HeFH, PHC and Mut Neg groups respectively) and
all were similar to the reported literature average (6.73 ± 0.713) (Table 4.4).
For categorical assessment, unhealthy lifestyle was seen in 11%, 17% and 29%, intermediate
in 70%, 73% and 57%, and healthy in 19%, 10% and 14% for HeFH, PHC and Mut Neg groups
respectively (Table 4.4). From Kruskal-Wallis rank-sum test, the mean ranks were 75.49,
67.21 and 62.43 for HeFH, PHC and Mut Neg groups respectively; difference in rank was not
found to be statistically significant (Kruskal-Wallis chi-squared = 2.3923, degrees of freedom
= 2, p-value = .30236); difference in rank was also not statistically significant for the pooled
HeFH/PHC analysis (Kruskal-Wallis chi-squared= 1.2395, degrees of freedom = 1, p-value
.266) (Table 4.4).
4.2.3.5 Generalized Anxiety Measure:
There were no statistically significant differences in mean GAD-7 score between the
respective groups (5.69 ± 3.70, 4.54 ± 5.09 and 5.61 ± 5.09 for HeFH, PHC and Mut Neg
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groups respectively (Table 4.5). Scores were also similar to the literature average of 4.9 ±
4.8.
For categorical assessment, anxiety scores were scored as minimal in 60%, 71% and 57%,
mild in 23%, 21% and 36%, moderate in 13%, 8% and 4% and severe in 5%, 0% and 4% in
HeFH, PHC and Mut Neg groups respectively. From Kruskal-Wallis rank-sum test, the mean
ranks were 73.0, 63.6 and 71.9 for HeFH, PHC and Mut Neg groups respectively; difference
in rank was not found to be statistically significant (Kruskal-Wallis chi-squared = 1.6142,
degrees of freedom = 2, p-value = .44615); difference in rank was also not statistically
significant for the pooled HeFH/PHC analysis (Kruskal-Wallis chi-squared= 0.1277, degrees
of freedom = 1, p-value .721) (Table 4.5).
4.2.3.6 Perceived Cardiovascular Risk:
Cardiovascular risk was self-reported as low in 52.38%, 45.83% and 46.42%, moderate in
33.33%, 35.42% and 35.71%, high in 7.94%, 14.58% and 14.29%, and very high in 6.35%,
2.08% and 3.57% of individuals in HeFH, PHC and Mut Neg groups respectively (Figure 4.1).
The mean ranks were 71.7, 67.4 and 71.0 for HeFH, PHC and Mut Neg groups respectively.
From Kruskal-Wallis rank-sum test, the difference in rank was not found to be statistically
significant (Kruskal-Wallis chi-squared = 0.3278, degrees of freedom = 2, p-value = 0.84883).
In the pooled genetic data, 49.55%, 34.23%, 10.81% and 4.50% of the combined HeFH/PHC
group self-reported ASCVD risk as low, moderate, high and very high respectively. The
mean ranks were 71.7, and 68.9 for Mut Neg, and pooled HeFH/PHC groups respectively.
From Kruskal-Wallis rank-sum test, the difference in rank was not found to be statistically
significant (Kruskal-Wallis chi-squared = 0.1043, degrees of freedom = 1, p-value = 0.74673).
4.2.3.7 Perceived Impact:
Question 1: How do you feel having a genetic test for familial hypercholesterolemia has
impacted you?”
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Impact was reported as strongly negative in 4.84%, 0.00%, and 0.00%, as mildly negative in
1.61%, 2.13% and 3.57%, no impact in 27.42%, 36.17% and 28.57%, mildly positive in
19.35%, 27.66% and 46.43%, and strongly positive in 46.77%, 34.04% and 21.43% in HeFH,
PHC and Mut Neg groups respectively (Figure 4.2).
The mean ranks were 74.6, 64.8, and 71.1 for no mutation, heterozygous, and polygenic
groups respectively. From Kruskal-Wallis rank-sum test, the difference in rank was not
found to be statistically significant (Kruskal-Wallis chi-squared = 1.5409, degrees of freedom
= 2, p-value = 0.4628).
Pooled results from HeFH/PHC showed similar results with 2.75%, 1.83%, 31.19%, 22.94%
and 41.28% responding with strongly negative, mildly negative, no impact, mildly positive
and strongly positive impact respectively. The mean ranks were 74.6, and 67.6 for Mut Neg
and HeFH/PHC groups respectively. From Kruskal-Wallis rank-sum test, the difference in
rank was not found to be statistically significant (Kruskal-Wallis chi-squared = 0.7868,
degrees of freedom = 1, p-value = 0.3751).
Question 2: How likely are you to recommend genetic testing to your family members?
Responses indicated not at all likely in 1.61%, 4.26%, and 0%, somewhat unlikely in 1.61%,
2.13%, and 10.71%, neither likely or unlikely in 11.29%, 10.64% and 28.57%, somewhat
likely in 22.58%, 23.40% and 21.43% and very likely in 62.90%, 59.57% and 32.29% in HeFH,
PHC and Mut Neg groups respectively (Figure 4.3).
The mean ranks were 63.9, 66.8 and 83.9 in HeFH, PHC and Mut Neg groups respectively.
Compared to Mut Neg, HeFH and PHC groups were both statistically more likely to answer
higher (Kruskal-Wallis chi-squared = 6.4167, degrees of freedom = 2, p-value = 0.04042).
The man ranks for Mut Neg and HeFH/PHC groups in the pooled analysis were 83.9, and
65.2. Compared to Mut Neg, the pooled HeFH/PHC group was more likely to answer higher
(Kruskal-Wallis chi-squared = 6.2319, degrees of freedom = 1, p-value = 0.01255).
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Question 3: Did you make changes to your dietary habits after learning your genetic
testing results?
Diet was reported to have significantly worsened in 0% of all respondents, mildly worsened
in 0%, 4.26% and 7.14%, stayed the same in 22.58%, 23.40%, and 46.43%, mildly improved
in 45.16%, 57.45% and 28.57%, and significantly improved in 32.26%, 14.89% and 17.86% in
HeFH, PHC and Mut Neg groups respectively (Figure 4.4).
The mean ranks were 60.1, 71.8 and 84.1 in HeFH, PHC and Mut Neg groups respectively.
The answers were more likely to be higher for the HeFH group followed by PHC then Mut
Neg (Kruskal-Wallis chi-squared = 8.5178, degrees of freedom = 2, p-value = 0.01414).
For the pooled analysis, the mean ranks were 84.1, and 65 for Mut Neg and HeFH/PHC
respectively. The answers were more likely to be higher for the pooled
heterozygous/polygenic group than the no mutation group (Kruskal-Wallis chi-squared =
5.8408, degrees of freedom = 1, p-value = 0.01566).
Question 4: Did you make changes to your physical activity habits after learning your
genetic testing results?
Physical activity was reported as significantly deceased in 1.61%, 2.13% and 0%, mildly
decreased in 3.23%, 2.13% and 0%, 45.16%, 42.55% and 60.71%, mildly increased in 37.10%,
36.17% and 28.57% and significantly increased in 12.9%, 17.02% and 10.71% in HeFH, PHC
and Mut Neg groups respectively (Figure 4.5).
The mean ranks were 69.1, 65.7 and 74.2 in HeFH, PHC and Mut Neg groups respectively
and were not found to be significantly different (Kruskal-Wallis chi-squared = 0.9437,
degrees of freedom = 2, p-value = 0.6238).
In the pooled analysis, mean ranks were 74.2, and 67.7 for Mut Neg and HeFH/PHC, which
were not found to be statistically different (Kruskal-Wallis chi-squared = 0.71657, degrees of
freedom = 1, p-value = 0.3973).
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Question 5: Did you make changes to taking all medications as prescribed after learning
your genetic testing results?
Medication adherence was reported to have significantly worsened in 0%, 2.13% and 3.57%,
mildly worsened in 1.61%, 2.13% and 0%, stayed the same in 54.84%, 61.70% and 64.29%,
mildly improved in 9.68%, 6.38% and 25% and significantly improved in 33.87%, 27.66% and
7.14% in HeFH, PHC and Mut Neg groups respectively (Figure 4.6).
The mean ranks were 63.7, 71.1 and 77.1 in HeFH, PHC and Mut Neg groups respectively,
which were not found to be statistically different (Kruskal-Wallis chi-squared = 3.0874,
degrees of freedom = 2, p-value = 0.2136).
For the pooled HeFH/PHC analysis, the mean ranks were 77.1, and 66.9 for Mut Neg and
HeFH/PHC respectively, which were also not found to be statistically different (KruskalWallis chi-squared = 1.8978, degrees of freedom = 1, p-value = 0.1683).
Question 6: Compared to before you underwent genetic testing, how do you feel about
your state of overall health?
In response to this question, perceptions of overall health were reported as significantly
worse in 1.61%, 2.13% and 0%, mildly worse in 12.9%, 8.51% and 10.71%, stayed the same
in 30.65%, 34.04% and 64.29%, mildly improved in 33.8%, 42.55% and 14.29%, and
significantly improved in 20.97%, 12.77% and 10.71% in HeFH, PHC and Mut Neg groups
respectively (Figure 4.7).
The mean ranks were 65.2, 66.4 and 81.8 in HeFH, PHC and Mut Neg groups respectively,
which were not found to be statistically different (Kruskal-Wallis chi-squared = 4.0918,
degrees of freedom = 2, p-value = 0.1293).
Pooling the HeFH and PHC groups resulted in mean ranks of 81.8, and 65.7 for Mut Neg and
HeFH/PHC respectively. Compared to the Mut Neg group, the pooled HeFH/PHC group
were statistically more likely to have a higher score (Kruskal-Wallis chi-squared = 4.063,
degrees of freedom = 1, p-value = 0.04383).
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Question 7: Compared to before genetic testing, how would you rate your level of worry
or concern over your health?
Responses from this question reported that respondents were much less concerned in
9.68%, 4.26% and 0%, slightly less concerned in 11.29%, 19.15% and 14.29%, no change was
reported in 41.94%, 34.04% and 50.00%, slightly more concerned in 27.42%, 36.17% and
28.57% and significantly more concerned in 9.68%, 6.38% and 7.14% in HeFH, PHC and Mut
Neg groups respectively (Figure 4.8).
The mean ranks were 70.1, 68.4 and 67.5 for HeFH, PHC and Mut Neg groups respectively,
which were not found to be statistically different (Kruskal-Wallis chi-squared = 0.1037,
degrees of freedom = 2, p-value = 0.9495).
Pooling the HeFH/PHC data generated mean ranks of 67.5, and 69.4 for Mut Neg and
HeFH/PHC respectively. This difference was not found to be statistically significant (KruskalWallis chi-squared = 0.053269, degrees of freedom = 1, p-value = 0.8175).
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Table 4.1: Survey Respondents
Study Group:

Number of Responders:

Heterozygous FH

63

Polygenic FH

48

Mutation-negative HC

28

TOTAL:

139

HC: hypercholesterolemia
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Table 4.2: SF-12 Health Related Quality of Life Scores
Physical Score
p-value
± SD

Mental Score
± SD

P-value

HeFH
n=63

51.58 ± 8.54

-

52.14 ± 7.92

-

PHC
n =48

48.91 ± 7.92

-

51.51 ± 9.27

-

Mut Neg HC
N= 28

47.73 ± 10.44

-

50.30 ± 8.48

-

Literature
Average

50 ± 10

-

50 ± 10

-

Mut Neg HC vs
HeFH

.093

.336

Mut Neg HC vs
PHC

.609

.565

HeFH vs PHC

.091

.709

Genetic FH
(HeFH + PHC) vs
Mut Neg

.213

.388

HeFH: heterozygous familial hypercholesterolemia; PHC: polygenic hypercholesterolemia;
Mut Neg: mutation negative hypercholesterolemia; SD: standard deviation.

232

Table 4.3: MASS-8 Scores
Average
Score +/- SD

p-Value

Low (%)

Medium
(%)

High (%)

P-Value

HeFH
n= 60

6.41 +/- 1.84

-

32%

32%

37%

PHC
n= 46

7.20 +/- 0.84

-

9%

54%

37%

Mut Neg HC
n= 26

6.36 +/- 1.88

-

31%

35%

35%

Literature
Average

-

32%

52%

16%

Mut Neg HC
vs HeFH

.889

.951

Mut Neg HC
vs PHC

.0105

.260

HeFH vs
PHC

.00841

.194

Genetic FH
(HeFH +
PHC) vs Mut
Neg

.255

0.558

-

HeFH: heterozygous familial hypercholesterolemia; PHC: polygenic hypercholesterolemia;
Mut Neg: mutation negative hypercholesterolemia; SD: standard deviation; bold:
statistically significant
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Table 4.4: Simple Lifestyle Indicator:
Score ± SD
p-value
HeFH
n=63
PHC
n=48
Mut Neg HC
n=28
Literature
Average
Mut Neg HC
vs
HeFH
Mut Neg HC
vs
PHC

7.36 ± 1.38

-

11%

Intermediate Healthy pValue
(%)
(%)
70%
19%
-

6.98 ± 1.4

-

17%

73%

10%

-

6.79 ± 1.99

-

29%

57%

14%

-

-

-

-

-

-

6.73 ± 0.713

Unhealthy
(%)

.169

.164

.65

.599

HeFH vs PHC

.15

.273

Genetic FH
(HeFH + PHC)
vs Mut Neg

.3079

.266

HeFH: heterozygous familial hypercholesterolemia; PHC: polygenic hypercholesterolemia;
Mut Neg: mutation negative hypercholesterolemia
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Table 4.5: GAD-7 Score
Score ±
SD
Mut Neg HC 5.61 ±
5.09
n=28
HeFH
n=63
PHC
n=48
Literature
Average
Mut Neg HC
vs HeFH

p-Value
-

Minimal Mild
(%)
(%)
57%
36%

Moderate Severe p(%)
(%)
value
4%
4%
-

5.69 ±
3.70

-

60%

23%

13%

5%

-

4.54 ±
5.09

-

71%

21%

8%

0%

-

4.9 ± 4.8

-

-

-

-

-

-

.35

.886

Mut Neg HC
vs PHC

.30

.366

HeFH vs
PHC

.93

.230

Genetic FH
(HeFH +
PHC) vs Mut
Neg

.294

.721

HeFH: heterozygous familial hypercholesterolemia; PHC: polygenic
hypercholesterolemia:Mut Neg: mutation negative hypercholesterolemia

235

How would you categorize your risk of having a heart
attack or stroke within the next 10 years??
60.00%
50.00%
40.00%
30.00%
20.00%
10.00%
0.00%

Mut Neg
Low

HeFH

PHC

Moderate

High

HeFH + PHC
Very High

Figure 4.1: Perceived cardiovascular risk
Cardiovascular risk was self-reported as low in 52.38%, 45.83% and 46.42%, moderate in
33.33%, 35.42% and 35.71%, high in 7.94%, 14.58% and 14.29%, and very high in 6.35%,
2.08% and 3.57% of individuals in HeFH, PHC and Mut Neg groups respectively. No
statistically significant differences were seen between groups in terms of perceived
cardiovascular risk (Kruskal-Wallis chi-squared = 0.3278, degrees of freedom = 2, p-value =
0.84883).
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How do you feel having a genetic test for
familial hypercholesterolemia has impacted you?
50.00%
45.00%
40.00%
35.00%
30.00%
25.00%
20.00%
15.00%
10.00%
5.00%
0.00%

HeFH

PHC

Mut Neg

Strongly negative impact

Mildly negative impact

Mildly positive impact

Strongly positive impact

HeFH + PHC

No impact

Figure 4.2: Perceived impact of genetic testing
Impact was reported as strongly negative in 4.84%, 0.00%, and 0.00%, as mildly negative in
1.61%, 2.13% and 3.57%, no impact in 27.42%, 36.17% and 28.57%, mildly positive in
19.35%, 27.66% and 46.43%, and strongly positive in 46.77%, 34.04% and 21.43% in HeFH,
PHC and Mut Neg groups respectively. There were no statistically significant differences
between groups in terms of perceived impact (Kruskal-Wallis chi-squared = 1.5409, degrees
of freedom = 2, p-value = 0.4628).
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How likely are you to recommend genetic testing to your family
members?
70.00%
60.00%
50.00%
40.00%
30.00%
20.00%
10.00%
0.00%

HeFH

PHC

Mut Neg

Not at all likely

Somewhat unlikely

Somewhat likely

Very likely

HeFH + PHC
Neither likely or unlikely

Figure 4.3: Recommendation to family members
Responses indicated not at all likely in 1.61%, 4.26%, and 0%, somewhat unlikely in 1.61%,
2.13%, and 10.71%, neither likely or unlikely in 11.29%, 10.64% and 28.57%, somewhat
likely in 22.58%, 23.40% and 21.43% and very likely in 62.90%, 59.57% and 32.29% in HeFH,
PHC and Mut Neg groups respectively. Compared to no mutation, heterozygous and
polygenic groups are more likely to answer higher (Kruskal-Wallis chi-squared = 6.4167,
degrees of freedom = 2, p-value = 0.04042). Compared to no mutation, the pooled
heterozygous/polygenic group was more likely to answer higher (Kruskal-Wallis chisquared = 6.2319, degrees of freedom = 1, p-value = 0.01255).
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70.00%

Did you make changes to your dietary habits
after learning your genetic testing results?

60.00%
50.00%
40.00%
30.00%
20.00%
10.00%
0.00%

HeFH

PHC

Significantly worsened
Mildly improved

Mut Neg

Mildly worsened
Significantly improved

HeFH + PHC
Stayed the same

Figure 4.4: Perceived dietary changes
Diet was reported to have significantly worsened in 0% of all respondents, mildly worsened
in 0%, 4.26% and 7.14%, stayed the same in 22.58%, 23.40%, and 46.43%, mildly improved
in 45.16%, 57.45% and 28.57%, and significantly improved in 32.26%, 14.89% and 17.86% in
HeFH, PHC and Mut Neg groups respectively. The answers were more likely to be higher
for the heterozygous group followed by polygenic then no mutation (Kruskal-Wallis chisquared = 8.5178, degrees of freedom = 2, p-value = 0.01414). Additionally, the answers
were more likely to be higher for the pooled heterozygous/polygenic group than the no
mutation group (Kruskal-Wallis chi-squared = 5.8408, degrees of freedom = 1, p-value =
0.01566).
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Did you make changes to your physical activity habits
after learning your genetic testing results?
70.00%
60.00%
50.00%
40.00%
30.00%
20.00%
10.00%
0.00%

HeFH

Significantly decreased
Mildly increased

PHC

Mut Neg

Mildly decreased
Significantly increased

HeFH + PHC
Stayed the same

Figure 4.5: Physical activity changes
Physical activity was reported as significantly deceased in 1.61%, 2.13% and 0%, mildly
decreased in 3.23%, 2.13% and 0%, 45.16%, 42.55% and 60.71%, mildly increased in 37.10%,
36.17% and 28.57% and significantly increased in 12.9%, 17.02% and 10.71% in HeFH, PHC
and Mut Neg groups respectively. There were no statically significantly differences between
groups in terms of reported changes in physical activity habits (Kruskal-Wallis chi-squared =
0.9437, degrees of freedom = 2, p-value = 0.6238).
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Did you make changes to taking all medications as prescribed
after learning your genetic testing results?
70.00%
60.00%
50.00%
40.00%
30.00%
20.00%
10.00%
0.00%

HeFH

PHC

Mut Neg

Significantly worsened

Mildly worsened

Mildly improved

Significantly improved

HeFH + PHC
Stayed the same

Figure 4.6: Perceived medication adherence:
Medication adherence was reported to have significantly worsened in 0%, 2.13% and 3.57%,
mildly worsened in 1.61%, 2.13% and 0%, stayed the same in 54.84%, 61.70% and 64.29%,
mildly improved in 9.68%, 6.38% and 25% and significantly improved in 33.87%, 27.66% and
7.14% in HeFH, PHC and Mut Neg groups respectively. No statistically significant results
were found between groups in terms of perceived improvements in medication adherence
(Kruskal-Wallis chi-squared = 3.0874, degrees of freedom = 2, p-value = 0.2136).
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Compared to before you underwent genetic testing,
how do you feel about your state of overall health?
70.00%
60.00%
50.00%
40.00%
30.00%
20.00%
10.00%
0.00%

HeFH

PHC

Mut Neg

Significantly worse

Mildly worse

Mildly improved

Significantly improved

HeFH + PHC
Stayed the same

Figure 4.7: Perceived state of health
Perceptions of overall health were reported as significantly worse in 1.61%, 2.13% and 0%,
mildly worse in 12.9%, 8.51% and 10.71%, stayed the same in 30.65%, 34.04% and 64.29%,
mildly improved in 33.8%, 42.55% and 14.29%, and significantly improved in 20.97%,
12.77% and 10.71% in HeFH, PHC and Mut Neg groups respectively. For the pooled
analysis, the difference was found to be statistically significant with individuals with in
the pooled HeFH/PHC having higher scores compared to those with no mutation
identified (Kruskal-Wallis chi-squared = 4.0918, degrees of freedom = 2, p-value = 0.1293).
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Compared to before genetic testing, how would
you rate your level of worry or concern over your health?
60.00%
50.00%
40.00%
30.00%
20.00%
10.00%
0.00%

HeFH

PHC

Mut Neg

HeFH + PHC

Much less concerned

Slightly less concerned

No change

Slightly more concerned
Figure 4.8: Perceived worry or concern

Responses from this question reported that respondents were much less concerned in
9.68%, 4.26% and 0%, slightly less concerned in 11.29%, 19.15% and 14.29%, no change was
reported in 41.94%, 34.04% and 50.00%, slightly more concerned in 27.42%, 36.17% and
28.57% and significantly more concerned in 9.68%, 6.38% and 7.14% in HeFH, PHC and Mut
Neg groups respectively. There were no statistically significant differences between the
groups (Kruskal-Wallis chi-squared = 0.1037, degrees of freedom = 2, p-value = 0.9495).
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4.2.4 Discussion:
The overall findings suggest that in the population studied, genetic testing for FH had either
neutral or positive impacts on most individuals undergoing testing.
In terms of health related quality of life, both the validated survey as well as the patient
perceptions of overall health suggested no negative impact from genetic testing or from the
underlying hypercholesterolemia, and perhaps a feeling of improved overall health in those
with a genetic diagnosis . The results of the SF-12 survey showed that all three study groups
appeared similar to the population reported literature average, with no differences noted
between groups (Table 4.2). This is consistent with prior use of this survey to assess quality
of life in individuals undergoing cascade genetic screening for FH, which did not find an
association between quality of life by this measure and affected or non-affected status (20).
Patient perceptions of their overall health after genetic testing were reported to be neutral
or improved in the majority of individuals in all three study groups (85.49%, 89.36% and
89.29% in HeFH, PHC and Mut Neg respectively). In the pooled analysis, individuals with a
genetic diagnosis were significantly more likely to report higher scores than those without a
genetic cause identified. Potential explanations for this difference include the relief from
diagnostic uncertainty that comes with a genetic diagnosis that could potentially improve
individuals understanding of their medical condition. It may also be that once they were
diagnosed, individuals took active steps to improve their health. There may also be a sense
of relief among the individuals with a genetic diagnosis that their elevated cholesterol levels
are predominantly hereditary and not due to lifestyle choices.
In terms of medication adherence, MASS-8 scores were similar to reported literature
average, with individuals with PHC reporting significantly higher rates of adherence than
those in the other two groups. Patient perceptions of medication adherence were not
significantly different between the three study groups, but there was a higher percentage of
individuals in the HeFH and PHC groups that reported “significantly improved” medication
adherence following their genetic testing results compared to those who were not found to
244

have a mutation (33.87%/27.66% vs 7.14% for HeFH/PHC and Mut Neg groups respectively).
The reasons for this difference are unclear, but could be due to improved appreciation for
the role of medications over lifestyle changes in controlling hypercholesterolemia in those
with an underlying genetic cause.
There was also a higher percentage of individuals with high adherence on the MASS-8 in all
three study groups compared to the literature reported average (35-37% vs 16%), which
may suggest that patients attending the lipid clinic may be more likely in general to take
prescribed medications than the average population. This may be in line with other studies
examining lifestyle patterns and medication adherence, where one study found that in
women with hypercholesterolemia, medication adherence was generally high and did not
differ between those with a diagnosis of definite or probable FH and those with no FH
diagnosis (21). While we did not examine an association with these factors here, in other
prior studies of FH, non-adherence with medications has been associated with younger age
and lower untreated cholesterol values (22).
Assessment of lifestyle with the SLIQ did not reveal any statistical differences between
groups, with average scores for all groups falling close to the literature average. Patient
perceived physical activity habits also showed no differences between the three groups.
However, patient perceived changes to diet showed that scores were highest for the HeFH
group, followed by the PHC group then the Mut Neg group. This may suggest that those
with a genetic diagnosis are, at minimum, making more of an effort to address any dietary
contribution to their elevated cholesterol, though further investigation to clarify this finding
would be required.
Individuals undergoing genetic testing were not found to have higher levels of anxiety when
study groups were compared to each other or with the literature average. Similarly, patient
perceived worry or concern over health was not statistically different between the three
study groups. This suggests that the genetic diagnosis does not appear in this study to be
associated with higher rates of health-related concerns or anxiety. As higher levels of
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generalized anxiety have also been associated with higher ASCVD event rates (23), this is a
reassuring finding in this population.
Perceived cardiovascular risk was also similar between the three study groups, and overall
was perceived to be low or moderate by the majority in all groups (85.71%, 81.25% and
82.13% in HeFH, PHC and Mut Neg respectively), further suggesting that the genetic
diagnosis did not lead to increased perceptions of having a high-risk condition.
Perhaps one of the most important questions to gauge the patient perspective on genetic
testing was the responses to the question “How do you feel having a genetic test for familial
hypercholesterolemia has impacted you?”. Responses were not statistically different
between the three study groups, but all reported high rates of neutral or positive impacts
(93.54%, 97.87% and 96.43% for HeFH, PHC and Mut Neg groups respectively). Importantly,
46.77% of individuals diagnosed with HeFH reported a “strongly positive impact”.
When asked if they would recommend genetic testing to family members, both the HeFH
and PHC study groups were statistically more likely to recommend testing, with the majority
of individuals in all three study groups reporting neutral or affirmative responses (96.77%
93.61% and 89.29% in HeFH, PHC and Mut Neg groups respectively). The fact that those
who ultimately received a genetic diagnosis are more likely to recommend testing to other
family members makes intuitive sense, as relatives of these individuals would be at higher
risk of carrying the same pathologic variants, whereas family members of those without
identified genetic risk would be less likely to have informative findings. The high overall
rates of test recommendation is further support of the overall positive testing experience.
However, despite the overall findings of neutral or positive impact, it is important to note
that 6.45% of patients with a diagnosis of HeFH reported that they felt that genetic testing
had a mildly (1.61%) or strongly (4.84%) negative impact on them. While this is a minority
of the patients tested, it highlights the need to properly counsel patients before and after
the genetic testing process to explain the diagnosis, prepare them for the possible
outcomes and support them in managing the condition if diagnosed.
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4.2.4.1 Strengths and limitations
The strengths of this study include the use of a range of validated surveys as well as patient
perceptions to assess several aspects of genetic testing impact. Some limitations include
the relatively low numbers of respondents, which may have led to a lack of power to detect
differences between the groups. However, since the data captured trended towards neutral
or positive impact when not statistically different, the likelihood that a significant negative
impact was missed is low. Given that the patients included in this study were all followed in
a speciality lipid clinic, which may be different in terms of the patient population (ie more
motivated or concerned patients), or healthcare delivery (ie administered by experts in the
field), the results of this study may not be generalizable to patients in other settings, such as
general medicine clinics or family doctor’s offices. Furthermore, these results may be
specific for FH/hypercholesterolemia, and may not be generalizable to other genetic
conditions.

4.2.5 Conclusions:
Perceived experiences with genetic testing in this study were neutral or positive across all
groups and most would recommend testing to other family members. Ultimately, it does
not seem that a genetic diagnosis of HeFH or polygenic hypercholesterolemia negatively
affected the mental health or well-being of individuals who underwent testing.
Furthermore, a genetic diagnosis may have led to greater efforts to improve lifestyle factors
such as diet and possibly medication adherence in PHC, and improved feelings of overall
health in some patients, though more investigation is needed to confirm these
observations. While the results of this study may not be generalizable to all inherited
conditions, the lack of significant negative impact in this study is reassuring. Ultimately, this
study suggests that genetic testing for HeFH or polygenic hypercholesterolemia can be used
by physicians to help guide management, more accurately assess cardiovascular risk and
identify at-risk family members without adversely affecting the patient.

247

4.3 References Chapter 4
1.
Akioyamen LE, Genest J, Shan SD, Reel RL, Albaum JM, Chu A, et al. Estimating the
prevalence of heterozygous familial hypercholesterolaemia: a systematic review and metaanalysis. BMJ Open. 2017;7(9):e016461.
2.
Hopkins PN, Lane SR. Genotype-guided diagnosis in familial hypercholesterolemia:
clinical management and concerns. Curr Opin Lipidol. 2017;28(2):144-51.
3.
Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Lowdensity lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic,
epidemiologic, and clinical studies. A consensus statement from the European
Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459-72.
4.
Khera AV, Won HH, Peloso GM, Lawson KS, Bartz TM, Deng X, et al. Diagnostic Yield
and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With
Severe Hypercholesterolemia. J Am Coll Cardiol. 2016;67(22):2578-89.
5.
Wiegman A, Gidding SS, Watts GF, Chapman MJ, Ginsberg HN, Cuchel M, et al.
Familial hypercholesterolaemia in children and adolescents: gaining decades of life by
optimizing detection and treatment. Eur Heart J. 2015;36(36):2425-37.
6.
Senior V, Smith JA, Michie S, Marteau TM. Making sense of risk: an interpretative
phenomenological analysis of vulnerability to heart disease. J Health Psychol.
2002;7(2):157-68.
7.
Weiner K, Durrington PN. Patients' understandings and experiences of familial
hypercholesterolemia. Community Genet. 2008;11(5):273-82.
8.
Brown SN, Jouni H, Marroush TS, Kullo IJ. Effect of Disclosing Genetic Risk for
Coronary Heart Disease on Information Seeking and Sharing: The MI-GENES Study
(Myocardial Infarction Genes). Circ Cardiovasc Genet. 2017;10(4).
9.
Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic
data capture (REDCap)--a metadata-driven methodology and workflow process for
providing translational research informatics support. J Biomed Inform. 2009;42(2):377-81.
10.
Gandek B, Ware JE, Aaronson NK, Apolone G, Bjorner JB, Brazier JE, et al. Crossvalidation of item selection and scoring for the SF-12 Health Survey in nine countries: results
from the IQOLA Project. International Quality of Life Assessment. J Clin Epidemiol.
1998;51(11):1171-8.
11.
Ware J, Jr., Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction
of scales and preliminary tests of reliability and validity. Med Care. 1996;34(3):220-33.

248

12.
Chrystoja CC, Diamandis EP. Whole genome sequencing as a diagnostic test:
challenges and opportunities. Clinical chemistry. 2014;60(5):724-33.
13.
Moon SJ, Lee WY, Hwang JS, Hong YP, Morisky DE. Accuracy of a screening tool for
medication adherence: A systematic review and meta-analysis of the Morisky Medication
Adherence Scale-8. PLoS One. 2017;12(11):e0187139.
14.
Grover A, Oberoi M, Rehan HS, Gupta LK, Yadav M. Self-reported Morisky Eight-item
Medication Adherence Scale for Statins Concords with the Pill Count Method and Correlates
with Serum Lipid Profile Parameters and Serum HMGCoA Reductase Levels. Cureus.
2020;12(1):e6542.
15.
Godwin M, Pike A, Bethune C, Kirby A, Pike A. Concurrent and convergent validity of
the simple lifestyle indicator questionnaire. ISRN Family Med. 2013;2013:529645.
16.
Godwin M, Streight S, Dyachuk E, van den Hooven EC, Ploemacher J, Seguin R, et al.
Testing the Simple Lifestyle Indicator Questionnaire: Initial psychometric study. Can Fam
Physician. 2008;54(1):76-7.
17.
Lowe B, Decker O, Muller S, Brahler E, Schellberg D, Herzog W, et al. Validation and
standardization of the Generalized Anxiety Disorder Screener (GAD-7) in the general
population. Med Care. 2008;46(3):266-74.
18.
Bonadona V, Saltel P, Desseigne F, Mignotte H, Saurin JC, Wang Q, et al. Cancer
patients who experienced diagnostic genetic testing for cancer susceptibility: reactions and
behavior after the disclosure of a positive test result. Cancer Epidemiol Biomarkers Prev.
2002;11(1):97-104.
19.
Easton K, Coventry P, Lovell K, Carter LA, Deaton C. Prevalence and Measurement of
Anxiety in Samples of Patients With Heart Failure: Meta-analysis. J Cardiovasc Nurs.
2016;31(4):367-79.
20.
Souto AC, Miname MH, Fukushima J, Jannes CE, Krieger JE, Hagger M, et al. Health
related quality of life in individuals at high risk for familial hypercholesterolemia undergoing
genetic cascade screening in Brazil. Atherosclerosis. 2018;277:464-9.
21.
Benson G, Witt DR, VanWormer JJ, Campbell SM, Sillah A, Hayes SN, et al.
Medication adherence, cascade screening, and lifestyle patterns among women with
hypercholesterolemia: Results from the WomenHeart survey. J Clin Lipidol. 2016;10(4):93743.
22.
Galema-Boers JM, Lenzen MJ, van Domburg RT, Roeters van Lennep J, van Bruchemvan de Scheur GG, Sijbrands EJ, et al. Predicting non-adherence in patients with familial
hypercholesterolemia. Eur J Clin Pharmacol. 2014;70(4):391-7.

249

23.
Martens EJ, de Jonge P, Na B, Cohen BE, Lett H, Whooley MA. Scared to death?
Generalized anxiety disorder and cardiovascular events in patients with stable coronary
heart disease:The Heart and Soul Study. Arch Gen Psychiatry. 2010;67(7):750-8.

250

Chapter 5: Discussion, Conclusion and next steps
5.1 Overview:
This work has explored several ways in which genetic knowledge and laboratory techniques
can be translated into the clinical sphere for select endocrine and metabolic conditions. To
accomplish this goal, this work has examined laboratory and bioinformatic techniques that
can help improve diagnosis of MODY (chapter 2), has looked for phenotypic features of
extreme monogenic and polygenic triglyceride phenotypes (chapter 3), and assessed the
patient impact associated with genetic testing for familial hypercholesterolemia (chapter 4).
Collectively, the findings presented here have advanced knowledge of select translational
aspects of genetics and how they may be optimally applied within the endocrine clinic.

5.2 Summary of Findings:
5.2.1 Use of NGS and provider clinical suspicion as criteria to screen for
MODY
In chapter 2.2, this work showed that gestalt provider clinical suspicion has a reasonable
genetic confirmation rate for MODY of approximately 40%. The addition of CNV detection
explored in chapter 2.3 further improved this confirmation rate to approximately 47%. The
use of NGS examining all MODY genes simultaneously was found to improve diagnostic yield
compared to sequential single gene testing for the most common MODY subtypes.

5.2.2 CNVs in the diagnosis of MODY:
Prior to the work presented in chapter 2.3, CNVs were not actively sought during the
investigation of potential MODY cases due to the need for separate testing procedures that
were of uncertain value. The bioinformatic reassessment of the NGS data for 51 suspected
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MODY patients in whom initial genetic testing via NGS was negative found that 6 of these
individuals had pathogenic CNVs underlying their MODY phenotype.
Taken together, the findings from chapter 2.2 and 2.3 suggest that to optimize diagnosis of
MODY, the use of NGS testing that incorporates CNV detection is preferred.

5.2.3 Distinguishing FCS phenotypes from different molecular etiologies
In chapter 3.2, the features of a relatively large cohort of rare FCS patients were compared
by molecular etiology to determine if clinical phenotypic differences were present. While a
few minor differences were seen (in post-heparin LPL activity, insulin resistance markers,
LDL-C and possibly minor differences in other lipid levels), FCS caused by mutations in LPL
were largely similar to FCS from other molecular etiologies, highlighting the role of genetic
testing in establishing a definitive diagnosis.

5.2.4 Incidence, predictors and care patterns for extreme
hypertriglyceridemia
In chapter 3.3, a 5-year retrospective cohort study of all adults within Ontario with VS-HTG
was conducted to investigate the incidence rate of HTG, the strongest predictors for
expression of VS-HTG and the patterns of care for these individuals. This study showed that
diabetes, alcohol abuse and obesity were the most significant modifiable predictors of VSHTG expression. This study provides valuable information to aid in counselling those with
polygenic risk for VS-HTG regarding which risk factors can be addressed to minimize the
expression of VS-HTG and its complications.

5.2.5 Triglyceride rate of fall in the conservative management of
hypertriglyceridemia-associated pancreatitis
The most severe complication of VS-HTG from monogenic, polygenic or other causes is
pancreatitis. The optimal method of treatment for HTG-associated pancreatitis has not yet
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been established. In chapter 3.4, retrospective analysis of triglyceride rates of decline in 22
cases of HTG-associated pancreatitis managed supportively, demonstrates the validity and
safety of the conservative approach to management and also approximates the serum halflife of triglycerides in the fasting state at 30.6 hours. This study also demonstrated the dual
role of polygenic susceptibility coupled with secondary risk factors in the expression of this
severe presentation of HTG.

5.2.6 Patient impact of genetic testing for familial hypercholesterolemia
In chapter 4.2, survey results for 139 individuals who underwent genetic testing for FH and
were found to carry a heterozygous rare variant (HeFH), have high polygenic risk scores for
hypercholesterolemia (PHC) or who had elevated cholesterol (LDL-C >5mmol/L) without a
mutation detected were assessed for the impact of this diagnosis on quality of life,
motivation to adhere to lifestyle and medication advice, levels of anxiety and cardiovascular
risk. Overall findings suggest that the impact of genetic testing was neutral or positive for
most individuals for the measures assessed. This is a reassuring finding and supports the
continued use of appropriate genetic testing in the clinic.

253

5.3 Discussion:
While the findings presented here are only stepping stones in the application of genetic
testing for the clinical management of inherited endocrine conditions, there are several
important findings from each chapter that collectively inform various aspects of patient
care.

5.3.1 Identification of Monogenic Conditions:
One of the most potentially impactful uses of genetic testing within the endocrine clinic is
for the investigation and confirmation of monogenic conditions, especially those that can
result in improved management or outcomes for the proband tested.
This was demonstrated through the confirmation of MODY in chapter 2 of this work, which
resulted in management changes for most of the individuals identified. This work also
demonstrated that incorporating NGS and CNV detection are important additions to
standard Sanger sequencing that allowed for the identification of additional cases in an
efficient and cost-effective manner.
This was also seen in chapter 3.2 when examining FCS patients, who were clinically similar
despite different molecular origins. This study demonstrated that genetic confirmation was
the most effectual method of clearly determining the etiology of this rare condition.
Determining the underlying genotype in these cases may have an impact of responsiveness
to various treatments or to long term outcomes.
Chapter 4 of this work demonstrated that genetic confirmation of monogenic
hypercholesterolemia was a neutral to positive experience for patients, and most would
recommend testing to family members, suggesting that this type of testing is also
worthwhile from a patient perspective.
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5.3.2 Improved counselling:
An understanding of the genetic origins of an endocrine disorders can also improve the
evaluation and counselling delivered surrounding the diagnosis, and allow for an
explanation about what can be done to prevent, modify or manage the risks associated with
the condition.
This was seen in chapter 2.3 of this work where by establishing the correct diagnosis of
MODY subtype providers were able to more accurately predict disease course and
prognosis, allowing for a more informed discussion of treatment options and their risks and
benefits.
The predictors for the expression of severe hypertriglyceridemia identified in chapter 3.3
allows for more informed discussions regarding susceptibility and how to overcome genetic
risk.
The results of the surveys in chapter 4.2 raise awareness about the potential psychological
impacts of receiving a genetic diagnosis. While no adverse effects were noted in this work,
it is important to appropriately counsel patients during the genetic testing process to avoid
causing undue anxiety and to ensure understanding of any results obtained. This was
highlighted in this work by the fact that 6.45% of respondents diagnosed with HeFH
described the impact of genetic testing to have had a strongly (4.84%) or mildly (1.61%)
negative impact. While this was clearly a minority of individuals, these concerns and
experiences should not be discounted.

5.3.3 Personalized Management:
One of the most tangible outcomes of genetic testing within the endocrine and metabolic
clinic context is the ability to personalize management based on individual needs and
findings. This is one of the major benefits of identifying a patient with a monogenic
condition such as MODY, FCS or FH.
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In many cases, this results in improved quality of life, was seen in chapter 2.3 of this work
where in HNF1A and HNF4A MODY, sulfonylureas can be used to optimize control of
hyperglycemia, allowing discontinuation of insulin in some cases, or de-escalation of
treatment in others. In GCK-MODY, patients can be reassured that no special monitoring or
treatment are required, and no long term risks are expects.
Similarly, chapter 3.2 describes some of the features of FCS, a very rare condition that has
not previously been systematically studied in a large group of patients. The descriptions of
FCS provided in this work may help clinicians more appropriately distinguish FCS patients
from the more common polygenic HTG patients.
Similarly, being able to recognize those individuals that have major modifiable risk factors
contributing to their extreme phenotype, as identified in chapter 3.3, and convey this
information to patients can potentially lead to a sense of empowerment to control and
improve their condition.
The results of the work describing the fall of triglycerides during conservative management
of pancreatitis in chapter 3.4 can also be used to optimize management of this condition as
well as illustrate to patients the influence of diet and other secondary factors on their
serum lipid profile.
In chapter 4.2 of this work, a diagnosis of HeFH was demonstrated to be acceptable for
patients, and most felt satisfied that they had undergone the testing. It may also have led
to improved motivation to adhere to recommended diet, prescribed medication, and
increase overall sense of health, but this needs further validation. Irrespective of the
personal patient impact, a diagnosis of FH can change recommended management and
potentially improve access to medications such as PCSK9 inhibitors.

5.3.4 Judicious use of genetic testing:
An understanding of the genetic landscape of endocrine and metabolic conditions can also
allow for more informed discussions with patients regarding their own risk, as well as the
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risk that their family members might carry, and to discuss why and when genetic testing
might be helpful.
For example, when considering MODY testing (chapter 2.2 and 2.3), if pancreas
autoantibodies are present, or if there are clear physical stigmata of insulin resistance,
genetic testing may not be indicated as it would be unlikely to yield positive findings.
Similarly, genetic testing for triglyceride disorders might be best for those who have
features of FCS discussed in chapter 3.2 of this work. Those with likely polygenic HTG may
not derive benefit from genetic study, but may find a discussion of the modifiable nature of
their condition, as evidenced in chapter 3.3 and 3.4, helpful.
The findings from chapter 4.2 suggest that if genetic testing is deemed to be important or
helpful for clinical indications, it does not seem to adversely affect the patient, at least in
the context of FH.

5.3.5 Improve diagnostic accuracy:
An increased awareness that some monogenic disorders that would benefit from detection
may be under-recognized is also an important finding in this work. While approximately
50% of patients referred for clinical suspicion of MODY in chapter 2.2 and 2.3 were
ultimately diagnosed with MODY, this high confirmation rate conversely suggests that many
MODY patients are going unrecognized.
Furthermore, for triglyceride disorders in chapter 3, it’s important to realize that most are
not monogenic, and to offer testing only to those who seem to fit the rare clinical picture
for FCS (chapter 3.2).
FH is more common, and more commonly considered; it can also be missed in younger
patients who have not had a lipid profile. It is important to consider family history of
premature ASCVD and/or elevated cholesterol, and to consider screening patients with this
history at an earlier age to lead to improved ASCVD outcomes. Anyone with a known family
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history should be screened early, ideally upon entering adulthood if not before, and timely
treatment initiated. Chapter 4.2 suggest most patients who undergo this testing will
experience a largely neutral or positive impact.

5.3.6 Test selection:
In terms of which tests are most appropriate, the findings in chapter 2.2 and 2.3 suggest
that NGS testing, either by gene panel or whole exome, that incorporates CNV analysis as a
single test may provide the highest yield when testing for monogenic conditions such as
MODY or FH. The use of validated testing methods is important due to the potential for
incorrect variant calls.
Genetic testing should be used judiciously when assessing polygenic traits, such as most
cases of hypertriglyceridemia (chapter 3.3, chapter 3.4). Caution should also be exercised
when considering the use of polygenic risk scores, as these are largely unstandardized and
their prognostic value still uncertain.
However, chapter 4.2 of this work suggests that testing for polygenic hypercholesterolemia
(PHC) was associated with neutral or positive impact in most patients, with PHC patients in
particular showing a significant increase in medication adherence following their diagnosis.

5.3.7 Cascade testing:
Many individuals found to carry genetic risk for an endocrine or metabolic condition will be
concerned about the possibility that it may also be present in other family members. For
monogenic dominant traits, such as HeFH (chapter 4) and MODY (chapter 2), 50% of all first
degree relatives of identified probands will also carry the pathologic variant. Therefore,
effort should be made to convey this information through family groups and facilitate
testing in a cascading manner. For polygenic conditions, such as most cases of
hypertriglyceridemia (chapter 3), familial testing is less helpful. These conditions can cluster
within families but the inheritance pattern is variable and phenotypes can vary significantly,
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therefore cascade testing is not often warranted, or useful, for polygenic traits. For
recessive traits such as FCS (chapter 3.2), both parents are usually carriers of the pathologic
variant. Therefore, genetic counselling for the parents of the affected child may be
appropriate, as there is a 25% chance of a subsequent child born to the same parents
expressing the condition. Testing other relatives to determine their carrier status in the
context of genetic counselling for family planning purposes may also be considered. As
chapter 4.2 indicates, most patient with HeFH would recommend genetic confirmatory
testing to their family members, suggesting cascade testing would be reasonable and
acceptable to most patients.

5.3.8 Optimize Care:
Another finding highlighted by this work is the importance of modifying what can be
modified to optimize care for the patient. For example, in MODY, medications and
screening programs can be modified to align with the genetic diagnosis and specific risk
factors (chapter 2). Important secondary risk factors can be addressed in patients with
hypertriglyceridemia (chapter 3). The identification of HeFH can modify the risk assessment
and treatment targets for cholesterol (chapter 4). By understanding the most important
genetic and non-genetic factors influencing expression of these traits, an informed
discussion and personalized care plan are possible.

5.3.9 Future Advances:
Another important take-away from this work is that knowledge is always evolving,
especially when it comes to genetics. Variants may be re-classified from being of
undetermined significance to being pathogenic with the incorporation of new information;
pathogenic changes may be detected with the use of refined testing techniques, as was
seen with the detection of CNVs in chapter 2 of this work; or new causal genes may be
detected. Ongoing work is being done on the utility of polygenic risk scores. These may
become standardized, and may be useful in refining risk stratification in polygenic
conditions such as hypertriglyceridemia (chapter 3) and other complex traits. It is important
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to leave the door open, in both the clinician and patient’s minds to allow for the
incorporation of potential new discoveries.

5.4 Study strengths and limitations
Individual study strengths and limitations of included studies are discussed within each
relevant section. Here, the strengths and limitations of the data as a whole are discussed.

5.4.1 Strengths:
Strengths of the study include the availability and use of LipidSeq, a targeted NGS panel that
was used in the genetic testing for chapters 2.2, 2.3, 3.2, 3.4 and 4.2. LipidSeq is designed
to capture all MODY related genes as well as genes related to other lipid and metabolic
phenotypes (Appendix C). It has also been designed to capture the SNPs used to generate
the TG and FH PRS in chapter 3.4 and chapter 4.2, respectively. Due to the high depth of
coverage (approximately 300-times), output data from LipidSeq was also able to be used for
CNV analysis in the diagnosis of MODY, FH and FCS in chapters 2.3, 3.2 and 4.2. This
allowed for a single test to be conducted rather than using separate methodologies to
capture SNPs, CNVs and single candidate genes.
Another major strength of this work is the large population available for chapter 3.3
through the ICES network, which draws on data from multiple databases, with a wealth of
information available for the majority of residents within Ontario, providing a large and
robust data set. Access to this powerful tool allowed for a population-wide assessment of
the incidence, predictors, care patterns and outcomes for the hypertriglyceridemia
phenotype of interest.
Additionally, through collaboration with multiple clinical sources, this work had access to
genetic and clinical information from patients with relatively rare clinical conditions such as
MODY in chapter 2.2 and 2.3 and FCS in chapter 3.2, FH in chapter 4.2, and HTG-associated
pancreatitis in chapter 3.4.
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5.4.2 Limitations:
A notable limitation of this study is the potential lack of generalizability in many of the
findings. The CNV analysis in chapter 2.3 was conducted using the LipidSeq NGS testing
and bioinformatic software pipeline to identify CNVs from NGS data. The ability to
accurately detect the CNVs is dependent on the depth of coverage for the sample assessed.
Other panels may be less accurate in detecting CNVs.
The data obtained in chapter 3.3 may also suffer from lack of generalizability outside the
population of Ontario studied due to differences in ethnicity, genetic backgrounds,
environmental influences, healthcare systems and population demographics.
Generalizability of the results in chapter 4.2 may also be a concern given that the patient
population studied was drawn from a specialized lipid clinic and may not reflective of the
average patient presenting with severe hypercholesterolemia.
Polygenic risk scores (PRS) for triglycerides (chapter 3.4) and hypercholesterolemia (chapter
4.2) used in this study were generated using only 16 and 10 SNPs respectively. Some data
suggests that incorporation of more SNPs may provide greater prognostic information.
However, the SNPs chosen are ones that have been found to have the largest effect sizes,
minimizing any loss of discernability.
Furthermore, the data used to generate and validate the PRSs used in this study were
derived largely from subjects of European background and may not be generalizable to
populations from other ethnic backgrounds. Similarly, most of the patient data presented
here was from a population of predominantly European descent, which may further impact
generalizability.
Additionally, while CNVs were found in 6 initially negative suspected MODY patients, the
true population frequency of these mutations amongst MODY patients is unavailable as the
provided samples may have been enriched for these cases. More extensive case finding
study may be required to gain a better understanding of the role of CNVs in MODY cases.
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Furthermore, the findings regarding clinical suspicion for MODY being a reasonable
selection criteria for MODY genetic testing may not hold true for other populations of
providers.
Finally, given the breadth of the topics studied, this work leaves many unanswered
questions that will require additional study to adequately address. This is particularly true
for the findings favouring conservative management of HTG-associated pancreatitis in
chapter 3.4 and the patient impact of genetic testing in chapter 4.2.

5.5 Future Directions:
5.5.1 MODY case finding:
Given the importance of identifying MODY to achieve optimal management, and the overall
high rates of missed MODY diagnoses, future research plans include studies aimed at
actively seeking potential candidates who may benefit from genetic testing for MODY.
Initial efforts will address two distinct populations: 1) pregnant individuals who have
screening positive for GDM; 2) patients with an established diagnosis of either type 1 or
type 2 diabetes followed in the pediatric or adult endocrine clinics who are assessed at
having >50% probability of MODY based on a validated clinical prediction tool.
5.5.1.1 Identifying pregnant patients with MODY:
MODY can be picked up during routine glucose tolerance tests conducted during pregnancy
and is often misdiagnosed as gestational diabetes (GDM). Studies have estimated that up to
5-6% of women diagnosed with GDM actually have MODY (1, 2). Optimal care of women
with MODY and their unborn children can depend on distinguishing MODY from GDM.
Confirming a diagnosis will also have long-term management implications for both mother
and baby. A definitive diagnosis of MODY in the mother can be made by performing a
genetic test on DNA extracted from a routine blood sample. For this project, all women
evaluated in our Endocrine and Pregnancy Clinic would be clinically screened for MODY at
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their initial consult visit. Any individual deemed to be at high risk of MODY would be
appropriately counselled and offered confirmatory genetic testing.
5.5.1.2 Identifying MODY amongst established diabetes patients:
MODY continues to be underrecognized clinically, but affects up to 5% of individuals
diagnosed with diabetes under the age of 35. There are 14 genes associated with MODY
subtypes, which are usually inherited in an autosomal dominant pattern. Many patients
with MODY are misdiagnosed as having either type 1 or type 2 diabetes. Each subtype of
MODY is unique, and establishing the correct diagnosis can help with selecting the most
appropriate treatment options, lead to improvements in glycemic control and provide a
clearer picture of the expected course of the diabetes over time. As a start to this project,
our clinic practice has been screened using the local online diabetes database to identify
those individuals diagnosed with diabetes under the age of 35 and have identified up to 359
individuals who may benefit from additional screening and potentially genetic testing for
this condition (Table 5.1). For this project, this additional screening would be conducted
and genetic testing and counselling offered to any individual who has a >50% probability of
having MODY based on a validated clinical prediction tool.
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Table 5.1: Preliminary data for MODY case finding from online database query
MODY Probability
MODY Probability
Combined
<50%
Potentially >50%
Population
N

262

359

621

Age at Diagnosis
-mean
-median
-range

28.96
30
6-35

13.59
13
1-34

20.2
20
1-35

Sex
-male
-female

123 (46.9%)
139 (53.1%)

147 (40.9%)
212 (59.1%)

270 (43.5%)
351 (56.5%)

BMI
-mean
-median
-range

33.75
32.7
19.3-64.9

26.05
25.1
14.4-46.3

29.31
27.7
14.4-64.9

HbA1c
-mean
-median
-range

8.78%
8.4%
5.4-15.1%

8.16%
8%
4.4-13.4%

8.42%
8.2%
4.4-15.1%

Current Age
-mean
-median
-range

51.01
51
15-85

34.4
31
8-82

41.43
41
8-85

N/A

3.41
0.7
0.7-75.5

N/A

15.79
4.6
4.5-45.5

72.81
75.5
58-75.5

48.33
62.4
4.5-75.5

Min Prob Score:
-mean
-median
-range
Max Prob Score:
-mean
-median
-range
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5.5.2 Assessing the genetic confirmation rate of genetic testing for other
monogenic conditions:
As seen for MODY in chapter 2, confirming the presence of a monogenic condition may
provide a powerful clinical tool to provide more personalized and effective care for patients
and their family members. Investigating how this tool may be best applied clinically will
help guide the incorporation of genetic tests into clinical practice. This study will help
establish how to select patient who are most likely to benefit from testing and identify
specifically how they may benefit in terms of measurable clinical outcomes as well as
patient and provider satisfaction.
Following the principles discussed above, testing for conditions for which genetic testing
results may materially affect patient management or outcomes, have the highest potential
benefit. The three conditions below meet this criteria and will be studied in an attempt to
assess those clinical features that are predictive of a positive or negative genetic
confirmation test. The main goals of this assessment would be to develop more
discriminating selection criteria for testing, as well as to assess for the presence of
meaningful changes to management or outcomes that could be attributed to the genetic
diagnosis.
5.5.2.1 Familial Hypocalciuric Hypercalcemia (FHH):
FHH is a benign condition caused by mutations in CASR, encoding for the calcium sensing
receptor, that leads to a higher setpoint for calcium mediated suppression of parathyroid
hormone (PTH) release and renal excretion of calcium. Distinguishing this condition from
alternative diagnoses that can mimic the presentation of FHH, mainly primary
hyperparathyroidism, is important as the management of each condition is drastically
different. The management of primary hyperparathyroidism would usually be surgical
removal of an autonomously functioning and hypertrophied parathyroid gland, whereas
treatment is not usually required for FHH. FHH tends to follow a benign course, with mild
biochemical abnormalities seen and no end organ damage or dysfunction. Therefore
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management of FHH is reassurance in most cases. While there are urinary tests that can be
helpful in distinguishing FHH from primary hyperparathyroidism there can be significant
overlap in findings between these two conditions. In cases of ambiguity, genetic testing to
look for a pathologic variant in CASR may help guide appropriate management.
5.5.2.2 Thyroid Hormone Resistance:
Thyroid hormone resistance is caused by defective receptors to thyroid stimulating
hormone (TSH) on target tissues throughout the body. There are multiple subtypes of
thyroid hormone resistance, with the most common caused by mutations affecting the beta
type receptors. Thyroid hormone alpha receptors can also be affected, though less
commonly. These receptors are variably distributed throughout the body with different
tissues having higher or lower concentration ratios of beta to alpha receptors. This
condition can manifest with symptoms of hypothyroidism, hyperthyroidism, or patients may
be asymptomatic. A mosaic pattern of symptoms, with some tissues displaying features of
hyperthyroidism and others features of hypothyroidism are also possible based on
inconsistent receptor distribution among different body tissues. Variable patterns of
thyroid function tests can be seen with this condition and it is possible that this condition
could be mistaken for either central hyperthyroidism, or hypothyroidism if an isolated TSH
is assessed. Incorrect treatment can therefore be initiated in some cases. Confirming this
condition with genetic testing can help guide optimal management as well as help identify
this condition in other family members, avoiding potentially unnecessary or incorrect
treatments such as thyroidectomy, thyroid ablation, or inappropriate use of thyroid
hormone replacement.
5.5.2.3 Familial Partial or Complete Lipodystrophy
There are several subtypes of familial partial or complete lipodystrophy (Table 5.2).
Lipodystrophies are characterized by abnormal distribution of adipose tissue, with a paucity
of subcutaneous fat and consequent pathological deposition of fat within other body
regions such as within organs (ie the liver) or viscerally. Lipodystrophy is commonly
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characterized by severe insulin resistance and severe hypertriglyceridemia. While
management of lipodystrophy generally follows the same principles as managing these
manifestations in non-lipodystrophy individuals, some medications, such as the
thiazolidinediones (TZDs) may be more beneficial in patients this population and may be
preferentially used. Additionally, making this diagnosis provides relief of uncertainty for
both the patient and provider. In extreme cases characterized by refractory metabolic
derangements, Metreleptin, a synthetic leptin analog, may also be used under research
protocols in these patients, although long-term safety and efficacy of this treatment has yet
to be established (3). Lipodystrophies are underrecognized clinically and active assessment
for potential cases that may benefit from genetic testing may be warranted.
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Table 5.2: Lipodystrophies

Partial
lipodystrophies

Generalized
lipodystrophies

Gene/chromosome

Inheritance

MIM
reference
numbers

LMNA/1q22

AD

151660

PPARG/3p25.2

AD

604367

PLIN1/15p26.1

AD

613877

CIDEC/3p25.3

AR

615238

AGPAT2/9q34.3

AR

608594

BSCL2/11q12.3

AR

269700

CAV1/7q31.2

AR

612526

CAVIN1/17q21.2

AR

613327

Clinical features and
comorbidities
-distinctive patterns of
regional lipoatrophy
associated with
simultaneous
lipohypertrophy in
unaffected areas
-insulin resistance
-recurrent pancreatitis
- absence of
subcutaneous fat in
subcutaneous tissues
-insulin resistance
-recurrent pancreatitis
-hepatosplenomegaly

Comments

-elevated TG
which can be
severe in 1020% of cases

-elevated TG
which can be
severe in
majority of
cases
-elevated
liver enzymes

AD: autosomal dominant; AR: autosomal recessive; TG: triglyceride; MIM: mendelian inheritance in man
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5.5.3 Creating an updated reference for the population distribution of
lipid levels across residents of Ontario
Previous cross-sectional data on population-wide lipid distribution has been obtained in
other populations. However since these studies were conducted, there has been significant
changes in population characteristics such as age distribution, ethnic variability, rates of
overweight and obesity, prevalence of diabetes and metabolic syndrome and a shift in
dietary patterns and rates of physical activity, as well as increased prescribing of lipiddirected medications. Consequently, this older data may not reflect current trends.
This study will look at all individuals residing in Ontario with a valid OHIP card and a lipid
profile obtained and available in OLIS for 2019. If more than one lipid profile is available for
a single individual, data collection will be restricted to the first value over the accrual
period. It will determine the lipid distribution for total, LDL, HDL and non-HDL cholesterol,
as well as fasting and non-fasting triglyceride levels for the population, subdivided by sex
and age by decade to generate the data necessary to determine mean, SD median, 1st, 5th,
10th, 25th, 50th, 75th, 90th, 95th, 99th percentile for each lipid parameter.

5.5.4 ASCVD and pancreatitis among patients with HTG Ontario Cohort
This study will look at the HTG cohort population in Ontario obtained from the previous
investigation into the incidence, predictors and care patterns in the population described in
chapter 3.3 but will be optimized to assess the rates and predictors of outcomes, such as
ASCVD events and pancreatitis risk based on degree of triglyceride elevation in order to
further improve counselling and management of genetic triglyceride disorders.

5.5.5 Prospective Assessment of patients tested for FH for medication
adherence
The initial investigation into the patient impact of genetic testing for familial
hypercholesterolemia (FH) found that a genetic diagnosis of FH may improve adherence to
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recommended medications in PHC individuals (chapter 4.2). To further investigate and
confirm this preliminary signal, a dedicated prospective study will be done assessing
medication adherence at baseline, prior to disclosure of genetic testing results, and then
again at 6 months and one year following disclosure of a genetic confirmation of FH or PHC.

5.6 Conclusions:
The information gained from this work has allowed for several important advances and acts
as a stepping stone to expand current understanding of how knowledge of disease genetics
may be applied within the endocrine clinic. This work has helped to define genetic testing
techniques that can improve case detection among patients with monogenic endocrine
conditions such as MODY, and has helped to establish the importance of assessing for CNVs
in suspected MODY cases to improve diagnostic yield. It has provided valuable insight into
severe monogenic triglyceride phenotypes and highlighted the importance of seeking
genetic confirmation in suspected cases of FCS. Data obtained from the identification of
the most important predictors of severe hypertriglyceridemia, such as diabetes, obesity and
alcohol, as well as safe and effective options for the management of HTG-associated
pancreatitis will improve counselling and management of patients with genetic triglyceride
disorders. Furthermore, this work has demonstrated that the patient impact of genetic
testing for FH is largely neutral or positive, suggesting that genetic testing does not
adversely affect individuals and may be appropriately used by clinicians to help optimize
and personalize care for patients within the endocrine clinic.
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Appendix D: Databases Utilized for Chapter 3.3
Variable

Database

Codes

Age

RPDB

Sex

RPDB

Income quintile

RPDB

Rostered to family doctor

CAPE

Charlson comorbidity status

CIHI-DAD

Coronary artery disease
(excluding angina)

CIHI-DAD

ICD10: "I21", "I22", "Z955", "T822", "I25"

NACRS

CCI: "1IJ50", "1IJ76"

OHIP

OHIP fee codes: "R741", "R742", "R743",
"G298", "E646", "E651", "E652", "E654",
"E655", "Z434", "Z448"
OHIP Dx codes: "410", "412"

Cerebrovascular disease

CIHI-DAD

ICD10: "I60", "I600", "I601", "I602", "I603",
"I604", "I605", "I606", "I607", "I608", "I609",
"I61", "I610", "I611", "I612", "I613", "I614",
"I615", "I616", "I618", "I619", "I630", "I631",
"I632", "I633", "I634", "I635", "I638", "I639",
"I64", "H341", "G450",
"G451","G452","G453","G458","G459","H340"

NACRS

OHIP Dx codes: "436", "432", "435"

Diabetes

ODD (ICES
validated cohort)

295

Lorraine L. Lipscombe, Jeremiah Hwee, Lauren
Webster, Baiju R. Shah, Gillian L. Booth and
Karen Tu. Identifying diabetes cases from
administrative data: a population-based
validation study. BMC Health Services

Peripheral vascular disease

CIHI-DAD

ICD10: "I700", "I702", "I708", "I709", "I731",
"I738", "I739", "K551"

OHIP

CCI: "1KA76", "1KA50", "1KE76", "1KG50",
"1KG57", "1KG76MI", "1KG87", "1IA87LA",
"1IB87LA", "1IC87LA", "1ID87", "1KA87LA",
"1KE57"
OHIP fee codes: "R787", "R780", "R797",
"R804", "R809", "R875", "R815", "R936",
"R783", "R784","R785", "E626", "R814",
"R786", "R937", "R860", "R861", "R855",
"R856", "R933", "R934", "R791", "E672",
"R794", "R813", "R867", "E649"

Chronic kidney disease

CIHI-DAD

ICD10: "E102", "E112", "E132", "E142", "I12",
"I13", "N00", "N01", "N02", "N03", "N04",
"N05", "N06", "N07", "N08", "N10", "N11",
"N12", "N13", "N14", "N15", "N16", "N17",
"N18", "N19", "N20", "N21", "N22", "N23"

OHIP

OHIP Dx codes: "403", "585"

Pancreatitis

CIHI-DAD

ICD10: "K85", "B252", "B263", "K860", "K861"

Hypertension

HYPER (ICES
validated cohort)

Tu K, Chen Z, Lipscombe LL, Canadian
Hypertension Education Program Outcomes
Research Taskforce. Prevalence and incidence
of hypertension from 1995 to 2005: a
population-based study. Canadian Medical
Association Journal. 2008 May
20;178(11):1429-35.

Chronic liver disease

CIHI-DAD

ICD10: "B16", "B17", "B18", "B19", "I85",
"R17", "R18", "R160", "R162", "B942", "Z225",
"E831", "E830", "K70", "K713", "K714",
"K715", "K717", "K721", "K729", "K73", "K74",
"K753", "K754", "K758", "K759", "K76", "K77"

NACRS
OHIP
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OHIP Dx codes: "571", "573", "070"
OHIP fee codes: "Z551", "Z554"

Alcohol use

CIHI-DAD

ICD10: "E244", "E512", "E52", "F10", "G312",
"G621", "G721", "I426", "K292", "K70",
"K860", "T51", "X45", "X65", "Y15", "Y573",
"Z502", "Z714", "Z721"

Hypothyroidism

CIHI-DAD

ICD10: "E00", "E01", "E02", "E03", "E890"

Multiple myeloma

CIHI-DAD

ICD10: "C900"

Obesity

CIHI-DAD

ICD10: "E66.25", "E66.26", "E66.27",
"E66.28", "E66.29", "E66.0", "E66.1", "E66.2",
"E66.8", "E66.9", "E66.2”,"E66.2"

Pregnancy

CIHI-DAD

ICD10: “Z34", P95", "Z371", "Z373", "Z374",
"O00", "O021", "O03", "O04", "O08", "O60",
"O42", "P072", "P073"

CCI: "5CA88", "5CA20FK", "5CA24", "5MD5",
"5MD6", "5MD4"

OHIP FEE: "A922", "A920", "P001", "S752",
"S785", "S756", "S768", "S784", "S770",
"P006", "P007", "P008", "P009", "P010",
"P011", "P013", "P014", "P014", "P015",
"P016", "P016", "P018", "P020", "P022",
"P023", "P027", "P028", "P029", "P030",
"P031", "P032", "P034", "P036", "P038",
"P039", "P041", "P042", "P045", "P046"
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OHIP DX: "632", "633", "634", "640"

Gallstone disease

CIHI-DAD

ICD10: "K80", "K81", "K82", "K83", "K85"

Acute myocardial infarction

CIHI-DAD

ICD10: "I21", "I22"

Nephrotic Syndrome

CIHI-DAD

ICD 10: "N044", "N022", "N043", "N040",
"N08", "N048", "N049", "N033", "N052"

Ischemic Stroke:

CIHI-DAD

ICD-10: "I63", "I64", "I65", "I66", "I67", "I68

GP/FP visit

OHIP

OHIP spec: “00”

IPDB

IPDB Mainspecialty: “GP/FP”

OHIP

OHIP spec: “13”

IPDB

IPDB Mainspecialty: “INTERNAL MEDICINE”

OHIP

OHIP spec: “15”

IPDB

IPDB Mainspecialty: “ENDOCRINOLOGY”

HbA1c

OLIS

LOINC: “17855-8”, “17856-6“, “41995-2“,
“4548-4”, “59261-8”, “71875-9”

LDL-C

OLIS

LOINC: “22748-8“, “39469-2“

HDL-C

OLIS

LOINC: “14646-4“, “32309-7

Non-HDL

OLIS

LOINC: “70204-3“

Total Cholesterol

OLIS

LOINC: “14647-2“

Corrected calcium

OLIS

LOINC: “29265-6”, “2000-8”, “1751-7”

Internist visit

Endocrinologist visit
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ALT

OLIS

Lipid medication

ODB

Triglyceride value

OLIS

LOINC: “1742-6“, “1743-4“, “1744-2“

LOINC: “14927-8“, “47210-0“

Abbreviations: RPDB: registered persons database; CAPE: Client Agency Program Enrolment database: CIHI-DAD: Canadian Institutes for
Health Information’s Discharge Abstract Database; NARCRS: National Ambulatory Care Reporting System; OHIP: Ontario Health Insurance
Program; ICD-10: the International Classification of Diseases 10th Revision; CCI: Canadian Classification of Health Interventions; HYPER:
hypertension database; ODD: Ontario Diabetes Database; ODB: Ontario Drug Benefit (ODB) database. OLIS: Ontario Laboratories
Information System (OLIS).
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Appendix E: RECORD checklist for Chapter 3.3
Item
No

Recommendation

Reported

1.1 The type of data used should be specified in the
title or abstract. When possible, the name of the

Abstract

databases should be included.
1.2 If applicable, the geographic region and time
Title and abstract

1

frame within which the study took place should be

Abstract

reported in the title or abstract.
1.3 If linkage between databases was conducted for
the study, this should be clearly stated in the title or

Abstract

abstract
Introduction

Background/rationale

2

Objectives

3

Explain the scientific background and rationale for
the investigation being reported
State specific objectives, including any pre-specified
hypotheses

Introduction

Introduction

Methods

Study design

4

Present key elements of study design early in the
paper

Methods

Describe the setting, locations, and relevant dates,
Setting

5

including periods of recruitment, exposure, follow-

Methods

up, and data collection
6.1 The methods of study population selection
Participants

6

should be listed in detail. If this is not possible, an
explanation should be provided.

300

Methods

6.2 Any validation studies of the codes or algorithms
used to select the population should be referenced.
If validation was conducted for this study and not

Methods

published elsewhere, detailed methods and results
should be provided.
6.3 If the study involved linkage of databases,
consider use of a flow diagram or other graphical
display to demonstrate the linkage process,

Figure 3.1

including the number of individuals with linked data
at each stage.
A complete list of codes and algorithms used to
Variables

7

classify exposures, outcomes, confounders, and
effect modifiers should be provided. If these cannot

Appendix D

be reported, an explanation should be provided.
For each variable of interest, give sources of data
Data sources/
measurement

8

and details of methods of assessment
(measurement). Describe comparability of
assessment methods if there is more than one group

Bias

9

Study size

10

Quantitative
variables

Describe any efforts to address potential sources of
bias
Explain how the study size was arrived at

Appendix D

Methods

Methods

Explain how quantitative variables were handled in
11

the analyses. If applicable, describe which groupings

Methods

were chosen and why
12.1 Describe all statistical methods, including those
used to control for confounding

Statistical methods

Methods,

Methods

12
12.2 Describe any methods used to examine
subgroups and interactions
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Methods

12.3 Explain how missing data were addressed
12.4 If applicable, explain how loss to follow-up was
addressed
12.5 Describe any sensitivity analyses

Not applicable

Not applicable

Not applicable

12.6 Authors should describe the extent to which
the investigators had access to the database
Data access and

Methods

population used to create the study population.

cleaning methods
12.7 Authors should provide information on the data
cleaning methods used in the study

Methods

12.8 State whether the study included person-level,
institutional-level, or other data linkage across two
or more databases. The methods of linkage and

Linkage

Methods

methods of linkage quality evaluation should be
provided.
Results
13.1 Describe in detail the selection of the persons
included in the study (i.e. study population
Participants

13

selection), including filtering based on data quality,
data availability, and linkage. The selection of

Results, Figure 3.1

included persons can be described in the text and/or
by means of the study flow diagram.
14.1 Give characteristics of study participants (e.g.
demographic, clinical, social) and information on
Descriptive data

14

exposures and potential confounders
14.2 Indicate number of participants with missing
data for each variable of interest
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Results, Tables 3.53.8

Results, Figure 3.1

14.3 Summarize follow-up time (e.g. average and
total amount)

Outcome data

15

Results, Table 3.10

Report numbers of outcome events or summary

Results, Figure 3.2

measures over time

Table 3.6-3.9

16.1 Give unadjusted estimates and, if applicable,
confounder-adjusted estimates and their precision
(e.g. 95% confidence interval). Make clear which

Results, Table 3.8

confounders were adjusted for and why they were
included
Main results

16

16.2 Report category boundaries when continuous
variables were categorized

Tables 3.5 – 3.8

16.3 If relevant, consider translating estimates of
relative risk into absolute risk for a meaningful time

Not applicable

period

Other analyses

17

Report other analyses done—e.g. analyses of

Results, Table 3.6,

subgroups and interactions, and sensitivity analyses

3.7

Discussion

Key results

18

Summarize key results with reference to study
objectives

Discussion

Discuss the implications of using data that were not
created or collected to answer the specific research
Limitations

19

question(s). Include discussion of misclassification
bias, unmeasured confounding, missing data and

Discussion

changing eligibility over time, as they pertain to the
study being reported.

Interpretation

20

Give a cautious overall interpretation of results
considering objectives, limitations, multiplicity of

303

Discussion

analyses, results from similar studies, and other
relevant evidence

Generalizability

21

Discuss the generalizability (external validity) of the
study results

Discussion

Other information
22.1 Give the source of funding and the role of the
funders for the present study and, if applicable, for

Funding

the original study on which the present article is

Declarations

based
The dataset from
this study is held
securely in coded
form at the Institute
for Clinical Evaluative
Sciences (ICES).
While data sharing
agreements prohibit
ICES from making

22
Accessibility of
protocol, raw data
and programming
code

22.2 Authors should provide information on how to
access any supplemental information such as the
study protocol, raw data, or programming code.

the dataset publicly
available, access may
be granted to those
who meet prespecified criteria for
confidential access,
available at
www.ices.on.ca/DAS.
The full dataset
creation plan and
underlying analytic
code are available
from the authors
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upon request,
understanding that
the programs may
rely upon coding
templates or macros
that are unique to
ICES.

*Reference: Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, et al. The
REporting of studies Conducted using Observational Routinely-collected health Data
(RECORD) statement. PLoS Med. 2015;12(10):e1001885.
*Checklist is protected under Creative Commons Attribution (CC BY) license.
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Appendix F: Paper-based survey for chapter 4.2
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310
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